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Abstract
Upon ageing, a progressive disruption of protein homeostasis often leads to extensive protein
aggregation and neurodegeneration. It is therefore important to study at the proteome level the
origins and consequences of such disruption, which so far have remained elusive. Addressing
this problem has recently become possible by major advances in mass spectrometry-based (MS)
proteomics, which allows the identifications and quantification of thousands of proteins in a variety
of biological samples.
In the first part of this thesis, I analyse proteome-wide MS data for the nematode worm C.
elegans upon ageing, in wild type (WT), long-lived and short-lived mutant strains. By comparing
the total abundance and the soluble abundance for nearly 4000 proteins, I provide extensive evidence
that proteins are expressed in adult worms at levels close to their solubility limits. With the use of
sequence-based prediction tools, I then identify specific physico-chemical properties associated
with this age-related protein homeostasis impairment. The results that I obtained reveal that the
total intracellular protein content remains constant, in spite of the fact that the proteome undergoes
wide remodeling upon ageing, resulting into severe protein homeostasis disruption and widespread
protein aggregation. These results suggest a protein-dependent decrease in solubility associated
with the protein homeostasis failure.
In the second part of the thesis, I determine and classify potential interactions of misfolded pro-
tein oligomers with other proteins. This phenomenon is widely believed to give rise to cytotoxicity,
although the mechanisms by which this happens are not fully understood. To address this question,
I process and analyse MS data from structurally different oligomers (toxic type A and nontoxic
type B) of the protein HypF-N, incubated in vitro with proteins extracted from murine cell cultures.
I find that more than 2500 proteins are pulled down with the misfolded oligomers. These results
indicate that the two types of oligomers interact with the same pool of proteins and differ only in
the degree of binding. Functional annotation analysis on the groups reveals a preference of the
oligomers to bind proteins in specific biological pathways and categories, including in particular
mitochondrial membrane proteins, RNA-binding proteins and molecular chaperones.
Overall, in this study I complement the powerful and high-throughput experimental approach
of MS proteomics with bioinformatics analyses and prediction algorithms to define the physical,
chemical and biological features of protein homeostasis disruption upon ageing and the interactome
of misfolded oligomers.
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Chapter 1
Quantifying protein homeostasis in
ageing and neurodegeneration
1.1 Ageing and neurodegeneration
1.1.1 A definition of ageing
Ageing has been described as a time-dependent functional decline associated with
an increase in probability of death and a diminution in fertility affecting essentially
all living organisms [1]. It is a very general phenomenon involving a variety of
processes at different biological scales, from the macroscopic scale of the whole
organism to the microscopic scales of cellular and molecular mechanisms [2]. At
the organismal level, some of the most familiar age-related phenotypes exhibited in
humans include the redistribution of body fat, greying and thinning of hair, loss of
vigour, muscle and skin tone [3]. While describing the ageing features may appear
straightforward, characterising the miscroscopic origins of the overall phenomenon
and the connections among all the different components is a complex task [4, 5]. Over
the last 30 years, ageing research has been greatly facilitated by the isolation of the
first long-lived strains in Caenorhabditis elegans (C. elegans) [6] which demonstrated
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that genetic pathways and biochemical processes conserved in evolution can control,
to some extent, the rate of ageing [7–14].
It has so become increasingly recognised that such progressive loss of physiolog-
ical integrity, impaired functioning and increased vulnerability to death characteristic
of the ageing phenotype can be directly related to the presence at a microscopic level
of a time-dependent accumulation of cellular and molecular damage. Ageing is thus
considered the primary risk factor for the most significant human pathologies of our
century, namely cancer, diabetes, cardiovascular disorders and neurodegenerative
diseases [9, 16–32].
1.1.2 Impact of neurodegenerative diseases
Of all the pathological conditions mentioned above, neurodegenerative disorders,
including Alzheimer’s, Parkinson’s and Huntington’s diseases, typical of aged in-
dividuals, have grown to become the most debilitating, common and expensive
medical conditions of our age [16, 23–25, 33–39]. By contrast, deaths from other
major causes have decreased significantly due to medical advances and improved
social and environmental conditions (see Fig. 1.2A). These improvements have
led to a substantial increase in the average human lifespan [40]. As a result, the
worldwide population aged 60+ is projected to more than double in size between
2015 and 2030 (see Fig. 1.1A), eventually reaching about 2.1 billion people (see Fig.
1.1), as presented in a 2015 United Nation report on world population ageing [15].
These ageing trends are not only restricted to the western wealthy areas. Increas-
ing of the life expectancy is affecting the human population globally. Indeed, the
biggest contribution to such an increase is estimated to come from the less developed
regions [15]. Also, in the more developed areas, the fastest growth rate will come
from the oldest people, those in age range over 80 years old, who will reach about
434 million in 2015, more than three-fold the number present in 2015 (Fig. 1.1).
Such an improvement in life expectancy, however, comes at a price. As neither
treatments nor efficient diagnostic tools have been found yet for neurodegenerative
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(A)
(B)
Fig. 1.1
Estimated population growth in 2000-2050
(A) Relative increase in world population by age group between 2000 and 2050.
Solid lines represent calculated values, while dashed lines indicate projections. (B)
Population size aged 60-79 years and 80+ years, separated by development group,
calculated in 2000 and 2015, and predicted for 2030 and 2050.
Figure reproduced from [15], see section 1.1.
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disorders, these diseases have become the most dreaded pathologies of old age
[16, 23–25, 33–39] not only in terms of mortality rate, but also in terms of social
and economic burden. Indeed, Alzheimer’s disease (AD) has been named "the
twenty-first century plague" [35, 41] and is the most common cause of dementia,
the condition of chronic cognitive decline that affect patient’s day-to-day functions
and spans multiple cognitive domains [36, 42–44]. In terms of mortality rates,
American records [24] report that deaths from AD are the only kind of deaths that
increased between 2000 and 2013, even massively (71%), compared to the current
most common causes of death by disease (see Fig. 1.2A). In terms of economical
and social burden, according to a 2011 economic report in the United Kingdom [43],
the figures for dementia expenses to the UK economy in 2008, combining social
care and health services, were about £10.5 billion, more than twice those for cancer
(£4.5 billion), and over three fold those for stroke (£2.7 billion) and Coronary Hearth
Disease (£2.3 billion).
1.1.3 Clinical features of neurodegenerative diseases
Despite the great social and economic burden that dementia has been causing, this
condition is still under-detected, under-diagnosed, under-treated and under-managed
in primary care [39]. As already mentioned, the term dementia usually refers to a
pathological state characterised by a progressive cognitive impairment, associated
with a decline in memory, reasoning and language, resulting into severe issues in
performing daily activities [25, 45]. Such impairment is the result of the damage and
death of neurons in the regions of the brain responsible for cognitive function. This
damage can be most often caused by four general categories of diseases: metabolic
deficiencies (such as B12 thyroid hormone deficiencies), infections (such as syphilis
and AIDS), structural lesions (such as neoplasm, tumours, and stroke), and neurode-
generation. However, since advanced diagnostic tests and early treatments currently
exist for the first three processes but not for neurodegeneration, the vast majority
1.1 Ageing and neurodegeneration 5
(A)
(B)
Fig. 1.2
Incidence of Alzheimer’s disease in the U.S. population
(A) Percentage changes between 2000 and 2013 in the current most widespread
pathological conditions. (B) Projected number of people in the US older than 65
suffering from Alzheimer’s disease, from 2010 to 2050, grouped by age ranges.
Figure reproduced from [25], see section 1.1.
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of patients suffering from dementia are those ending up having neurodegenerative
diseases [36].
Diseases belonging to this class are varied in symptoms and characteristics
[31, 46–55] as they target separate regions of the brain, especially in the early
stages of the pathology. Mapping the anatomical sites of dysfunction is currently
considered the most effective method for diagnosis. However, since there are no
definitive markers available yet for the regional mapping of different neurodegenera-
tive diseases, distinguishing among the different types of neurodegeneration remains
a current problem at the clinical level [36]. In case of Alzheimer’s disease, the
most widespread among the neurodegenerative disorders [25, 35–38, 56], cognitive
disability get combined with motility and swallowing problems, as neuronal damage
and destruction progressively affect other parts of the brain responsible for basic
bodily functions [57, 58]. As the transfer of information at the neuronal synapses
starts to fail, the number of synapses decreases and neurons die. In a later stage, the
increase of dead neurons leads to a dramatic shrinkage of the brain, and inflammation
is also observed [25]. At the latest stage, the individual becomes bed-bound and
eventually dies [25].
Despite the differences in the anatomical spreading patterns, brain regions in-
volved and consequent symptoms, neurodegenerative diseases share a common
attribute at the molecular level. While ageing is considered to be the greatest risk
factor, a nearly universal hallmark of these disorders, and a common feature of other
"non-neuronal diseases", like type II diabetes, is the formation and accumulation
of protein aggregates, in the form of amyloid deposits [35, 59–63]. For this reason,
such diseases have also been called protein conformational or misfolding diseases
[59–62]. Description of this process and its relation with ageing, disease and cellular
impairment will be discussed in section 1.2.3.
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1.2 Protein homeostasis and aggregation
1.2.1 The role of protein homeostasis in ageing
and neurodegeneration
We have seen in section 1.1 how the ageing mechanism has recently gained the
interest of the scientific community with the increase of the average human lifespan
and concomitant diffusion of neurodegenerative disorders. Each level of biological
organisation at which the ageing process can be defined is characterised by one or
more physiological and cellular change, but the interplay between these processes
and their causality relations are far from being fully understood [4]. The first attempt
to define and categorise the main cellular hallmarks of ageing only dates to four
years ago [9]. In that work, nine candidate hallmarks were proposed to contribute to
the mammalian ageing process, and were functionally categorised as:
• primary cause of the cellular damage
• response to the damage
• subsequent reflection on the phenoype
Four physiological sources were suggested as primary cause of the cellular
damage: genomic instability, telomere attrition, epigenetic alterations, and loss of
protein homeostasis [64]. Of these four, the latter has emerged as a important factor
also in neurodegenerative diseases [64–67]. Improving protein homeostasis through
genetic manipulations has been shown to delay ageing in mammals [68, 69], while
perturbation of protein homeostasis has been associated with ageing and fastening of
age-associated pathologies [70–73].
Protein homeostasis refers to the state in which the proteome of a living organism
is in functional balance, by the production and maintenance of correctly folded and
soluble proteins [75, 76]. There are various biological mechanisms responsible for
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(A)
(B)
Fig. 1.3
The protein states and protein homeostasis network (PN)
(A) Diagram of the possible states in which a protein can exist coupled with the PN
pathways which ensure the functional balance of the proteome through the three
mechanisms of protein biogenesis (yellow components in the figure), maintenance
(blue components in the figure) and degradation (red components in the figure)
which control the levels of functional proteins and prevent or reduce the formation
of toxic aggregates. (B) Approximate numbers of the PN components of the human
proteome. 200 of the 1400 unities are molecular chaperones (shown in green).
Adapted from [67, 74] and [61].
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protein homeostasis. Some have been conserved through evolution, while others
have appeared more recently with the increasing complexity of cellular constituents,
networks and organisms [74, 77, 78]. The main mechanisms responsible for the
regulation of the folding state and the concentration distribution of the proteome can
be grouped into three categories (see also Fig. 1.3):
• protein biogenesis, from transcription to translation
• protein maintenance, i.e. folding and refolding by molecular chaperones
• protein degradation, like autophagy and the proteasome system
These array of quality controls processes are necessary for cells to preserve the
functionality and stability of their proteomes [70, 71, 79, 80].
1.2.2 The interplay of protein homeostasis and aggregation
Despite the great variety of such control mechanisms, as organisms age a progressive
decline of protein homeostasis occurs as the cellular stress response and quality
control become compromised [68, 73, 81].
In addition, disruption of protein homeostasis may occur when proteins fail to
stay soluble and aggregate into non-functional and/or toxic species [82, 83]. This
could produce an alteration of the normal protein homeostatic mechanism. One
example is the failure of the proteasome in degrading insoluble protein aggregates
and its subsequent loss of function from the association with the aggregates [84–
86]. Also molecular chaperones, which are responsible for the protein maintenance
machinery, have been seen to bound with aggregates in dynamic and complex ways
[87–89]. Inhibiting these homeostatic mechanisms place a burden to the cell. This,
in turn, can degenerate into a positive feedback loop in which the cell produce more
proteins that aggregate, as they cannot be degraded nor refolded, and cause further
inhibition of protein homeostasis (see Fig. 1.4, reproduced from [67]).
10 Quantifying protein homeostasis in ageing and neurodegeneration
Fig. 1.4
Cycle of cellular impairment in ageing and disease
Aberrant misfolded species chronically produced with age, stress or disease place a
burden to the protein homeostasis network (PN). Inhibition of this network in turns
worsen the clearance of the non-functional/toxic aggregated species, which keep
engaging the PN components impairing further the protein homeostasis and
eventually leading to its collapse.
Figure reproduced from [67].
The features of protein homeostasis impairment and widespread aggregation oc-
curring during the ageing process will be the subject of Chapter 2, a work performed
from the collaboration with the group of Prof. F. Ulrich Hartl at the Max Planck
Institute of Biochemistry in Martinsried, Germany [90].
1.2.3 Protein aggregation in neurodegeneration
Even if aggregation of non-disease related proteins has been recently observed to
occur upon stress [91, 92] and during the ageing process [90, 93–95], the formation
of protein aggregates and their implication in the failure of cellular machinery have
first raised an interest in both the research and medical community because associated
with a great variety of human diseases, from Type II diabetes and liver and skin
amylodosis to neurodegenerative disorders [96, 59–62, 97, 98]. These diseases
are very diverse in symptoms and span over organ and tissue types [62], however
they all share a common feature: the pathology involves the aggregation of one or
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Fig. 1.5
Protein aggregates in brain patients affected with neurodegenerative
disorders
Disease-specific proteins are shown in brown.
Figure reproduced from [99].
more proteins, specific to the disease (see Fig. 1.5, reproduced from [99]). For this
reason, diseases that seem so diverse have been grouped and classified as protein
conformational or misfolding diseases. A list of the most widespread disorders
among the various that fall under the category of misfolding diseases, together with
the information on the characteristic aggregating protein, are found in Table 1.1.
The most notorious subset of disorders among the protein misfolding diseases
is represented by the neurodegenerative pathologies like Alzheimer’s disease (AD),
Parkinson’s disease (PD), and Huntington’s disease (HD). In the case of AD, the
accumulation of the protein amyloid-β outside neurons and of the protein tau intra-
cellularly into amyloid aggregates, named respectively amyloid-β plaques and tau
neurofibrillary tangles, represents the characteristic molecular fingerprint observed in
the brains of patients affected by the disease. According to the "amyloid hypothesis"
[59, 62], these aggregates are considered to contribute to the damage and destruc-
tion of neurons that result in memory loss and other symptoms of the pathology.
While amyloid-β is believed to interfere in the inter-neurons communication at the
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Table 1.1
Some of the various human disorders associated with amyloidosis
Adapted from [96].
Disease Aggregating protein/peptide Length
Neurodegenerative diseases
Alzheimer’s disease Amyloid-β peptide 37-43
Creutzfeldt-Jakob diseases Prion protein or its fragments 208
Gerstmann-Straussler-Scheinker disease Prion protein or its fragments 208
Kuru Prion protein or its fragments 208
Spongiform encephalopathies Prion protein or its fragments 208
Huntington disease-like 1 Prion protein or its fragments 208
Parkinson’s disease α-synuclein 140
Dementia with Lewy bodies α-synuclein 140
Multiple system atrophy α-synuclein 140
Pick disease Microtubule-associated protein tau Variable
Progressive supranuclear palsy Microtubule-associated protein tau Variable
Corticobasal degeneration Microtubule-associated protein tau Variable
Argyrophilic grain disease Microtubule-associated protein tau Variable
Tangle predominant dementia Microtubule-associated protein tau Variable
Guam Parkinson dementia complex Microtubule-associated protein tau Variable
Frontotemporal lobar degeneration Microtubule-associated protein tau Variable
Chronic traumatic encephalopathy Microtubule-associated protein tau Variable
Hallervorden-Spatz disease Microtubule-associated protein tau Variable
Lipofuscinosis Microtubule-associated protein tau Variable
Amyotrophic lateral sclerosis Superoxide dismutase 1 153
Huntington’s disease Huntingtin fragments Variable
Familial amyloidotic polyneuropathy Transthyretin mutants 127
Familial British dementia ABri peptide 34
Familial Danish dementia ADan peptide 34
Non-neuropathic systemic amyloidosis
Light chain (AL) amyloidosis Immunoglobulin light chains/fragments ∼90
Heavy chain (AL) amyloidosis Immunoglobulin heavy chains/fragments ∼190
AA amyloidosis Serum amyloid A protein fragments 45-104
Senile systemic amyloidosis Wild-type transthyretin 127
Familial amyloidotic polyneuropathy Wild-type transthyretin 127
Familial amyloid cardiomyopathy Wild-type transthyretin 127
Dialysis-related amyloidosis β2-microglobulin 99
Lysozyme amyloidosis Lysozyme mutants 130
Apolipoprotein amyloidoses Apo A-I, A-II, A-IV, C-II, C-III fragments Variable
Familial finnish amyloidosis gelsolin fragments 53 or 71
Non-neuropathic localized amyloidosis
Type II diabetes Islet amyloid polypeptide 37
Insulinoma Islet amyloid polypeptide 37
Medullary carcinoma of the thyroid Calcitonin 32
Atrial amyloidosis Atrial natriuretic factor (ANF) 28
Pituitary prolactinoma Prolactin fragments 34
Aortic medial amyloidosis Medin 50
Gelatinous drop-like corneal dystrophy Lactotransferrin 691
Injection-localized amyloidosis Insulin 21 and 30
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synapses, tau tangles seem to interfere with the intracellular transport of nutrients in
the neurons, both processes contributing to cell death [25]. In the case of PD, the
protein involved in the pathological aggregation is α-synuclein, a presynaptic protein
140 amino acids long, involved in vesicular transport [100–102]. Fibrillation of
α-synuclein happens intracellularly in the dopaminergic neurons cell body, starting
from brainstem structures (substantia nigra) and spreading to limbic and neocortical
areas in the later stages of the disease [48, 46]. The formed aggregated structures are
named Lewy bodies.
1.2.4 The generality of the aggregation process
Table 1.1 shows that each neurodegenerative disease involves the aggregation of one
or more specific proteins. Despite the different nature of these proteins, the final
structures in the aggregation process, the amyloid fibrils, have common characteris-
tics that are independent of the constituting protein [103–106]. Amyloid structures
appear as unbranched thread-like structures with diameters in the nanoscale and
length ranging even up to micrometers, composed of multiple protofilaments twisted
around each other [107]. They are highly ordered, closely packed, and possess a
generic cross-β architecture [63, 108–112]. The cross-β structure allows the forma-
tion of a continuous array of hydrogen bonds along the length of the fibril, giving it
high stability [107, 113, 114].
The observation that amyloid fibrils of different proteins possess this generic con-
served architecture prompted the hypothesis that aggregation is a general mechanism
that any polypeptide chain can be subject to. Evidence in support of this hypothesis
has been reported both with in vitro and in vivo experiments. In the first case, it has
been shown that almost every protein, even unrelated to diseases, can aggregate into
amyloid fibrils under specific conditions [60, 115, 116]. In the latter case, work on
C. elegans and yeast showed that many proteins unrelated to disease are found to
form aggregates (widespread aggregation, see Chapter 2) with ageing or under stress
conditions (e.g. starvation) [83, 93, 94, 117].
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Fig. 1.6
Diagram of the energy landscape for the reactions of folding and aggregation
Competing reactions of protein folding and aggregation. A protein folds into its
native functional state by sampling various intermediate conformations in a folding
energy landscape. Energetically favourable intramolecular interactions (green) drive
the protein progressing toward the native state, with the help of molecular
chaperones. Molecular chaperones also try to avoid the formation of energetically
favourable but nonnative conformations which happen when intermolecular
interactions (red) occur and start the aggregation process. The amyloid fibrillar state
resulting at the end of the aggregation process is the most thermodynamically stable.
Adapted from [67, 74] and [61].
The hypothesis that every protein, under given conditions, can aggregate into an
amyloid fibrillar structure implies that the amyloid structure form is a physical state
that any protein in principle can assume. Furthermore, it implies that under those
specific conditions the amyloid state is more thermodynamically stable than the
functional native state of the protein itself [60, 74, 118, 119]. Strikingly, increasing
evidence is showing that for many protein the amyloid fibrillar conformation might be
the state of lowest free energy even under physiological conditions [106, 119–121].
The conditions under which a protein is pushed out of its soluble native-like
state and aggregates depend on both the difference in energy between the native
and amyloid state, and the height of the kinetic energy barrier that needs to be
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overcome in order for this transition to occur [83, 106, 120, 122–128]. The amyloid
state is characterised mostly by the intermolecular interactions, in contrast to the
soluble native state in which intramolecular interactions dominate [61]. Since
the conversion of proteins from the soluble to the aggregated state involve the
formation of intermolecular contacts, a key role for the thermodynamic stability of
the amyloid state is played by protein concentration. Indeed, as protein concentration
increases, the ability to form intermolecular contacts becomes higher and favours
the thermodynamic stability of the amyloid state, since the native state can be to
a good approximation considered independent of the concentration [61, 120, 129].
Eventually, a critical concentration will be reached over which the free energy of the
amyloid state will be lower than that of the native state.
Some proteins, however, have been reported to exist in vivo at physiological
concentrations higher than the critical concentration [76, 120, 130, 131]. In this
scenario, either spontaneous aggregation occurs; or high kinetic energy barriers
prevent the transition from the native to the amyloid state, and the native state
becomes metastable [119–121]. In vivo, the kinetic barrier is enhanced by the
presence of molecular chaperones and the protein homeostasis network, which help
proteins staying in their native state and prevent them from aggregate [77, 79, 120,
132, 133] (see Fig. 1.6). Whether the critical concentration in vivo is a general
threshold for every protein under given conditions or is a protein-dependent value
will be discussed in Chapter 3, with the results obtained from the measurements of
proteome-wide protein abundances in C.elegans.
1.2.5 Oligomers toxicity in the amyloid hypothesis
The conversion of a protein from its soluble native form to the amyloid state is a com-
plex self-assembly mechanism which involves the formation of multiple precursor
soluble and insoluble species [98, 120, 123, 134–139]. These intermediate structures
differ in size and characteristics, and range from early-stages small heterogeneous
oligomeric assemblies to protofibrillar structures,smaller in length and width than the
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final amyloids but organised in the same cross-β structure [105, 140, 141] (Fig.1.3A
and Fig.1.6). Fig.1.3A and Fig.1.6 also show that amorphous aggregates can be
formed, as an alternative pathway to the amyloid state formation [142, 143].
Despite the fact that the current diagnosis of neurodegenerative diseases is based
on the spatial spreading pattern of amyloid fibrils, and the amyloid formation has
been associated with the onset of the pathological event, little is known about the
specific mechanisms of toxicity of the aggregates in the pathology [144–146]. While
in systemic amyloidoses the mass of large fibrils in vital organs seems to represent
the primary cause of the disease [62], an increasing number of studies now identifies
the oligomeric pre-fibrillar species as the main pathogenic agents in neurodenerative
diseases [62, 98, 115, 146, 147].
Fig. 1.7
Oligomers are more toxic to cells than larger aggregates
Toxicity versus size of Aβ40 and Aβ42 aggregates, measured by treating cultured
cells with oligomers added to the extracellular medium and quantifying their MTT
reduction relative to untreated cells. Aggregate toxicity is expressed as percentage of
MTT reduction where the extremes, 0% and 100%, represent full cell death and full
cell viability respectively. Small oligomeric species are found to compromise cell
viability much stronger than fibrils and bigger aggregated species.
Figure reproduced from [148].
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This hypothesis is the results of multiple observations: from the presence of
many cases in which the amount of fibrillar aggregates does not correlate with the
spreading of the disease [144, 145], to the evidence that oligomeric intermediates
formed during the aggregation process are more toxic to cells than the mature
amyloids (see Figure 1.7) [98, 115, 146–151]. Misfolded oligomers originated from
proteins not associated with any pathology have also been demonstrated to bring
damage to cells by making inappropriate interactions with lipid membranes and other
functional cellular components [98, 150, 152]. Formation of larger structures like
fibrils could be, in this context, a cellular response to the oligomeric damage. Indeed,
we have detected the formation of bigger and more insoluble deposits have been
detected in a long-lived strain of C. elegans. Results of this study, especially in terms
of the physico-chemical principles of the insoluble aggregates, will be discussed in
Chapter 2 and are found in [90].
In Chapter 4 we will present results on the interaction of misfolded oligomers that
were found to mimic synaptic toxicity [152] with the functional cellular component
that perform the vast majority of biological activities in the cell: the proteome.
This results will provide insights in understanding how protein homeostasis can
be potentially affected upon the presence of early-stages aggregated species in
neurodegeneration.
1.3 Mass spectrometry-based proteomics
1.3.1 Tools to measure the molecular changes in ageing
and neurodegeneration
So far, large-scale studies of the molecular factors associated with ageing and neu-
rodegeneration have been mainly performed using genomics and transcriptomic
approaches [4, 8, 153–157]. These studies tend to come from two different perspec-
tives. On one side, they focus on finding features associated with longevity and
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exceptional lifespan, predisposition and cause of disease, mostly in terms of genetic
mutations. Genome-wide association studies (GWAS) have recently emerged as
a powerful technique to address this task [154, 156, 158, 159]. On the other side,
gene and mRNA expression analyses have become common practise to identify
molecular changes that occur in healthy ageing and in neurodegeneration, either
upstream as fingerprint of vulnerability or downstream as a response to the damage
[155, 157, 160–162]. The systematic use of both techniques has also prompted
the creation of numerous tools and databases aimed at integrating, collecting and
extracting the biology and genetics of ageing and neurodegeneration from these
large-scale information data [4, 157, 163, 164].
However, techniques that work at the gene and mRNA level provide only one type
of information concerning what happens in a cell [165, 166]. In the cell, essentially
all processes are catalysed and controlled by proteins, which account altogether for
about 50% of the cell dry mass, with a concentration of more than 106 entities per
cell volume [167].
Biophysics and biochemistry methods are conventionally used to isolate specific
proteins and analyse their function and structure, but there are various ways in which
proteins carry out their task and influence the behaviour of the cell in the cell: they
can work at specific times, in precise locations, by themselves or in association with
other proteins and molecules, organised in networks and structures. Collectively,
proteins form a "proteome network" which determines the phenotype of the cell and
is responsible for its functional state by dynamically adapting to external or internal
perturbations, including genetic modifications [168].
Also, for any given protein a wide range of processes are required for its produc-
tion and maintenance: from the transcription, processing and degradation of mRNAs,
to the translation, localisation and degradation of the subsequent protein itself. The
dynamic balance of these processes determines the cellular protein abundance at any
given time, which in turns contributes to the balance of the proteome network and
the maintenance of the protein homoestasis.
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(A)
(B)
Fig. 1.8
Individual and functional-associated comparison of mRNA levels and protein
abundances
(A) mRNA abundances do not correlate much with their respective proteins levels,
as it is shown in the scatterplot on the left from data on mouse fibroblast cells where
5028 proteins and corresponding transcripts were quantified. On the right, a pie
chart obtained from human DAOY medulloblastoma cell line shows that mRNA
abundances can explain only for 30-40% of the variance in protein abundance.
Figure reproduced from [166]. (B) An example of scatterplot, from yeast cells
proteomics and transcriptomics measurements, of the 2D-annotation enrichment
[169] that quantitatively estimates significant upregulation or downregulation of
entire biological processes and protein functional classes between the transcriptomic
level and the proteomic level. Some processes belonging mostly to mitochondrial
pathways are upregulated at the transcriptomic level compared to the proteomic
level, while proteins belonging the amino acid transmembrane transport process and
the glucose transport show an opposite behaviour. Figure reproduced from [169].
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The importance of protein homeostasis and aggregation in ageing and neurode-
generation has thus prompted the need of large-scale studies of protein abundances
and interactions. Since GWAS studies cannot monitor expression levels, the most
common procedure so far consisted in using mRNA concentrations as proxies of
activity and concentrations of the corresponding proteins. This choice follows the
assumption that transcript levels are the main determinants of protein abundances.
However, recent evidence obtained from actual measurements of protein abundances
(see section 1.3.2) shows that for almost every organism tested, mRNA levels do not
mirror cellular protein levels, but can only account for one to two third of their varia-
tions in the cell [166, 170, 171] (see Fig. 1.8A). This suggests that other processes
beside and downstream mRNA translation, like post-transcriptional and translational
regulation and protein degradation can give a dominant contribution to the regulation
of protein expression levels. Moreover, the poor correlation between mRNA and
protein abundances is not only restricted to single expression levels, but sometimes
even involves the differential expression of entire biological pathways or functional
components [169] (Figure 1.8B). For this reason, an accurate quantification of direct
protein levels becomes fundamental for the study of protein homeostasis and protein
interactions.
1.3.2 Mass Spectrometry-based proteomics for the direct
measure of proteomes and protein interactions
In the last decades, major technological improvements in mass-spectrometry (MS)-
based methods boosted the field of proteomics, the scientific area that aim to quanti-
tatively study the proteome and the mechanisms that it mediates [172–192]. In terms
of instrumentation, the development of the Orbitrap detector in 2005 [193] repre-
sented a milestone for the diffusion and affordability of rapid, high-sensitivity mass
spectrometers, and permitted the nearly complete analysis of proteomes, an approach
now addressed as "shotgun proteomics" [166, 181, 183, 188, 189, 194]. In such ex-
periments, complete proteomes or proteins in a complex mixtures are enzymatically
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digested and subsequently separated and analysed by nanoflow chromatography and
high-resolution tandem mass spectrometry [172, 176, 179, 181, 183, 188, 195, 196].
This allows the identification of up of thousands proteins in a sample ("bottom-up
proteomics").
Fig. 1.9
Bottom-up proteomic workflow for shotgun proteomics
Proteins are first enzymatically digested, usually by trypsin protease, then separated
by nanoflow chromatography and subsequently electrosprayed and analysed by
high-resolution tandem mass spectrometry (MS), usually with an Orbitrap machine
[193]. The first level of MS (MS1) acquires a full spectrum of the peptides that were
eluting in the column in each recording time frame (MS run), while the second level
(MS2) further fragments the most abundant MS1 peptides for identification of their
amino acid sequence. Software packages can process the spectra and determine the
protein content of the sample. Figure reproduced from [197].
A schematic representation of this MS-based proteomics workflow is shown
in Fig. 1.9. The sample preparation is the first stage of the workflow, in which
proteins are extracted from the sample and digested by a sequence-specific enzyme
like trypsin. The peptides obtained from enzymatic digestion are then separated
via liquid chromatography and electrosprayed before entering the vacuum of the
mass spectrometer. As already mentioned, the most common mass spectrometer for
bottom-up proteomics is the Orbitrap type mass analyser [193], which consists of
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two MS levels: a first level (MS1) which allows the acquisition of the full spectrum
of peptides eluting in the column with their intensities, followed by a second level
(MS2) which collects of as many fragmentation spectra as possible, within a cycle
of 1-3 seconds, in order to identify the amino acid sequence of the most abundant
peptides detected in the MS1 [168, 180, 193]. Resulting MS1 and MS2 spectra can
be processed to obtain peptides identifications as well as protein identifications from
the mapping of detected peptide sequences with a proteome sequence database.
This bottom-up proteomics approach has also been able to become quantitative
[177, 198–201] with the development of data-processing software packages, which
measure either spectral counts or ion intensities derived from each peptide, and
reconstruct the signal of the parental protein. Among the softwares available that
process the MS-MS data and measure ion intensities, which have been demonstrated
to be more robust indicator of the protein levels in a sample than spectral counts
[177, 202, 189, 203], the MaxQuant software has become highly recommended for
proteome-wide protein quantification analyses, both in labelled or label-free condi-
tions, thanks to his high peptide identification rates, mass accuracy and quantification
technology [203–206].
In MaxQuant, peptide quantities are determined at the MS1 level by integrating
the signal from peaks of the ions that elute from the chromatography column, with
an alignment and normalisation step that allows comparison across MS runs. Also,
a "match between runs" feature is present in the software to maximise the number
of peptides identified and decrease the noise in their quantification, by transferring
the information of peptide identity among runs in which the same aligned peak has
been found (with same mass and elution time) but was not fragmented. The protein
content of the sample is identified by mapping all detected and quantified peptides
sequences to a database of protein sequences, which is the proteome (or protein
mixture) of reference for the sample. The list of protein sequences in the reference is
usually given as an input from the user, as it is experiment-dependent (e.g. in terms
of organism or condition). In case of sequence degeneration, which occurs when a
group of peptides is found to map multiple proteins (e.g. in case protein isoforms),
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a single protein cannot be matched from the peptides and the ensemble of proteins
containing the peptide sequences is reported (protein group). Absolute quantities
for each protein (or protein group) can be estimated by summing up the intensities
from the peak volumes of all peptides identifying the protein and normalising with
respect to the number of theoretically expected peptides for that protein sequence
upon in silico digestion with the enzyme used in the experiment: this method is
called intensity-based absolute quantification (iBAQ) [203].
Overall, these recent advances in both instrumentation and downstream data
analysis now show the capability of the MS-based proteomics technologies to both
identify and accurately quantify proteins in large mixture, in either a labelled or
label-free environment [207, 208], which represent a key step for the large-scale
study of the proteome and of its interactions. In particular, it represents an invaluable
resource for the investigation of protein homeostasis and widespread aggregation
under various conditions, like ageing or neurodegeneration.
1.4 Overview
We described in section 1.2 the central role of protein homeostasis in ageing and
neurodegeneration, and the hypothesis of misfolded oligomers toxicity in the neu-
rodegenerative process. In this work, we studied these phenomena using MS-based
proteomics coupled with sequence-based prediction algorithms and bioinformatic
functional annotation analyses.
In Chapter 2, we will show how this approach can be applied to the identification
of the features and physico-chemical principles responsible for age-related protein
homeostasis impairment and widespread aggregation in the nematode C.elegans.
In Chapter 3, we will provide the first proteome-level support to the observation
that proteins are expressed in the cells at their solubility limits. This hypothesis
was firstly postulated by Tartaglia and co-workers based on a strong anticorrelation
between the aggregation rates measured in vitro of the limited group of proteins
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available in the literature at that time and the corresponding human mRNA expression
levels measured in vivo [130].
In Chapter 4, we perform MS proteomic analysis to identify and quantify the the
interaction of proteins with misfolded oligomers, the potential most toxic species of
the aggregation process. In this chapter, we couple the processing of MS data with
bioinformatic functional annotation analysis to obtain biological insights into the
interactions that oligomers can make, providing the functional oligomer interactome.
Both knowledge of the features of the proteome, its impairment with ageing,
and its potential interaction with misfolded oligomers represent key questions for
the understanding of neurodegeneration and may give rational insights for potential
prevention or therapeutic approaches. Mass spectrometry and the recent advances
in the technique are now allowing quantification of protein abundances in vivo on a
proteome-wide scale, therefore this technique combined to our algorithms can be
extremely useful in tracking upon aging the changes in the proteome system that
result into protein homeostasis impairment.
Lastly, Chapter 5 shows the ensemble of results obtained from this work and the
future perspectives that this study has opened.
Chapter 2
Protein homeostasis imbalance
and widespread aggregation
in ageing C. elegans
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2.1 Summary
The content of this chapter is a published research article [90], which has been
reprinted in section 2.3 with permission from Elsevier.
During my PhD studies, I contributed to the development of a computational
method, called CamSol intrinsic, to determine the aggregation propensity of a
protein/peptide, together with an array of other physico-chemical properties, from
the information of its primary sequence only (see section 2.2). In this work, I use
the CamSol instrinsic method and the s2D predictor [209] to understand physico-
chemical principles underlying the age-related disruption of protein homeostasis and
the widespread aggregation observed in nematode C.elegans.
The proteome in WT, long-lived and short-lived nematode strains was quantified
upon ageing with MS in the group of Prof. F. Ulrich Hartl at the Max Planck Institute
of Biochemistry, Germany. The main results of the analysis that I performed by
complementing the biological information of the absolute abundances and relative
changes in the both total protein concentration and the aggregated fraction with the
results from the sequence-based physico-chemical and secondary structure calcula-
tions are shown in Figure 5 (D to G) and in Figure S5 (B and C) of the article (see
section 2.3).
The analysis of physico-chemical properties from CamSol instrinsic and average
coil propensity calculated from s2D was able to provide insightful information on
the difference between the widespread aggregation observed in long-lived animals
compared to short-lived animals. This, in turn, led to the first formulation of the
hypothesis that the process of protein aggregation might be triggered by the cell as a
mechanism for restoring protein homeostasis or delaying proteostasis impairment, a
key novelty in the paper. Also, it revealed that the aggregation propensity of proteins
is modulated by their abundance distribution in the cell, prompting the investigation
of the proteome-wide evidence of the life on the edge hypothesis (see Chapter 3).
2.2 The Camsol Intrinsic method 27
2.2 The Camsol Intrinsic method
Camsol Intrinsic is a computational method developed in this thesis in collaboration
with Dr. Pietro Sormanni. Primarily, it is an extension of the Camsol method [210]
tailored to the in silico sequence-based prediction of the aggregation propensities of
proteins on a proteome-wide scale, but it also allows the calculation of an array of
other key physico-chemical properties related.
There are two main reasons behind the choice of developing a sequence-based
prediction method over a structure-based method for the analysis of proteome-wide
data:
1. the amount of information available
2. the presence of intrinsically disordered proteins (IDPs) and proteins with
intrinsically disordered regions (IDRs)
Regarding point 1, in fact, despite the great increase in the number of protein
structures resolved in the recent years, the number of protein structures available is
still an order of magnitude less than the number of protein sequences. To date, the
number of all sequences present in the Uniprot database of proteins and peptides
counts ∼ 109 entries of which more than 550000 manually reviewed [211, 212],
compared to the∼ 130000 structures stored in the Protein Data Bank (PDB) database
[213, 214].
Also, it has become clear that not all proteins possess a stable structured fold
but some are naturally structurally disordered (IDPs) or contain long stretches of
disordered regions (IDRs) [215–218]. Such proteins play important functions in
the cell, such as signalling and regulation [219–221]. Most importantly, more and
more recent studies have highlighted that such proteins are extremely abundant in
cells and especially in eukaryotic systems, where they make up ∼ 30%−45% of the
proteome [217, 220, 222–228]. Given that about a third of the proteome consists
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of IDPs, the choice of choosing a sequence-based prediction method should allow
consistent results to be obtained for high-throughput experimental data.
Given the amino-acid sequence, CamSol intrinsic evaluates the net charge, the
fraction of charged residues, the average and total hydrophilicity and predicts an
intrinsic aggregation propensity score, which represent the inherent predisposition of
the protein/peptide to aggregate. In particular, CamSol intrinsic allows to evaluate the
most/least vulnerable proteins of an ensemble (or a proteome) in terms of aggregation,
by ranking them according to their CamSol intrinsic aggregation score (called
zscore).
The method relies on the use the CamSol method [210] for the calculation
of the residue-specific properties profiles from which the global properties are
obtained with an optimisation strategy that allows comparison of the scores among
different proteins of a proteome, unlike the CamSol method itself which is optimised
for detecting differences in solubility from small variations in the sequence of
a given protein [210], or the Zyggregator method [229] which was developed to
specifically estimates amyloid aggregation rates of proteins. Details of the method are
found in the supplementary information, section "In Silico Aggregation Propensity
Calculation", in section 2.3.
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SUMMARY
Aging has been associated with a progressive
decline of proteostasis, but how this process affects
proteome composition remains largely unexplored.
Here, we profiled more than 5,000 proteins along
the lifespan of the nematode C. elegans. We find
that one-third of proteins change in abundance at
least 2-fold during aging, resulting in a severe prote-
ome imbalance. These changes are reduced in the
long-lived daf-2 mutant but are enhanced in the
short-lived daf-16 mutant. While ribosomal proteins
decline and lose normal stoichiometry, proteasome
complexes increase. Proteome imbalance is accom-
panied by widespread protein aggregation, with
abundant proteins that exceed solubility contributing
most to aggregate load. Notably, the properties by
which proteins are selected for aggregation differ in
the daf-2 mutant, and an increased formation of ag-
gregates associated with small heat-shock proteins
is observed. We suggest that sequestering proteins
into chaperone-enriched aggregates is a protective
strategy to slow proteostasis decline during nema-
tode aging.
INTRODUCTION
Protein homeostasis (proteostasis), the state in which the prote-
ome of a living organism is in functional balance, must be tightly
controlled within individual cells, tissues, and organs. Maintain-
ing proteome balance requires a complex network of cellular fac-
tors, including the machineries of protein synthesis, folding, and
degradation (Balch et al., 2008; Hartl et al., 2011), as well as
neuronal signaling pathways that regulate proteostasis at the
organismal level (Prahlad and Morimoto, 2009; Taylor and Dillin,
2013; van Oosten-Hawle and Morimoto, 2014). An important
function of these systems is to prevent the accumulation of
potentially toxic misfolded and aggregated protein species
(Knowles et al., 2014). However, as organisms age, quality con-
trol and the cellular response to unfolded protein stress become
compromised (Ben-Zvi et al., 2009; Douglas and Dillin, 2010),
and the defense against reactive oxygen species declines (Finkel
and Holbrook, 2000). Indeed, aging is considered the principal
risk factor for the onset of a number of neurodegenerative disor-
ders associated with aggregate deposition, such as Alzheimer’s,
Huntington’s, and Parkinson’s diseases (Knowles et al., 2014).
The accumulation of aberrant protein species in these pathologic
states in turn places a burden on the proteostasis machinery and
thus may accelerate aging by interfering with protein folding and
clearance, and other key cellular processes (Balch et al., 2008;
Gidalevitz et al., 2006; Hipp et al., 2014; Olzscha et al., 2011).
Understanding these relationships requires systematic analyses
of the changes that occur in proteome composition and balance
during aging.
The nematode C. elegans is one of the most extensively stud-
ied model organisms in aging research, owing to its relatively
short lifespan and the availability of genetic tools to identify path-
ways that regulate longevity. Inhibition of the insulin/insulin-like
growth factor 1 signaling (IIS) pathway in strains carrying muta-
tions in the DAF-2 receptor (or the downstream PI(3) kinase
AGE-1) activates the DAF-16/FOXO transcription factor and
leads to a dramatic lifespan extension (Kenyon et al., 1993;
Murphy et al., 2003). Several lines of evidence suggest that the
lifespan-prolonging effect of IIS reduction involves an improve-
ment in cellular stress resistance and proteostasis capacity
through upregulation of the machineries mediating protein
folding and preventing the formation of toxic aggregate species
(Morley et al., 2002; Cohen et al., 2009; Demontis and Perrimon,
2010). In addition to DAF-16 activation, the longevity phenotype
in daf-2mutants requires the function of HSF-1, the transcription
factor regulating the expression of multiple heat-shock proteins
and molecular chaperones (Hsu et al., 2003; Morley and Mori-
moto, 2004). These pathways of proteostasis maintenance
appear to be conserved in evolution from worms to mammals
(Cohen et al., 2009; Demontis and Perrimon, 2010).
Aging and the effect of the IIS pathway have been studied in
C. elegans by transcriptome analysis (Budovskaya et al., 2008;
Golden and Melov, 2004), but only limited information exists
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Figure 1. Proteomic Analysis of Aging in C. elegans
(A) Experimental design of total proteome analysis. Synchronized worm populations at different time points were lysed and mixed with a metabolically (SILAC)
labeled internal protein standard. After digestion, peptides were either analyzed directly or after fractionation by isoelectric focusing, followed by nano-HPLC
coupled MS.
(B) Proteome changes in WT animals 6, 12, 17, and 22 days of age relative to day 1 animals (Table S1B). The proportions of proteins that are at least 2-fold
increased or decreased in abundance are marked in yellow or blue, respectively.
(C) Contribution to the total proteome of the proteins that change at least 2-fold in abundance between young (day 1) and aged (day 22) animals, as displayed in (B)
and estimated by label free quantification (absolute LFQ) (Table S1B).
(D) Proteome changes in subcellular compartments. The fractions of the total proteome that increased (yellow) or decreased (blue) at least 1.5-fold in abundance
in old (day 22) versus young (day 1) animals are shown. The color grey represents proteins that remained within the indicated abundance thresholds. Numbers of
identified proteins are indicated. Protein subcellular localization was predicted using WoLF PSORT.
(legend continued on next page)
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about changes at the proteome level (Dong et al., 2007). Here,
we exploit the recent progress in mass spectrometry-based pro-
teomics, which now enables the identification and quantification
of thousands of proteins in complex mixtures (Bensimon et al.,
2012; Cox and Mann, 2011). We applied stable isotope labeling
with amino acids in cell culture (SILAC) (Ong et al., 2002) to pro-
file the abundance levels of more than 5,000 different proteins at
multiple time points during the lifespan of C. elegans. We then
extended our study to short-lived and long-lived strains carrying
mutations in the IIS pathway and performed a detailed analysis
of age-related protein aggregation. Our data show that during
aging, the proteome of the animal undergoes extensive remod-
eling, escaping proteostasis, and ultimately reaching a state of
marked proteome imbalance. These changes are accompanied
by widespread protein aggregation, with abundant proteins that
exceed their solubility limit making the major contribution to
aggregate load. Interestingly, the intrinsic aggregation propen-
sity of proteins is modulated in long-lived daf-2 mutant worms,
resulting in the enhanced formation of chaperone-containing
aggregates. Thus, protein aggregation may occur not just as a
consequence of proteostasis decline, but may also be induced
to improve proteostasis by sequestering surplus, potentially
harmful protein species.
RESULTS
Extensive Proteome Remodeling during Aging
To study proteome changes in aging nematodes in depth and
with high accuracy, we established a quantitative proteomics
approach using SILAC (Ong et al., 2002). Near-complete incor-
poration of 13C6-
15N2-lysine into the proteome was achieved
by feeding worms with SILAC labeled (‘‘heavy’’) E. coli cells
(Larance et al., 2011). We used a pool of lysates prepared from
labeled worms of different ages as internal standards for quanti-
fying protein expression. These standards were added to lysates
of synchronized worm populations, followed by digestion and
peptide analysis by mass spectrometry (MS) (Figure 1A). Repli-
cate analyses indicated a high degree of reproducibility between
individual experiments (Figure S1A; Table S1A). We analyzed the
proteomes of adult wild-type (WT) worms from 1 day up to
22 days of age, when less than 30% of the animals remain alive
(L4 larval stage defined as day 0). More than 5,000 different
proteins were identified and quantified at a false discovery rate
of 1% (Table S1B).
Our analysis reveals a broad remodeling of theC. elegans pro-
teome during aging. About one-third of the quantified proteins
increased or decreased in abundance by at least 2-fold, when
equal amounts of total protein were analyzed (Figure 1B; Table
S1B). The proteins that increased by at least 2-fold amounted
to approximately 50% of total protein in aged animals, as deter-
mined by label free absolute quantification (absolute LFQ values)
(Schwanha¨usser et al., 2011) (Figure 1C). Protein abundance
changes were progressive until day 22 (Figures 1B and S1B;
Table S2A) and were observed in most cellular compartments
(Figure 1D). Thus, proteome composition and the relative stoichi-
ometries of proteins change dramatically during aging, presum-
ably impeding overall proteostasis. A similar mechanism of
proteostasis impairment has been suggested to occur as a result
of aneuploidy (Oromendia et al., 2012; Stingele et al., 2012).
Changes in transcript levels previously observed during aging
(Budovskaya et al., 2008; Golden and Melov, 2004) contribute
to the changes in protein abundance observed here, but the
overall correlation is only moderate (R = 0.3) (Figure S1C).
Thus, the age-dependent accumulation of a substantial fraction
of the proteome is likely to be largely due to posttranscriptional
processes. Taking into consideration that microRNA (miRNA)-
mediated translational repression of mRNAs is relieved during
aging and stress (Iba´n˜ez-Ventoso et al., 2006), we compared
our proteome data with a published transcriptome analysis of
Dicer mutant worms with defective miRNA biogenesis (Welker
et al., 2007). We find that 30% of proteins that increased
more than 2-fold between day 6 and 22 (99 of 357 proteins),
i.e., after the worms have reproduced, have significantly
elevated transcript levels in dicer mutants, and this proportion
increases to nearly 40% for the subset of proteins with a more
than 4-fold abundance change (50 out of 133 proteins) (Fig-
ure S1D). Thus, miRNA-mediated translational derepression
is likely to contribute to the observed increase in protein
abundance.
We analyzed the proteomic changes in C. elegans aging in
terms of various criteria, including subcellular compartments,
pathways, and cell types. Among the proteins that increased
more than 2-fold in aged worms (22 days) were 183 extracellular
proteins (out of 490 extracellular proteins quantified) (Figure S1E;
Table S2B). These included multiple transthyretin (TTR)-like
factors, which increased up to 100-fold (Figure S1F), as well as
all six of the vitellogenin egg storage proteins, despite egg for-
mation having been completed before day 6. Likewise, proteins
involved in DNA replication and repair processes were upregu-
lated (Figure S1E), even though all somatic cells of adult
C. elegans are postmitotic. These examples suggest that many
changes in protein abundance during aging do not correlate
with biologically relevant activities but instead reflect proteome
dysregulation. Among the proteins that declined during aging
are nucleolar ribosome biogenesis factors, various peroxisomal
enzymes, and proteins involved in lipid glycosylation (Figure S1E;
Table S2C). The levels of many mitochondrial proteins also
decreased (Figure 1D). For example, subunits of respiratory
chain complex I declined gradually by up to 50% during the life-
span (Figure S1G), which may result in the production of reactive
oxygen species.
To discern cell-type specific patterns of change, we grouped
proteins into clusters using the fuzzy c-means method (Kumar
and Futschik, 2007) and analyzed these by tissue-specific
expression scores (Chikina et al., 2009) (Figure 1E). We find
that age-dependent changes in proteome composition affect
(E) Clustering of time course expression patterns in WT animals using the fuzzy c-means algorithm (Kumar and Futschik, 2007). Significantly enriched tissues
as determined by Wilcoxon rank sum test at 2% false discovery rate against predicted expression scores (Chikina et al., 2009) are indicated for each cluster.
Warm (red) and cold (blue) colors indicate low and high deviation from the consensus profile, respectively.
See also Figure S1 and Tables S1 and S2.
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a range of tissues. For example, proteins that are predominantly
expressed in the germline strongly increase during the first
6 days of adulthood (cluster 1), when the animals reproduce,
but surprisingly retain constant levels later in life. Proteins en-
riched in neuronal cells either increase in abundance throughout
the lifespan or after day 6 (clusters 2 and 3). In contrast, the levels
of many proteins enriched in intestine, muscle, and hypodermis
decline (clusters 4–6), consistent with an age-related deteriora-
tion of these tissues.
Age-Related Changes in Proteostasis Network
Components
Approximately 440 proteostasis network components involved
in protein synthesis, folding, and degradation were quantified
throughout the nematode lifespan (Figure S2A; Table S3).
A 25% reduction in the median level of cytosolic ribosomal
proteins occurred between day 1 and day 12 (Figure 2A, left).
This reduction correlates with a decrease in the transcript level
of ribosome proteins (Golden and Melov, 2004) and an overall
age-associated reduction in polysomes (Kirstein-Miles et al.,
2013). A similar decrease was observed for mitochondrial ribo-
somes between day 1 and day 6 (Figure 2A, right). Interestingly,
aged animals displayed a pronounced imbalance in the relative
subunit stoichiometry of cytosolic, but not mitochondrial, ribo-
somes, with several subunits decreasing more than 60% below
median subunit levels (Figure 2A, left).
Next, we employed SILAC to estimate protein synthesis in
aging C. elegans. Pulse labeling of worms with heavy bacteria
as the food source showed a sharp reduction in the incorporation
of labeled amino acids into protein between day 1 and day 4 of
adulthood (Figure S2B; Table S1C). This effect was not caused
by reduced food uptake, as eat-2 mutant animals, deficient in
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Figure 2. Abundance Changes in Specific Components of the Proteostasis Network
(A) Abundance changes of ribosomal proteins during the lifespan of C. elegans. There were 70 different cytosolic (left) and 34 mitochondrial ribosomal proteins
(right) that were quantified (see Table S3). Log2 values of fold-changes are shown in boxplot representation. Solid horizontal lines indicate the median values,
whisker caps indicate 10th and 90th percentiles, and circles indicate outliers. ****p < 4.35 3 1013 for cytosolic ribosomal proteins and 1.17 3 1010 for mito-
chondrial ribosomal proteins from Wilcoxon signed rank test. Only proteins quantified at both time points tested were considered.
(B) Abundance changes of proteasome subunits during lifespan. All 14 subunits of the 20S and 17 subunits of the 19S proteasome were quantified. Only subunits
quantified in at least two time points are displayed. ****p < 1.233 104 for 20S subunits and ****p < 1.533 105 for 19S subunits fromWilcoxon signed rank test.
(C–E) Abundance profiles of proteostasis network (PN) components along the lifespan of WT animals. Log2 relative changes in abundance are shown for HSP70
and HSP90 homologs (C), small HSPs (D), and proteins involved in oxidative stress defense (E). Only components quantified at day 1 and at least three
consecutive time points are displayed.
See also Figure S2 and Tables S1 and S3.
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pharyngeal pumping, showed protein labeling equivalent to WT
controls, despite their reduced food uptake (data not shown).
The reduction in protein synthesis between day 1 and 4 is greater
than the decrease in ribosomal levels (Figures 2A and S2B) and
probably reflects the reduction in growth of the animals.
In contrast to the effect on ribosomes, we observed an age-
dependent increase in 20S and 19S proteasomal subunits
(2-fold at day 22 for 20S subunits) (Figure 2B), correlating
with an increase in proteasome activity measured in worm
lysates in vitro (Figure S2C). Many E3 ubiquitin ligases and other
components of the ubiquitin proteasome system (UPS) also
increased moderately (Table S3B), while there was no system-
atic change in the components of autophagy (Figure S2D).
Age-dependent changes in the levels of abundant cytosolic
chaperones of the HSP70 and HSP90 (DAF-21) families (Fig-
ure 2C) as well as their DnaJ (DNJ/HSP40) and tetratricopeptide
repeat (TPR) co-factors were limited (Figures S2E and S2F).
Similarly, the subunits of the TRiC/CCT chaperonin remained
unchanged (Figure S2G). In contrast, multiple small HSPs, chap-
erones that function by buffering aggregation, increased dramat-
ically (13–90-fold), mainly between day 1 and day 6 (Figure 2D).
Several of these proteins are under regulation by DAF-16 and
HSF-1 (Hsu et al., 2003).
Several components mediating the defense against oxidative
stress, including glutathione peroxidase isoform GPX-5 and
superoxide dismutases (SOD), increased during aging (up to
12-fold) (Figure 2E; Table S3B). While changes in mitochondrial
proteostasis components were generally moderate (Figure S2H;
Table S3B), we observed diverse alterations in the proteostasis
network of the ER during the nematode lifespan (Figure S2I).
For example, protein disulfide isomerases (PDI-2 and C14B9.2),
the chaperone calreticulin (CRT-1), as well as the HSP70
homolog HSP-3 decreased 2-fold, and the pro-collagen
modifying enzymes lysyl hydroxylase (LET-268) and prolyl-4-
hydroxylase a (DPY-18 and PHY-2) decreased 3–10-fold.
These findings suggest an age-dependent decline in ER quality
control and collagen synthesis capacity.
In summary, the levels and activities of two main branches
of proteostasis control, protein synthesis and degradation,
change in opposite directions during aging. The decrease in
ribosomal subunit proteins is accompanied by a dysregulation
of cytosolic ribosome assembly, while the increase in protea-
some subunits is likely to reflect an attempt at removing surplus
or damaged proteins. Other notable changes in the proteosta-
sis system include an increase in the abundance of small HSP
chaperones and of components involved in the defense against
oxidative stress, as well as a decline in ER protein quality con-
trol machinery.
Proteome Changes in Long-Lived and Short-Lived
Mutant Strains
To understand in more detail the relationship between the
observed proteome changes during the lifespan and the aging
process, we next analyzed the proteomes of long-lived daf-2
(e1370), short-lived daf-16 (mu86), and hsf-1 (sy441) mutant
worms. The increase in levels of specific proteins observed dur-
ing aging of WT animals was considerably less pronounced in
daf-2 mutant animals and enhanced in daf-16 mutant animals
(Figure S3A, left), indicating that the long-lived daf-2 mutant
strain is more effective in controlling the accumulation of surplus
proteins. The extent to which proteins decreased in abundance
during agingwas also greater indaf-2mutantworms (Figure S3A,
right).
The changes in components of the proteostasis network
observed in the mutant strains occurred again predominantly
in the protein synthesis and degradation pathways, but at
different rates compared to WT. The upregulation of proteaso-
mal subunits commenced earlier during the lifespan of the
daf-2 mutant and was more pronounced than in the WT worms
(Figures 3A and 3B); such upregulation was instead less promi-
nent in the short-lived daf-16 and hsf-1 mutant strains (Figures
3C and 3D). These results are consistent with the DAF-16 depen-
dent regulation of some proteasome subunits, including RPN6,
which is required for 26S proteasome assembly (Vilchez et al.,
2012). The decrease in ribosomal proteins occurred at a similar
rate in daf-2mutant worms as inWT (Figure 3A), but was strongly
enhanced in daf-16 mutant worms (Figure 3C), suggesting that
DAF-16 is involved in ribosome maintenance.
Components involved in the oxidative stress response
showed marked differences in levels between WT and daf-2
mutant animals. For example, cytosolic (CTL-1 and CTL-3) and
peroxisomal (CTL-2) catalases were 4–8-fold higher in the
daf-2 mutant than in WT worms throughout their lifespans
(Figure S3B). SOD-1 (cytoplasmic) and SOD-2 (mitochondrial)
were elevated 2-fold compared to WT and short-lived mutant
animals (Figure S3C), consistent with their DAF-16-dependent
transcriptional regulation (McElwee et al., 2003; Murphy et al.,
2003). Among the small HSPs, SIP-1was alreadymore abundant
in young daf-2mutant worms (day 1) and HSP-16.48 was mark-
edly elevated in hsf-1 mutant animals (Figure S3D).
The earlier and more pronounced increase in proteasome
abundance in daf-2 mutant animals may improve the capacity
of the organism for the clearance of surplus proteins that accu-
mulate during aging. The elevated levels of catalases and SOD
may provide improved defense against oxidative damage.
Age-Dependent Protein Aggregation and Its Relation
to Protein Abundance
Declining proteostasis capacity is thought to result in the accu-
mulation of protein aggregates, consistent with recent reports
of age-dependent aggregate formation in C. elegans (David
et al., 2010; Reis-Rodrigues et al., 2012). To analyze this process
systematically, we developed a sensitive method for the quanti-
fication of aggregated proteins (see Experimental Procedures)
and validated it in animals expressing muscle specific FlucDM-
GFP, a conformationally unstable mutant of firefly luciferase
fused to GFP (Gupta et al., 2011) (Figures S4A and S4B). We iso-
lated insoluble proteins from total lysates of WT animals by
centrifugation and performed MS analysis using lysate from
labeled worms for quantification (Figure S4C). About 90% of
the proteins that were quantified in three out of four experiments
(975 of 1,083 proteins) accumulated significantly in the insoluble
fraction of day 12 animals relative to day 1 (Table S1D). Age-
dependent aggregation was most pronounced between day 6
and day 12 (Figure 4A), i.e., after the hermaphrodite animals
ceased to lay eggs. Proteins with predicted transmembrane
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segments were not enriched in the insoluble fraction (Fig-
ure S5A), indicating that lysis was efficient.
To measure the aggregation propensities of proteins during
aging, we quantified the insoluble amount of each protein as a
fraction of its total amount in aged WT worms (day 12) (Fig-
ure S4D; Table S1E). The aggregation propensities of >2,100
analyzed proteins varied by more than two orders of magnitude
(Figure 4B), with the median insoluble fraction per individual
protein amounting to 9%.
Previous studies reported a negative correlation between
computationally predicted aggregation propensities and protein
abundance (Tartaglia et al., 2009). To investigate this depen-
dency at the proteome scale, we grouped proteins according
to their aggregation propensities measured at day 12 and esti-
mated the total abundance of each protein in the whole cell
lysate by absolute LFQ (Figure 4C). The most abundant proteins
were 10-timesmore soluble than the least abundant proteins. An
analysis of the physicochemical properties of the abundant pro-
teins based on their amino acid sequences revealed that they
were more hydrophobic (Figure S5B) and more structured
(data not shown) than the less abundant ones. These results
suggest that abundant proteins increase their solubility, at least
in part, by stabilizing their native states through formation of a
more extensive hydrophobic core. Indeed, a calculation of the
aggregation propensities (Z scores) (Tartaglia et al., 2008; Sor-
manni et al., 2015a) (see Extended Experimental Procedures)
predicts that the more abundant proteins, if correctly folded,
are also more soluble (Figure S5C). This conclusion is consistent
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Figure 3. Remodeling of the Proteostasis
Network during Aging
(A–D) Abundance changes in components of the
PN (see Figure S2A) during aging in daf-2 (A), WT
(B), daf-16 (C), and hsf-1 (D) mutant worms.
Concentric circles represent increasing age in
days from center to periphery. Circle size corre-
sponds with lifespan. Functional categories of
components are indicated in the center: green,
biosynthesis; red, degradation; and light blue,
conformational maintenance (see Figure S2A).
Abundance changes of components within these
categories relative to day 1 of each strain (yellow,
>1.5-fold up and blue, >1.5-fold down) are indi-
cated as bars, with the length of the bar repre-
senting the number of proteins undergoing
change. The total numbers of proteins quantified in
the respective categories are indicated. See also
Figure S3.
with the idea that the solubility of proteins
follows their abundance (Tartaglia et al.,
2009).
We found, however, that despite of
their lower intrinsic aggregation pro-
pensities, the most abundant proteins
contribute most to the total aggregate
load. A strong correlation (R = 0.75) was
observed between the abundance of
specific proteins in the aggregate fraction
and their level in the corresponding whole cell lysate (Figure 4D).
Apparently, the high solubility of abundant proteins is insufficient
to protect them from age-dependent aggregation, as eventually
these proteins exceed their critical concentrations, a phenome-
non referred to as ‘‘supersaturation’’ (Ciryam et al., 2013).
Notably, we also observed a medium correlation (R = 0.43)
between the age-dependent change in the total abundance of
proteins and their increase in the aggregate fraction (Figure 4E),
and this correlation became stronger as aging progressed (data
not shown). Thus, proteome remodeling during aging likely
drives the aggregation of numerous proteins.
We further investigated whether aggregation also correlates
with function. Gene ontology analysis showed that proteins
with a relatively high aggregation propensity in aged animals
are enriched in the nucleus, whereas abundant glycolytic
enzymes and mitochondrial proteins tend to be highly soluble
(Figure S5D; Table S4A). Interestingly, all identified small HSPs,
but not other chaperones, were highly insoluble at day 12 (Fig-
ure 4F), with a high rate of accumulation in the aggregate fraction
during aging (Figure S5E). The recruitment of these chaperones
into the insoluble fraction may reflect an attempt of the organism
to sequester protein aggregates.
Protein Aggregation in Long-Lived and Short-Lived
Mutant Strains
Is the age-dependent formation of insoluble aggregates merely
a reflection of declining proteostasis capacity, or is it a means
to improve proteostasis by sequestering surplus proteins?
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Consistent with the former possibility are findings that aggrega-
tion-prone model proteins increasingly aggregate in proteosta-
sis-compromised hsf-1 mutant strains (Ben-Zvi et al., 2009).
Indeed, compared to WT animals, the short-lived hsf-1 mutant
worms accumulated more insoluble proteins and aggregation
occurred earlier during aging (between day 1 and day 6) (Figures
5A and S6A). However, in support of a beneficial role for
aggregation, we found that the long-lived daf-2 mutant worms
also accumulated more insoluble proteins than age-matched
WT animals (Figures 5A, S6A, and S6B). This effect was not
observed in daf-16 mutant animals (Figures 5A and S6A),
suggesting that age-dependent aggregation is (at least in part)
an active process under regulation by DAF-16. The increased
aggregation in daf-2 mutant animals comprised preferentially
cytosolic proteins (Figure S6C; Table S4B) and initiated between
day 6 and day 12 as in WT (Figure S6A), i.e., when the long-lived
mutant worms are still youthful.
While there was a large overlap between the proteins identified
in the insoluble fractions, the extent to which specific proteins
aggregated varied greatly in a strain specific manner. Interest-
ingly, the proteins that showed increased aggregation in the
daf-2 mutant over WT are not generally more abundant at the
total proteome level (Figure 5B), indicating that abundance in
this case is not the main driver of aggregation. Similar findings
were made in the hsf-1 mutant (Figure 5C). On the other hand,
proteins that aggregated less in the daf-2 strain than in WT are
also generally less abundant (Figure 5B), which would allow
these proteins to maintain solubility.
Next, we compared the physico-chemical properties of the
insoluble proteins. Strikingly, the proteins that aggregate most
in the daf-2 mutant animals are predicted to have significantly
lower aggregation-propensity Z scores, are more charged,
display more structural disorder (coil average) (Sormanni et al.,
2015b), and are less hydrophobic compared to the proteins
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Figure 4. Proteome-wide Analysis of Protein Aggregation during Aging
(A) Relative abundance of proteins in the insoluble fraction of WT animals during aging determined by SILAC quantification (see Figure S4C; Table S1D). At least
1,355 proteins were quantified at the different time points (3,228 different proteins in total). ****p < 2.2 3 1016 from Wilcoxon signed rank test.
(B) Distribution of aggregation propensities of proteins (insoluble protein as fraction of total protein) in WT animals at day 12 (median from three independent
experiments; Table S1E). Whole worm lysates and insoluble fractions were quantified against the same SILAC standard and ratios were calculated for each
protein in % of total (see Figure S4D).
(C) Relationship between aggregation propensity and total protein abundance. Proteins were divided into quantiles based on their measured aggregation
propensities (median values are indicated in %). LFQ was used to estimate total protein abundance (displayed as relative abundance values). ****p < 2.23 1016
from Wilcoxon rank sum test.
(D) Protein abundance in the insoluble fraction is positively correlated with abundance in the total proteome (absolute LFQ values). Data for WT animals at day 12
are shown. The Pearson correlation coefficient R is indicated.
(E) Positive correlation between age-related protein abundance changes in the insoluble fraction and abundance changes for the same proteins in the total
proteome. Abundance differences measured by SILAC between aged (day 12) and young (day 1) WT animals are plotted. The Pearson correlation coefficient R is
indicated.
(F) Aggregation propensities of small HSP family members relative to the aggregation propensities of all quantified proteins in the proteome of day 12WT animals.
See also Figures S4 and S5 and Tables S1 and S4.
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Figure 5. Protein Aggregation in Lifespan Mutant Worms during Aging
(A) Increased aggregate load in daf-2mutant animals compared to WT, daf-16, and hsf-1mutant animals at day 12. Relative abundance values of proteins in the
insoluble fractionwere determined by SILACquantification. Therewere 1,367, 1,988, 1,449, and 1,485 proteins that were quantified inWT, daf-2, daf-16, and hsf-1
mutant animals, respectively (one representative out of four independent experiments is displayed; Table S1F). ****p < 2.23 1016 fromWilcoxon signed rank test.
(B and C) Quantiled abundance of proteins in the insoluble fraction of daf-2 (352–354 proteins per quantile) (B) and hsf-1 mutant (292 proteins per quantile) (C)
relative to WT animals at day 12 plotted against differences in total protein abundance values. Quantile median values are indicated on the x axis. Proteins that
aggregated less in the mutant strains than in the WT have been grouped separately (91 proteins in daf-2 and 259 in hsf-1 mutant).
(D–G) Physico-chemical properties of proteins enriched in the insoluble fractions of daf-2 and hsf-1 mutant relative to WT animals at day 12.
(D) Aggregation propensity scores (intrinsic Z scores, see Extended Experimental Procedures). ***p < 1.4 3 104 and *p < 0:016, Wilcoxon rank sum test.
(E) Net charge. ****p < 4.9 3 1011.
(F) Coil content. ***p < 1.1 3 104.
(G) Overall hydrophobicity. ****p < 2.9 3 107. Quantile median values are indicated on both axes and standard errors are reported on the y axis.
See also Figure S6 and Table S4.
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aggregating in WT (Figures 5D–5G). These findings support the
hypothesis of an extrinsic rescuing mechanism of aggregation
that is activated in the daf-2 mutant, modulating the intrinsic
properties of proteins that typically govern aggregation. As a
result, aggregation is enhanced for a set of proteins that have
certain properties resembling disease-associated proteins with
structural disorder (Knowles et al., 2014). By contrast, aggrega-
tion in the hsf-1 mutant correlates with intrinsic aggregation
scores (Figure 5D), consistent with a degeneration mechanism
arising from the premature decline of proteostasis.
Among the proteins that were strongly increased in the insol-
uble fraction of daf-2 mutant animals were several small HSPs
(Figure 6A). These proteins contribute 7% to total aggregate
load, suggesting that they may be involved in a ‘‘protective
aggregation response’’. Small HSPs were also enriched in
the insoluble fraction of hsf-1 mutant animals, although to a
lesser extent, but not in the aggregates of the daf-16 mutant
(Figure 6A). Besides small HSPs, 26S proteasome complexes
were enriched in the insoluble fractions (Figure 6B), most
A B
C
D E
Figure 6. Aggregation of Small HSPs and
Proteasome in Lifespan Mutant Worms
(A) Abundance of small HSPs in the insoluble
fraction of daf-2, daf-16, and hsf-1 mutant relative
toWT animals as determined by summed absolute
LFQ values. There were 6–11 different small
HSPs that were quantified. **p value < 0.0075 (WT
versus daf-2) and < 0.0022 (WT versus hsf-1) from
Welch’s t tests. Averages ± SD are given for four
replicate experiments.
(B) Abundance of 26S proteasome subunits in
the insoluble fraction of daf-2, daf-16, and hsf-1
mutant relative to WT animals. There were 19–27
subunits that were quantified. ***p < 2.1 3 104
(WT versus daf-2) and < 4.6 3 104 (WT versus
hsf-1) from Welch’s t tests. Averages ± SD are
given for four replicate experiments.
(C) Enrichment of the small HSPs HSP-16.1, HSP-
16.48, SIP-1, HSP-17, andQ9N350 in the insoluble
fractions of day 12WT (black circles), daf-2mutant
worms (red circles), and hsf-1 mutant worms
(purple circles). Data from two to four independent
experiments are shown.
(D and E) Formation of HSP-16.1 inclusions in
muscle cells is shown.
(D) Representative fluorescence images of muscle
cells of WT and daf-2 mutant animals expressing
HSP-16.1::GFP (top). Actin was stained with
rhodamine-phalloidin (bottom). Scale bar, 10 mm.
(E) Animals with HSP-16.1::GFP inclusions in
muscle cells were quantified (20 animals per
group). Averages ± SD are given in % of total.
*p < 0.01 from Welch’s t test.
See also Figure S6 and Table S1.
strongly in the daf-2 mutant strain, but
contributed only 1% to total aggregate
load.
Interestingly, the proportion of specific
small HSPs in the aggregates differed
between strains. SIP-1 and HSP-16.1
made the major contribution by mass to the aggregates in the
daf-2 mutant, while HSP-17 was most enriched in the aggre-
gates of hsf-1mutant animals (Figure 6C; Table S1F). To monitor
the behavior of HSP-16.1 during aging, we used strains express-
ing GFP-tagged HSP-16.1 (hsp-16.1::gfp) under its endogenous
promoter. HSP-16.1-GFP formed inclusions in muscle cells.
This phenomenon was strongly enhanced in daf-2 mutant
worms, with 60% of animals at day 12 containing inclusions,
compared to 20% in WT (Figures 6D and 6E). While the actin
architecture of muscle cells was well preserved in daf-2 mutant
animals, the muscles of day 15 WT animals showed a reduced
structural integrity (Figure 6D). Indeed, the daf-2mutant animals
displayed a higher proteostasis capacity, as reflected in their
ability to maintain the metastable FlucDM-GFP (Gupta et al.,
2011) expressed in muscle in a functionally active state. While
similar levels of total and soluble FlucDM-GFP protein were pre-
sent in day 12 WT and daf-2mutant worms, the latter contained
4-fold more luciferase activity (Figure S6D). In contrast, a mus-
cle specific poly-glutamine (polyQ) protein construct (Q35-GFP)
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aggregated more extensively in daf-2 mutant worms already
early in adulthood (day 2), and semi-denaturing detergent
agarose gel electrophoresis (SDD-AGE) of worm lysates
revealed that the protein accumulated predominantly in higher
molecular weight, SDS-resistant oligomers (Figure S6E).
Taken together, these results suggest that daf-2 mutant ani-
mals drive a set of aberrant, potentially toxic proteins into insol-
uble aggregates, thereby sequestering them and improving
overall proteostasis. Small HSPs are likely to play a role in this
process.
DISCUSSION
Age-Dependent Deterioration of Proteome Balance
Organisms allocate considerable resources toward maintaining
proteome composition, including the relative balance of subunits
of multi-protein complexes (Li et al., 2014). Using quantitative
mass spectrometric methods, we have shown here that aging
in C. elegans is associated with the progressive failure to main-
tain protein homeostasis, resulting in extensive proteome re-
modeling and protein imbalances. These imbalances are largely
due to changes at the level of protein translation and turnover
and give rise to the accumulation of potentially harmful, aggrega-
tion-prone species (Figures 7A and 7B). Our analysis revealed
that the sequestration of such proteins in insoluble aggregates
is a protective strategy that contributes to maintaining proteome
integrity during aging.
The extensive proteome remodeling during aging inC. elegans
is contrary to observations in tissues of aged mice, where
comparatively minor proteomic changes were detected with a
similar experimental approach (Walther and Mann, 2011).
Evidently, mammals devote greater resources to maintaining
proteome balance, resulting in a more protracted proteostasis
decline. These differences correlate with different reproductive
strategies in worms and mice, in which the former display a
more extensive, time-restrained burst of reproduction, followed
by a rather rapid and massive decline of somatic functions.
Future studies on a range of metazoans will be necessary to
establish whether deterioration of proteome integrity during
aging or proteome stability is more typical.
Changes in the Proteostasis System during Lifespan
We showed that aging inC. elegans affects multiple components
of the proteostasis system, most prominently protein bio-
synthesis and protein degradation. A decrease in the levels of
cytosolic and mitochondrial ribosomal proteins was accompa-
nied by an overall reduction in protein synthesis. In contrast,
we observed an increase in the abundance of proteasome
subunits and a corresponding increase of in vitro proteasome
activity. These changes may initiate as a response to the altered
physiological requirements of the aging organism (Shore and
Ruvkun, 2013), but ultimately may prove insufficient or even
detrimental (Figure 7B). The reduction of the levels of cytosolic
ribosomes was associated with a pronounced imbalance in
the stoichiometry of ribosomal proteins. Thus, attenuating the
translational machinery as an adaptive measure imparts the
danger of dysregulation of the essential machines that ensure
balance of the proteostasis network, which in turn may promote
aging. In contrast, the increase in proteasomal subunits is likely
to represent an attempt of the organism to remove aberrant
protein species. Whether this proteasome upregulation is effec-
tive in vivo is unclear, however, given that proteasome function
is generally thought to decline as a result of aging and protein
aggregation (Hipp et al., 2014).
Protein Aggregation and Lifespan Extension
Previous studies demonstrated the formation of insoluble protein
aggregates in aged worms (David et al., 2010; Reis-Rodrigues
et al., 2012). Here, we performed an in-depth quantitative anal-
ysis of aggregation along the lifespan of C. elegans. We found
that aggregation is a proteome-wide process which initiates
mainly after day 6 of adulthood. Highly abundant proteins are
generally more soluble and display lower intrinsic aggregation-
propensities than less abundant ones, as previously predicted
(Tartaglia et al., 2009). However, this higher solubility is still not
sufficient in the end, as abundant proteins make by far the major
contribution by mass to the age-dependent aggregate load.
Importantly, proteome remodeling acts as a driver of aggrega-
tion by raising the level of a subset of proteins beyond a critical
solubility limit (supersaturation) (Ciryam et al., 2013) (Figure 7D).
While protein aggregation may be merely a consequence of
declining proteostasis capacity, our results provide evidence
that a protective aggregation response is also an important
mechanism of the aging organism to improve proteostasis and
mitigate the effects of proteome imbalance. We observed that
long-lived daf-2mutant animals accumulate increasing amounts
of insoluble proteins during aging and that such accumulation
correlates with a more effective maintenance of proteome
composition (Figure 7C). Whereas the proteins that aggregate
most in the short-lived hsf-1 mutant are predicted to be more
aggregation-prone, the enhanced aggregation in the long-lived
daf-2 mutant is much less dependent on intrinsic properties:
the proteins that are most enriched in the insoluble fraction
have lower aggregation scores, are less hydrophobic, more
charged, and contain more structural disorder, arguing for the
existence of an active, proteome-wide mechanism in promoting
aggregation. This conclusion is consistent with the view that
soluble oligomers are the major proteotoxic species in neurode-
generative diseases and that their sequestration into insoluble
aggregates reduces proteotoxicity (Arrasate et al., 2004; Cohen
et al., 2006, 2009). Interestingly, several highly toxic disease-
associated proteins are rich in disordered structure and have
low overall hydrophobicity (Knowles et al., 2014; Vendruscolo
et al., 2011), properties resembling those of the proteins with
enhanced aggregation in the daf-2mutant. Indeed, amechanism
of aggregate deposition under regulation of the insulin signaling
pathway has been proposed for disease-related protein species,
such as toxic Ab peptide (Cohen et al., 2006). However, that
an overall protective aggregate response operates at the
proteome-scale during aging was not anticipated.
We assume that this protective aggregation response is only
partially activated during normal C. elegans aging. As a result,
WT worms are expected to accumulate a larger soluble pool of
aberrant, potentially toxic proteins than daf-2 mutant animals,
eventually exhausting the available chaperone capacity needed
for protein folding and conformational maintenance and the
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clearance of misfolded polypeptides (Figures 7B and 7C).
Formation of insoluble aggregates may also be an, albeit insuffi-
cient, rescue attempt in the short-lived hsf-1 mutant strain.
Among the proteostasis components with strongly enhanced,
age-dependent insolubility were multiple small HSPs, a specific
class of chaperones known to associate with aggregation-prone
A B C
D
Figure 7. Proteome Maintenance during Aging in C. elegans
(A) The proteome of young adult WT worms is maintained in balance by the proteostasis system. Aberrant protein species, including metastable conformers and
soluble aggregates (red) are efficiently cleared.
(B) In aged WT animals, numerous proteins increase in abundance and normal protein stoichiometries are lost due in part to a relief of miRNA-mediated
translational repression. The amount of aggregation-prone species exceeds clearance capacity and insoluble aggregates associated with small HSPs
accumulate. Mechanisms of protective aggregate formation are partially activated, and proteostasis is strongly reduced.
(C) Proteostasis collapse is delayed in aged daf-2mutant worms. Proteome imbalance and the soluble aggregate pool are reduced relative to age-matched WT
animals, as clearance by protein degradation may be more effective and protective aggregate formation is fully activated.
(D) Protein aggregate loads increase proportionally to protein abundance. Although abundant proteins have lower aggregation propensities, they contributemore
to aggregate load (see Figure 4). The age-dependent increase in expression level affects the subproteome of supersaturated proteins, which fail to maintain
solubility as their levels increase and proteostasis capacity declines.
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proteins (Haslbeck et al., 2005). The small HSPs were most en-
riched in the insoluble fraction of daf-2mutant worms, consistent
with the view that they may play a role as ‘‘extrinsic’’ promoters
of aggregation. In support of this possibility, individual RNAi
knockdown of several small HSPs, including SIP-1, caused a
25% shortening of lifespan in WT and daf-2 mutant worms
(Hsu et al., 2003) and overexpression resulted in lifespan exten-
sion (Walker and Lithgow, 2003). Having multi-valent binding
ability for aberrant proteins, the small HSPs may act to seed
and concentrate aggregate material, consistent with findings
in vivo (Escusa-Toret et al., 2013; Kaganovich et al., 2008;
Specht et al., 2011) and in vitro (Haslbeck et al., 2005; Jiao
et al., 2005). The co-existence of multiple small HSPs suggests
that different forms may vary in their structural specificity for
endogenous proteins. Notably, small HSPs are also transcrip-
tionally induced in the aging brain, while most other major
chaperone components are downregulated (Brehme et al.,
2014). The association of the 26S proteasome with the aggre-
gates may also be functionally relevant. Although aggregates
can inhibit the proteolytic activity of the proteasome (Andersson
et al., 2013; Hipp et al., 2014), evidence has been presented that
the ATPase chaperones of the 19S proteasome may promote
aggregation (Rousseau et al., 2009).
Collectively, our data suggest that aging in C. elegans is
associated with a progressive loss of proteome balance, which
drives the accumulation of surplus and aberrant protein species
that overburden the proteostasis system. As the maintenance
of protein solubility imposes stringent constraints on proteome
composition, effective aggregate management appears to be
critical in determining lifespan.
EXPERIMENTAL PROCEDURES
C. elegans Strains and Growth Conditions
A list of strains used in this study is provided in the Extended Experimental
Procedures. The Bristol strain N2 was used as WT. The L4 larval stage was
considered as day 0. Bacterial cultures (ET505) for SILAC labeling were grown
in 13C6-
15N2-lysine (heavy lysine) containing M63 minimal media (Krijgsveld
et al., 2003) (see Extended Experimental Procedures for details).
Sample Preparation for Total Proteome Measurements
Briefly, worms were suspended in lysis buffer (4% SDS, 0.1 M Tris/HCl pH 8.0,
and 1 mM EDTA), incubated at 95C for 5 min, and further treated by ultra-
sonication. Typically, an aliquot of lysate containing 40 mg of protein wasmixed
with an equal amount of a heavy lysine labeled lysate pool (Figure 1A).
Proteins were reduced, alkylated, and digested with endoproteinase LysC
using the filter-aided sample preparation (FASP) method (Wisniewski et al.,
2009). Peptide mixtures were either analyzed without fractionation or after
fractionation by isoelectric focusing, as described in the Extended Experi-
mental Procedures.
Isolation of Protein Aggregates
Worms were resuspended in lysis buffer (50 mM Tris/HCl pH 8.0, 0.5 M NaCl,
4 mM EDTA, 1% volume/volume (v/v) Igepal CA630, and complete protease
inhibitor cocktail; Roche Diagnostics), disrupted by sonication, and clarified
by low-speed centrifugation (1 min, 1,000 relative centrifugal force [rcf]). Insol-
uble proteins were sedimented by ultracentrifugation (500,000 rcf at 4C,
10 min), washed twice with lysis buffer containing 0.15 M NaCl and 0.5%
sodium deoxycholate, and solubilized in SDS sample buffer for 10 min at
95C. For quantitative proteome measurements of aggregated proteins, an
aliquot of pooled total lysate from heavy lysine labeled animals was added
prior to ultracentrifugation. For experiments measuring aggregation propen-
sities, unlabeled worm lysates were first fractionated and subsequently sup-
plemented with SILAC-labeled whole cell lysate.
MS and Data Analysis
Peptides were separated by reversed phase nano-high-performance liquid
chromatography (HPLC) and sprayed online into LTQ-Orbitrap Velos or
Orbitrap-Elite mass spectrometers (Thermo Fisher). In each scan cycle, frag-
mentation spectra of the ten most intense peptide precursors in the survey
scan were acquired in the higher-energy collisional dissociation (HCD) mode.
Raw data were processed using the MaxQuant software environment (Cox
and Mann, 2008) and peak lists were searched with Andromeda (Cox et al.,
2011) against a database containing the translation of all predicted proteins
listed in UniProt (release January 15, 2012), as well as a list of commonly
observed contaminants and the National Center for Biotechnology Information
(NCBI) protein database of E. coli strain K12. The minimal required peptide
length was set to seven amino acids and both protein and peptide identifica-
tions were accepted at a false discovery rate of 1%. To identify aggregation-
prone proteins that were significantly affected by aging, those proteins that
were quantified in at least three out of four biological replicate experiments at
day 1 and day 12 were subjected to a Welch’s t test and filtered based on a
5% permutation-based false discovery rate threshold.
Miscellaneous
Proteasome activity assays, detection of polyQ aggregates by SDD-AGE, light
microscopy, and methods used for bioinformatic analyses are described in
the Extended Experimental Procedures.
ACCESSION NUMBERS
Proteomics raw data and selectedMaxQuant output files have been deposited
to the ProteomeXchange Consortium via the PRIDE partner repository with the
data set identifier PXD001364.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and four tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2015.03.032.
AUTHOR CONTRIBUTIONS
F.U.H., M.M., D.M.W., and P.K. conceived the approach. D.M.W. and P.K.
designed and performed the experiments with contributions from M.Z. M.M.
supervised the proteomics analyses. D.M.W. and S.P. performed bioinformat-
ics analyses with contributions from P.K. G.V. and P.C. analyzed the protein
aggregation data and interpreted the results together with M.V., C.M.D., and
R.I.M. F.U.H., D.M.W., and P.K. wrote the manuscript with contributions
from M.M., M.V., C.M.D., and R.I.M.
ACKNOWLEDGMENTS
We thank the Caenorhabditis Genetics Center for providing most of the strains
used in this study. hsp-16.1::gfp transgenic wormswere provided byDr. Junho
Lee, Seoul National University. This work was supported by the European
Commission under FP7 GA number ERC-2012-SyG_318987-Toxic Protein
Aggregation in Neurodegeneration (ToPAG), the Wellcome Trust (094425/Z/
10/Z), the Center for Integrated Protein Science Munich (CIPSM), and the
Munich Cluster for Systems Neurology (SyNergy). We would further like to
thank Igor Paron and Korbinian Mayr for excellent technical assistance with
MS instrumentation, as well as Daniel Hornburg, Manajit Hayer-Hartl, and
members of the Hartl laboratory for critically reading this manuscript.
Received: October 23, 2014
Revised: January 12, 2015
Accepted: February 24, 2015
Published: May 7, 2015
930 Cell 161, 919–932, May 7, 2015 ª2015 Elsevier Inc.
40 Proteostasis imbalance and widespread aggregation in ageing C.elegans
REFERENCES
Andersson, V., Hanze´n, S., Liu, B., Molin, M., and Nystro¨m, T. (2013).
Enhancing protein disaggregation restores proteasome activity in aged cells.
Aging (Albany, N.Y. Online) 5, 802–812.
Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R., and Finkbeiner, S.
(2004). Inclusion body formation reduces levels of mutant huntingtin and the
risk of neuronal death. Nature 431, 805–810.
Balch, W.E., Morimoto, R.I., Dillin, A., and Kelly, J.W. (2008). Adapting proteo-
stasis for disease intervention. Science 319, 916–919.
Ben-Zvi, A., Miller, E.A., and Morimoto, R.I. (2009). Collapse of proteostasis
represents an early molecular event in Caenorhabditis elegans aging. Proc.
Natl. Acad. Sci. USA 106, 14914–14919.
Bensimon, A., Heck, A.J., and Aebersold, R. (2012). Mass spectrometry-based
proteomics and network biology. Annu. Rev. Biochem. 81, 379–405.
Brehme, M., Voisine, C., Rolland, T., Wachi, S., Soper, J.H., Zhu, Y., Orton, K.,
Villella, A., Garza, D., Vidal, M., et al. (2014). A chaperome subnetwork safe-
guards proteostasis in aging and neurodegenerative disease. Cell Rep. 9,
1135–1150.
Budovskaya, Y.V., Wu, K., Southworth, L.K., Jiang, M., Tedesco, P., Johnson,
T.E., and Kim, S.K. (2008). An elt-3/elt-5/elt-6GATA transcription circuit guides
aging in C. elegans. Cell 134, 291–303.
Chikina, M.D., Huttenhower, C., Murphy, C.T., and Troyanskaya, O.G. (2009).
Global prediction of tissue-specific gene expression and context-dependent
gene networks in Caenorhabditis elegans. PLoS Comput. Biol. 5, e1000417.
Ciryam, P., Tartaglia, G.G., Morimoto, R.I., Dobson, C.M., and Vendruscolo,
M. (2013). Widespread aggregation and neurodegenerative diseases are
associated with supersaturated proteins. Cell Rep. 5, 781–790.
Cohen, E., Bieschke, J., Perciavalle, R.M., Kelly, J.W., and Dillin, A. (2006).
Opposing activities protect against age-onset proteotoxicity. Science 313,
1604–1610.
Cohen, E., Paulsson, J.F., Blinder, P., Burstyn-Cohen, T., Du, D., Estepa, G.,
Adame, A., Pham, H.M., Holzenberger, M., Kelly, J.W., et al. (2009). Reduced
IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 139, 1157–
1169.
Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification
rates, individualized p.p.b.-range mass accuracies and proteome-wide pro-
tein quantification. Nat. Biotechnol. 26, 1367–1372.
Cox, J., and Mann, M. (2011). Quantitative, high-resolution proteomics for
data-driven systems biology. Annu. Rev. Biochem. 80, 273–299.
Cox, J., Neuhauser, N., Michalski, A., Scheltema, R.A., Olsen, J.V., and Mann,
M. (2011). Andromeda: a peptide search engine integrated into the MaxQuant
environment. J. Proteome Res. 10, 1794–1805.
David, D.C., Ollikainen, N., Trinidad, J.C., Cary, M.P., Burlingame, A.L., and
Kenyon, C. (2010). Widespread protein aggregation as an inherent part
of aging in C. elegans. PLoS Biol. 8, e1000450.
Demontis, F., and Perrimon, N. (2010). FOXO/4E-BP signaling in Drosophila
muscles regulates organism-wide proteostasis during aging. Cell 143,
813–825.
Dong, M.Q., Venable, J.D., Au, N., Xu, T., Park, S.K., Cociorva, D., Johnson,
J.R., Dillin, A., and Yates, J.R., 3rd. (2007). Quantitative mass spectrometry
identifies insulin signaling targets in C. elegans. Science 317, 660–663.
Douglas, P.M., and Dillin, A. (2010). Protein homeostasis and aging in neuro-
degeneration. J. Cell Biol. 190, 719–729.
Escusa-Toret, S., Vonk, W.I., and Frydman, J. (2013). Spatial sequestration of
misfolded proteins by a dynamic chaperone pathway enhances cellular fitness
during stress. Nat. Cell Biol. 15, 1231–1243.
Finkel, T., and Holbrook, N.J. (2000). Oxidants, oxidative stress and the
biology of ageing. Nature 408, 239–247.
Gidalevitz, T., Ben-Zvi, A., Ho, K.H., Brignull, H.R., and Morimoto, R.I. (2006).
Progressive disruption of cellular protein folding in models of polyglutamine
diseases. Science 311, 1471–1474.
Golden, T.R., and Melov, S. (2004). Microarray analysis of gene expression
with age in individual nematodes. Aging Cell 3, 111–124.
Gupta, R., Kasturi, P., Bracher, A., Loew, C., Zheng, M., Villella, A., Garza, D.,
Hartl, F.U., and Raychaudhuri, S. (2011). Firefly luciferase mutants as sensors
of proteome stress. Nat. Methods 8, 879–884.
Hartl, F.U., Bracher, A., and Hayer-Hartl, M. (2011). Molecular chaperones in
protein folding and proteostasis. Nature 475, 324–332.
Haslbeck, M., Franzmann, T., Weinfurtner, D., and Buchner, J. (2005). Some
like it hot: the structure and function of small heat-shock proteins. Nat. Struct.
Mol. Biol. 12, 842–846.
Hipp, M.S., Park, S.H., and Hartl, F.U. (2014). Proteostasis impairment in pro-
tein-misfolding and -aggregation diseases. Trends Cell Biol. 24, 506–514.
Hsu, A.-L., Murphy, C.T., and Kenyon, C. (2003). Regulation of aging and age-
related disease by DAF-16 and heat-shock factor. Science 300, 1142–1145.
Iba´n˜ez-Ventoso, C., Yang,M., Guo, S., Robins, H., Padgett, R.W., and Driscoll,
M. (2006). Modulated microRNA expression during adult lifespan in Caeno-
rhabditis elegans. Aging Cell 5, 235–246.
Jiao, W., Li, P., Zhang, J., Zhang, H., and Chang, Z. (2005). Small heat-shock
proteins function in the insoluble protein complex. Biochem. Biophys. Res.
Commun. 335, 227–231.
Kaganovich, D., Kopito, R., and Frydman, J. (2008). Misfolded proteins
partition between two distinct quality control compartments. Nature 454,
1088–1095.
Kenyon, C., Chang, J., Gensch, E., Rudner, A., and Tabtiang, R. (1993). A C.
elegans mutant that lives twice as long as wild type. Nature 366, 461–464.
Kirstein-Miles, J., Scior, A., Deuerling, E., and Morimoto, R.I. (2013). The
nascent polypeptide-associated complex is a key regulator of proteostasis.
EMBO J. 32, 1451–1468.
Knowles, T.P., Vendruscolo, M., and Dobson, C.M. (2014). The amyloid state
and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol.
15, 384–396.
Krijgsveld, J., Ketting, R.F., Mahmoudi, T., Johansen, J., Artal-Sanz, M.,
Verrijzer, C.P., Plasterk, R.H.A., and Heck, A.J.R. (2003). Metabolic labeling
of C. elegans and D. melanogaster for quantitative proteomics. Nat. Bio-
technol. 21, 927–931.
Kumar, L., and Futschik, M. (2007). Mfuzz: a software package for soft clus-
tering of microarray data. Bioinformation 2, 5–7.
Larance, M., Bailly, A.P., Pourkarimi, E., Hay, R.T., Buchanan, G., Coulthurst,
S., Xirodimas, D.P., Gartner, A., and Lamond, A.I. (2011). Stable-isotope
labeling with amino acids in nematodes. Nat. Methods 8, 849–851.
Li, G.W., Burkhardt, D., Gross, C., and Weissman, J.S. (2014). Quantifying
absolute protein synthesis rates reveals principles underlying allocation of
cellular resources. Cell 157, 624–635.
McElwee, J., Bubb, K., and Thomas, J.H. (2003). Transcriptional outputs of the
Caenorhabditis elegans forkhead protein DAF-16. Aging Cell 2, 111–121.
Morley, J.F., and Morimoto, R.I. (2004). Regulation of longevity in Caenorhab-
ditis elegans by heat shock factor and molecular chaperones. Mol. Biol. Cell
15, 657–664.
Morley, J.F., Brignull, H.R., Weyers, J.J., and Morimoto, R.I. (2002). The
threshold for polyglutamine-expansion protein aggregation and cellular
toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc.
Natl. Acad. Sci. USA 99, 10417–10422.
Murphy, C.T., McCarroll, S.A., Bargmann, C.I., Fraser, A., Kamath, R.S.,
Ahringer, J., Li, H., and Kenyon, C. (2003). Genes that act downstream of
DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 424,
277–283.
Olzscha, H., Schermann, S.M., Woerner, A.C., Pinkert, S., Hecht, M.H., Tarta-
glia, G.G., Vendruscolo, M., Hayer-Hartl, M., Hartl, F.U., and Vabulas, R.M.
(2011). Amyloid-like aggregates sequester numerous metastable proteins
with essential cellular functions. Cell 144, 67–78.
Ong, S.E., Blagoev, B., Kratchmarova, I., Kristensen, D.B., Steen, H., Pandey,
A., and Mann, M. (2002). Stable isotope labeling by amino acids in cell culture,
Cell 161, 919–932, May 7, 2015 ª2015 Elsevier Inc. 931
2.3 Publication 41
SILAC, as a simple and accurate approach to expression proteomics. Mol.
Cell. Proteomics 1, 376–386.
Oromendia, A.B., Dodgson, S.E., and Amon, A. (2012). Aneuploidy causes
proteotoxic stress in yeast. Genes Dev. 26, 2696–2708.
Prahlad, V., andMorimoto, R.I. (2009). Integrating the stress response: lessons
for neurodegenerative diseases from C. elegans. Trends Cell Biol. 19, 52–61.
Reis-Rodrigues, P., Czerwieniec, G., Peters, T.W., Evani, U.S., Alavez, S.,
Gaman, E.A., Vantipalli, M., Mooney, S.D., Gibson, B.W., Lithgow, G.J., and
Hughes, R.E. (2012). Proteomic analysis of age-dependent changes in protein
solubility identifies genes that modulate lifespan. Aging Cell 11, 120–127.
Rousseau, E., Kojima, R., Hoffner, G., Djian, P., and Bertolotti, A. (2009).
Misfolding of proteins with a polyglutamine expansion is facilitated by protea-
somal chaperones. J. Biol. Chem. 284, 1917–1929.
Schwanha¨usser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J.,
Chen, W., and Selbach, M. (2011). Global quantification of mammalian gene
expression control. Nature 473, 337–342.
Shore, D.E., and Ruvkun, G. (2013). A cytoprotective perspective on longevity
regulation. Trends Cell Biol. 23, 409–420.
Sormanni, P., Aprile, F.A., and Vendruscolo, M. (2015a). The CamSol method
of rational design of protein mutants with enhanced solubility. J. Mol. Biol. 427,
478–490.
Sormanni, P., Camilloni, C., Fariselli, P., and Vendruscolo, M. (2015b). The s2D
method: simultaneous sequence-based prediction of the statistical popula-
tions of ordered and disordered regions in proteins. J. Mol. Biol. 427, 982–996.
Specht, S., Miller, S.B., Mogk, A., and Bukau, B. (2011). Hsp42 is required for
sequestration of protein aggregates into deposition sites in Saccharomyces
cerevisiae. J. Cell Biol. 195, 617–629.
Stingele, S., Stoehr, G., Peplowska, K., Cox, J., Mann, M., and Storchova, Z.
(2012). Global analysis of genome, transcriptome and proteome reveals the
response to aneuploidy in human cells. Mol. Syst. Biol. 8, 608.
Tartaglia, G.G., Pawar, A.P., Campioni, S., Dobson, C.M., Chiti, F., and
Vendruscolo, M. (2008). Prediction of aggregation-prone regions in structured
proteins. J. Mol. Biol. 380, 425–436.
Tartaglia, G.G., Pechmann, S., Dobson, C.M., and Vendruscolo, M. (2009). A
relationship between mRNA expression levels and protein solubility in
E. coli. J. Mol. Biol. 388, 381–389.
Taylor, R.C., and Dillin, A. (2013). XBP-1 is a cell-nonautonomous regulator of
stress resistance and longevity. Cell 153, 1435–1447.
van Oosten-Hawle, P., and Morimoto, R.I. (2014). Organismal proteostasis:
role of cell-nonautonomous regulation and transcellular chaperone signaling.
Genes Dev. 28, 1533–1543.
Vendruscolo, M., Knowles, T.P., and Dobson, C.M. (2011). Protein solubility
and protein homeostasis: a generic view of protein misfolding disorders.
Cold Spring Harb. Perspect. Biol. 3, a010454.
Vilchez, D., Morantte, I., Liu, Z., Douglas, P.M., Merkwirth, C., Rodrigues, A.P.,
Manning, G., and Dillin, A. (2012). RPN-6 determines C. elegans longevity
under proteotoxic stress conditions. Nature 489, 263–268.
Walker, G.A., and Lithgow, G.J. (2003). Lifespan extension in C. elegans by a
molecular chaperone dependent upon insulin-like signals. Aging Cell 2,
131–139.
Walther, D.M., and Mann, M. (2011). Accurate quantification of more than
4000 mouse tissue proteins reveals minimal proteome changes during aging.
Mol. Cell. Proteomics 10, M110.004523.
Welker, N.C., Habig, J.W., and Bass, B.L. (2007). Genes misregulated in
C. elegans deficient in Dicer, RDE-4, or RDE-1 are enriched for innate
immunity genes. RNA 13, 1090–1102.
Wisniewski, J.R., Zougman, A., Nagaraj, N., and Mann, M. (2009). Universal
sample preparation method for proteome analysis. Nat. Methods 6,
359–362.
932 Cell 161, 919–932, May 7, 2015 ª2015 Elsevier Inc.
42 Proteostasis imbalance and widespread aggregation in ageing C.elegans
Supplemental Information
EXTENDED EXPERIMENTAL PROCEDURES
Strains
C.elegans strains were maintained by standard methods (Brenner, 1974). The Bristol strain N2 was used as wild-type. The following
mutants and transgenic strainswere used: CB1370 [daf-2 (e1370)III], CF1038 [daf-16 (mu86)I], PS3551 [hsf-1 (sy441)I], DA1113 [eat-2
(ad1113)II], AM140 [rmIs132 [P(unc-54) q35::yfp]], FUH135 [marIs135 [P(unc-54) Fluc-DM::gfp]+rol-6 (su1006)], FUH139 [marIs139
[P(unc-54) Fluc-DM::gfp]+rol-6 (su1006)], FUH179 [daf-2 (e1370); marIs139 [P(unc-54)Fluc-DM::gfp]+rol-6 (su1006)], FUH219
[(daf-2 (e1370); rmIs132 [P(unc-54) q35::yfp]], FUH236 [[P(hsp-16.1) hsp-16.1::gfp]+rol-6 (su1006)] and FUH237 [(daf-2 (e1370);
[P(hsp-16.1) hsp-16.1::gfp]+rol-6 (su1006)].
Growth Conditions
Bacterial cultures (ET505) for SILAC labeling were grown in 13C6-
15N2-lysine (heavy lysine) containing M63minimal media, harvested
by centrifugation and washed. Suspensions were spotted onto nitrogen-free agarose plates (Krijgsveld et al., 2003). The incorpora-
tion of heavy lysine into the proteome was more than 99% after four reproductive cycles. Worm eggs were collected and synchro-
nized populations of L1 larvae were obtained by overnight growth in M9medium. The L4 larval stage was considered to be day 0 and
larvae were transferred at this time point to new plates with or without 10 mM fluorodeoxyuridine (FUdR). For total proteome mea-
surements FUdR was omitted and progeny was removed by repeated sedimentation. Dead worms were removed manually before
harvesting.
Sample Preparation for Total Proteome Measurements
Wormswere rinsed off plates andwashedwithM9 salt solution tominimize bacterial contamination.Worm pellets were resuspended
in lysis buffer (4% SDS, 0.1 M Tris/HCl pH 8.0, 1 mM EDTA), incubated at 95C for 5 min and sonicated in a Bioruptor (Diagenode,
Lie`ge, Belgium) ultrasonication bath for 10min at high energy setting. Lysates were clarified by centrifugation (20,000 x g, 10min) and
protein concentration was quantified using the BCA assay kit (Pierce, Rockford, IL). In a typical experiment, 40 mg of total protein
lysate wasmixed with an equal amount of a 13C6-
15N2-lysine labeled lysate pool consisting of equal parts of lysates fromWT animals
aged 1, 6, 12 and 17 days. Proteins were reduced, alkylated and digested with endoproteinase LysC (Wako Bioproducts, Richmond,
VA) using the FASPmethod (Wisniewski et al., 2009). Peptide mixtures were either analyzed without fractionation or desalted via C18
solid phase extraction (SPE) cartridges (3M, St. Paul, MN) and subjected to isoelectric focusing on anOFFGEL system (Agilent, Santa
Clara, CA) using 13 cm linear immobilized pH gradient strips with a pH range from 3 to 10 according to published procedures (de
Godoy et al., 2008; Hubner et al., 2008). Fractionated or unfractionated peptides were purified via StageTips (Rappsilber et al., 2007).
Biochemical Isolation of Protein Aggregates
Approximately 600 worms were resuspended in 550 ml lysis buffer (50 mM Tris/HCl pH 8.0, 0.5 M NaCl, 4 mM EDTA, 1% (v/v) Igepal
CA630, Complete proteinase inhibitor cocktail (Roche Diagnostics, Mannheim, Germany)) and sonicated for 8 min at 0C in a Bio-
ruptor sonication bath at high energy setting. Lysates were clarified (1,000 g, 1 min, 4C) and protein content was adjusted to equal
levels. For proteomemeasurements, a lysate pool of 13C6-
15N2-lysine labeled animals wasmixed with each of the samples. Insoluble
proteins were sedimented by ultracentrifugation (500,000 rcf, 4C, 10min) and subsequently washed twice with modified RIPA buffer
(50 mM Tris/HCl pH 8.0, 0.15 M NaCl, 4 mM EDTA, 1% (v/v) Igepal CA630, 0.5% sodium deoxycholate, complete protease inhibitor
cocktail) before solubilization in 2% SDS containing sample buffer for 10 min at 95C. Proteins were resolved by SDS-PAGE and
either analyzed by Coomassie staining or immunoblotting, or processed for MS analysis by in gel digestion and StageTip purification.
MS and Data Analysis
Peptides were separated on C18 reversed phase nano-HPLC columns (Nagaraj et al., 2011; Walther and Mann, 2011) with gradient
durations of 140 or 280 min for fractionated or unfractionated samples, respectively, and sprayed online into LTQ-Orbitrap Velos or
Orbitrap-Elite mass spectrometers (Thermo Fisher Scientific, Bremen, Germany) (Michalski et al., 2012; Olsen et al., 2009). In each
scan cycle, fragmentation spectra of the 10 most intense peptide precursors in the survey scan were acquired in the higher-energy
collisional dissociation (HCD) mode (Olsen et al., 2005). Raw data was processed in the MaxQuant software environment (Cox and
Mann, 2008) and peak lists were searched with Andromeda (Cox andMann, 2011) against a database containing the translation of all
predicted proteins listed in Uniprot (release January 15, 2012) as well as a list of contaminants including commonly observed human
keratins as well as the NCBI protein database of E. coli strain K12 (release date January 25, 2010). The minimal required peptide
length was set to seven amino acids and both protein and peptide identifications were accepted at a false discovery rate of 1%.
Proteomics raw data and selected MaxQuant output files have been deposited to the ProteomeXchange Consortium (Vizcaı´no
et al., 2014) via the PRIDE partner repository with the dataset identifier PXD001364.
Proteasome Activity Assays
Worms were lysed by ultrasonication in the presence of 2 mM ATP and proteasomal activity was performed as previously described
using the fluorogenic substrate Z-Gly-Gly-Leu-AMC (Kisselev and Goldberg, 2005; Vilchez et al., 2012).
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Immunostaining and Microscopy
WT or daf-2 mutant worms expressing HSP-16.1::GFP were mounted on a 2% agar pad in 0.25 mM levamisole. A minimum of 20
wormswere scored for each strain. To visualize actin, wormswere fixed in acetone and stained with rhodamine-phalloidin (Molecular
Probes R415). Fluorescence imaging was performed on a Zeiss Axiovert fluorescence microscope.
In Silico Aggregation Propensity Calculations
As the observed insoluble aggregates are unlikely to be all of amyloid nature, to predict the intrinsic aggregation propensity of
proteins we adopted the recently developed CamSol method (Sormanni et al., 2015a), which avoids the bias of the Zyggregator
method of predicting specific amyloid aggregation rates (Tartaglia and Vendruscolo, 2008). We started from the CamSol intrinsic
solubility profile, which consists of a score for each residue along the sequence, and used it as a starting point to calculate a single
aggregation propensity score (‘Z-score’) for each protein. The main principle defining this Z-score from the CamSol intrinsic profile is
that the overall aggregation propensity of the protein should be proportional to the contribution given by the regions of the sequence
that are aggregation-prone, attenuated by the regions that are aggregation-resistant, and normalized with respect to the protein
length.
The CamSol intrinsic profile is calculated using a linear combination of physico-chemical properties of amino acids that have
generally been associated with the solubility of proteins (Chiti et al., 2003, Fernandez-Escamilla et al., 2004, Pawar et al., 2005, Pech-
mann et al., 2009), namely hydrophobicity, electrostatic charge, and a-helical and b sheet propensities. The Wimley-White scale
(Wimley and White, 1996) is selected as hydrophobicity scale and a-helix and b sheet propensities are calculated from the Protein
Data Bank (PDB) using representative structures with a filter of 50% sequence identity (Sormanni et al., 2015a). The linear combina-
tion results in the position-dependent score si, which for a given residue i, is thus:
si = ahydp
hyd
i + aCp
C
i + aap
a
i + abp
b
i (1)
where phydi , p
C
i , p
a
i and p
b
i are the hydrophobicity, the charge (at neutral pH), the a-helical and the b sheet propensities, respectively,
while the a values represent the constants of the linear combination (Sormanni et al., 2015a). The si values are then smoothed over a
seven amino-acid window in order to account for the effects of neighboring residues, and corrected with two additional terms to pro-
vide the intrinsic solubility profile Si
Si =
1
7
X3
j =3si + j + apatI
pat
i + agkI
gk
i (2)
where Ipati is the correcting term that takes into account the presence of specific patterns of alternating hydrophobic and hydrophilic
residues and Igki is the correcting term that takes into account the gatekeeping effect of individual charges, defined as
Igki =
X5
j =5e
 j4200 ci + j: (3)
where ci + j is the charge of the amino acid i+j.
Once the intrinsic CamSol profile Si is obtained, the overall aggregation propensity score (Z-score) can be defined as
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is the residue-specific aggregation-prone contribution, which is dependent on the parameter thdown, that represents a minimum
‘aggregating score threshold’ filtering the regions of the profile that contribute to the overall aggregation propensity,
~S
up
i ðthupÞ=

Si  thup if Si > thup
0 if Si% th
up
is the residue-specific aggregation-resistant contribution, which is dependent on thup parameter, which is the threshold that filters the
regions of the profile that act to attenuate the overall aggregation propensity, uupi and u
down
j are the soluble-region weights and ag-
gregation-prone region weights respectively, L is the length of the protein and g and d are two constants that specify the functional
law of the Z-score with respect to the protein length. The minus sign in the formula refers to our sign convention for which
higher Z-scores represent higher aggregation propensity, while lower Z-scores indicate higher solubility. The parameters
thup; thdown; uupi ;u
down
j ; g and d, have been tuned with aMonte Carlo simulation aimed at maximizing both the correlation coefficient
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of the Z-score with an ensemble of protein aggregation rates measurements available in the literature (DuBay et al., 2004), and the
efficiency in the separation of the Z-score distributions of two datasets of known non-aggregating and aggregating peptides respec-
tively, obtained from a systematic literature search.
Accuracy in the binary prediction of aggregate and non-aggregate peptide datasets has been tested upon finishing the optimiza-
tion, and an additional correlation control has been performed with the solubility of a set of protein mutants (Sormanni et al., 2015a).
Statistics and Bioinformatic Analysis
Prediction of subcellular localization, signal sequences and transmembrane segments were performed using WoLF PSORT (Horton
et al., 2007), SignalP (Petersen et al., 2011) and TMHMM v. 2.0 (Krogh et al., 2001) algorithms, respectively. Further annotation
included predicted tissue specificity of expression (Chikina et al., 2009), analysis of Pfam protein families (Finn et al., 2008) and
gene ontology databases (Ashburner et al., 2000). Benjamini-Hochberg FDR-controlled Fisher Exact test as well as one- and two-
dimensional annotation enrichment analysis was performed in the Perseus data analysis suite (Cox andMann, 2012). Fuzzy c-means
clustering of time course profiles was carried out using the Mfuzz package in the statistical programming language R (Kumar and
Futschik, 2007).
In time course analyses of individual proteins inWT animals, only those proteins were displayed that were quantified at day 1 and at
least at three consecutive time points. Statistical significance of abundance differences of protein subsets across different time
points or strains were generally performed using the Wilcoxon signed rank test in which only those proteins were considered that
were quantified in both conditions. To identify aggregation-prone proteins that were significantly affected by aging, those proteins
that were quantified in at least 3 out of 4 biological replicate experiments at day 1 and day 12 were subjected to a Welch’s t test
and filtered based on a 5% permutation-based false discovery rate threshold.
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Figure S1. Proteomic Analysis of Aging in C. elegans, Related to Figure 1
(A) Reproducibility of SILAC-based proteomic analyses. Four biological replicates of WT animals at the indicated ages were collected independently and their
proteomes were analyzed by quantification against the same SILAC spike-in standard. Each one of the four replicates (open circles) was prepared on a different
day than the remaining three (closed circles). Principal component analysis shows that different individuals of the same age cluster closely together in the two-
dimensional plot, demonstrating that the sum of technical and biological variation is much smaller than the age-related changes in theC. elegans proteome (Table
S1A). On a whole proteome level, this allows analyzing results as a function of age only, and to disregard technical variation and differences between individual
worms.
(B) Comparison of GO categories of proteins that changed in abundance in the early (day 6 versus day 1) and late stage in life (day 22 versus day 6) of WT animals
(Table S2A). All terms that were significantly affected in either of the two periods are displayed (Wilcoxon rank sum test at 5% Benjamini Hochber FDR) and their
relative changes were plotted against each other. The dashed gray line indicates the position of categories which are equally affected early and late in life.
Selected outliers are indicated in the plot.
(C) Correlation between transcriptome data (Golden andMelov, 2004) and the proteomics dataset of this study. The Pearson correlation R between both datasets
is displayed.
(D) Proteins that increase in abundance during aging are targets for dicer-mediated miRNA repression (Welker et al., 2007). The fractions of dicer (dcr-1) targets
(transcriptionally upregulated in dcr-1mutants) among proteins that increased > 4-fold (50 of 133 proteins) or > 2-fold (99 of 357 proteins) in abundance from day 6
to day 22 of aging as well as proteins that decreased < 4-fold (6 of 66 proteins) or < 2-fold (25 of 325 proteins) in abundance or remained within threshold (less than
2-fold change in either direction) (173 of 3307 protein) are shown.
(E) Significantly affected functional categories among the proteins that increased 2-fold (left panel) or decreased 2-fold (right panel) in abundance in aged (day 22)
animals. The enrichment factors of gene ontology (GO) terms are plotted against the p-value derived from Fisher Exact tests. Each term is represented by a circle.
The size of the circle reflects the number of proteins affected. Only categories with at least 4 members are displayed. Selected categories are indicated (Tables
S2B and S2C).
(F) Abundance change of TTR-like proteins during aging.
(G) Abundance change of quantified subunits of the mitochondrial respiratory chain complex I during aging. At least 17 subunits were quantified at each time
point. ****p-value < 1.53 3 1015 from Wilcoxon signed rank test.
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Figure S2. Abundance Changes in Components of the Proteostasis Network during Aging in WT Animals, Related to Figure 2
(A) The proteostasis network (PN) is divided into three main categories: protein synthesis (green), comprising transcription factors, translation factors and
ribosomal components; conformational maintenance (blue), comprising components involved in folding and stress response; and degradation (red), comprising
components involved in the ubiquitin proteasome system and autophagy (Table S3A).
(B) Decline of protein synthesis during aging determined by SILAC pulse labeling. Animals aged 1, 4, 6 or 12 days were transferred to a heavy lysine-labeled food
source for 24 hr. Boxplot shows the distribution of heavy lysine incorporation into proteins. At least 500 proteins were quantified at each time point (Table S1C).
p-value < 2.2 3 1016 from Wilcoxon signed rank test.
(C) Chymotryptic proteasome activity in lysates of old (day 12) and young (day 1) worms, as measured with fluorogenic synthetic peptide as substrate in the
presence of ATP (see Extended Experimental Procedures). Assays were performed in the absence (DMSO) or presence of proteasome inhibitors lactacystin
(100 mM) or MG132 (25 mM). Error bars represent standard deviations from 6 replicate experiments. p-value < 7.4 3 1013 from Welch’s t test.
(D–I) Abundance change of proteins involved in protein folding and stress response in WT. Autophagy-related components (D), DnaJ/Hsp40 homologs (E), TPR
domain proteins that potentially interact with chaperones (Haslbeck et al., 2013) (F), subunits of the TRiC/CCT chaperonin (G), components of the mitochondrial
PN (H), components of the endoplasmic reticulum PN (I) (Table S3B).
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Figure S3. Proteome Changes in WT and IIS Mutant Worms, Related to Figure 3
(A) Proteome imbalance in WT, daf-2, daf-16 and hsf-1 mutant animals expressed as proteome imbalance index. Abundance differences of proteins that
increased (left) or decreased (right) in abundance during aging relative to day 6 were summed up for each strain and normalized to the number of quantified
proteins. The total number of quantified proteins was similar in the different worm strains and ranged from 3743 to 4700 proteins (Table S1B).
(B–E) Abundance profiles of catalases (B), SOD proteins (C), and small HSPs (D) along the lifespan of WT, daf-2, daf-16 and hsf-1 animals. Log2 changes in
abundance are shown relative to WT animals at day 1.
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Figure S4. Isolation of Insoluble Aggregates from Worm Lysates, Related to Figure 4
(A and B) Validation of the biochemical procedure for the isolation of insoluble protein aggregates was performed with WT worms expressing FlucDM-GFP, a
destabilized double mutant of firefly luciferase fused to GFP (Gupta et al., 2011) in body wall muscle cells.
(A) FlucDM-GFP expressing worms (day 1) were exposed to heat shock (33C for 90 min), followed by recovery for 90 min at 20C. Insoluble fractions were
isolated from worm lysates by centrifugation (see Experimental Procedures), analyzed by immunoblotting with anti-luciferase antibodies, and quantified by
densitometry. Error bars represent standard deviations from three independent experiments. **p-value < 0.01, Welch’s t test.
(B) Fraction of insoluble FlucDM-GFP in young (day 1) and old (day 19) WT worm populations analyzed as above. Error bars represent standard deviations from
four independent experiments. **p-value < 0.01, Welch’s t test.
(C) Experimental design for the quantitative analysis of insoluble proteins. Synchronized worm populations at different ages were lysed and mixed with a
metabolically (SILAC) labeled internal protein standard. Insoluble proteins were isolated, separated by SDS-PAGE, subjected to in gel digestion and analyzed by
nano-HPLC coupled MS.
(D) Experimental design for the analysis of protein aggregation propensities. Lysates from aged worms (day 12) were fractionated. Total lysates as well as
insoluble and soluble fractions were quantified against an identical SILAC standard to determine the insoluble and soluble fraction of each protein.
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Figure S5. Proteomic Analysis of Protein Aggregation during Aging, Related to Figure 4
(A) Procedure for aggregate isolation does not enrich for membrane proteins. Proportions of identified proteins in total and insoluble fractions for soluble proteins
and proteins that were predicted to contain at least one transmembrane segment (TMS) are shown. TMS were predicted with THMM.
(B andC) Physico-chemical properties of proteins that affect aggregation behavior. The overall hydrophobicity (B) of proteins (which is associatedwith a tendency
of forming a stabilizing hydrophobic core) increases with their abundance, and the aggregation propensity score (Z-score; see Extended Experimental Pro-
cedures) of the proteins (C) decreases with their abundance, indicating that highly abundant proteins tend to be more soluble.
(D) GO annotation distribution among proteins with high and low intrinsic aggregation propensities in WT animals at day 12. Enrichment scores and p-values of a
Wilcoxon rank sum test are plotted against each other. Only categories with a cutoff of 5% Benjamini-Hochgerg FDR and at least 4 proteins are displayed
(Table S4A).
(E) Members of the small HSP family of molecular chaperones display a high aggregation rate compared to the overall distribution of aggregation propensities of
all quantified proteins in the proteome of day 12 WT animals (Wilcoxon rank sum test p-value: 3.4 e-3).
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Figure S6. Protein Aggregation in Lifespan Mutant Worms during Aging, Related to Figure 5
(A) Time course analysis of protein aggregation in daf-2, daf-16 and hsf-1mutants, compared to WT. Boxplots of SILAC ratios as in Figure 5A are shown. In this
experiment fractionation of hsf-1 mutant animals of 12 days of age was not reliable due to the limited number of live worms recovered. Number of quantified
proteins: WT day 1, 2010; day 6, 1698; day 12, 1987; day 17, 1355; daf-2mutant day 1, 1093; day 6, 1103; day 12, 2660; day 17, 1599; day 22, 1572; day 28, 1759;
daf-16mutant day 1, 1120; day 6, 993; day 12, 1366; hsf-1mutant day 1, 1318; day 6, 1739 (Table S1D). ****p-value < 2.23 1016 fromWilcoxon signed rank test.
(B) Analysis of differential aggregation between aged daf-2mutants andWT animals (day 12). Worm samples were separated into soluble and insoluble fractions
and analyzed by SDS-PAGE and Coomassie staining. Note that only 25% of total and soluble fraction is loaded. One representative out of 3 independent ex-
periments is shown.
(C) Annotation distribution analysis of differential aggregation between daf-2 and WT animals at 12 days of age. Enrichment scores and p-values of a Wilcoxon
rank sum test are plotted against each other (Table S4B).
(D) Increased proteostasis capacity in daf-2 mutant worms. Fluc-DM-GFP and luciferase activities were measured by immunoblotting with anti-luciferase
antibody and luminescence assay, respectively, in 12 days old WT and daf-2mutant worms expressing muscle-specific Fluc-DM-GFP. Protein levels, activities
and specific activities (activities per amount of FlucDM-GFP protein) are given in arbitrary units with values in WT set to 1. Results from 7 independent mea-
surements ± SD are shown. ***p-value < 0.0001; **p-value < 0.001, Welch’s t test.
(E) SDD-AGE analysis of WT and daf-2 mutant worms expressing muscle-specific Q35-GFP. Worm extracts from 2 days old animals were analyzed with and
without incubation at 95C for 10min. Q35-GFP was visualized by immunoblotting. Note that total amounts of Q35-GFP detected after heat treatment are similar
in WT and daf-2 mutant extracts.
S10 Cell 161, 919–932, May 7, 2015 ª2015 Elsevier Inc.
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2.4 Importance of the analysis
Experimental data of MS-based protein abundances shows that widespread protein
aggregation occurs upon ageing in WT nematodes as the proteostasis machinery
gets impaired and the proteome remodelled (Figure 4 and 1 in section 2.3). The
phenomenon of protein aggregation was already largely associated with pathological
events, namely misfolding and neurodegenerative diseases [59, 62, 67, 96, 230].
Intuitively, since we observe in WT animals that the amount of protein aggregates
increases upon ageing (Figure 4A, section 2.3), we would expect the long-lived
strain daf-2 to show a lower amount of inclusions than the WT when comparing age-
matched data points. Conversely, we would logically expect the short-lived mutant
strain, hsf-1, to accumulate more aggregates than the WT upon ageing. However,
both long-lived and short-lived mutants exhibit the presence of more insoluble protein
deposits than the WT strain as the animals grow older instead (Figure 5A and S6A,
section 2.3). Aggregation is also widespread in long-lived and short-lived strains,
with more than a thousand proteins forming insoluble aggregates. This translated
in a large overlap between the proteins identified as forming deposits, however the
extent by which each protein would aggregate was very diverse across the strains
(Figure 5 and S6, section 2.3).
To understand the differences in the aggregation observed in WT, short-lived
and long-lived strains, we asked whether the overall extent of insoluble material
accumulated differently across the strains could be explained in terms of some
specific, general physico-chemical principles. Since both short-lived and long-lived
animals were forming more aggregates than WT at day 12 of adulthood (when
proteostasis decline is observed in the WT strain), we separated in the analysis the
proteins forming less aggregates in hsf-1 (short-lived) compared to WT and daf-2
(long-lived) compared to WT. For all the remaining proteins in daf-2 or hsf-1 forming
more aggregates than WT at day 12, we looked for a collective differential behaviour
in terms of aggregated mass reflected in a given physico-chemical property. For each
mutant strain, long- or short-lived, we grouped the proteins forming more aggregates
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into four quartile groups, according to the fold difference in their aggregated mass
with respect to the WT strain. In each group, we then evaluated aggregation-related
physico-chemical properties using the Camsol Intrinsic method discussed in section
2.2 and 2.3 and the s2D predictor of secondary structure populations [209]. This
enabled us to highlight which kind of properties may drive the accumulation of
insoluble aggregates in the long-lived and short-lived strains compared to the WT
animals.
In Figure 5 D-G of section 2.3 we report the physico-chemical properties that we
found were significantly modulated by the amount of insoluble aggregates present in
either the long- or short-lived strains compared to the WT. Strikingly, a completely
different pattern emerges when we compare the aggregation increase in the daf-2
strain and in the hsf-1 strain against the WT in terms of physico-chemical principles.
While proteins aggregating the most in the short-lived strain compared to the WT
are the most aggregation prone (Figure 5D, right scatter plot with violet points),
this pattern is reversed in the long-lived strain (Figure 5D, left scatter plot with red
points). Also, proteins forming increasingly more aggregates in the daf-2 strain
compared to the WT are more charged, disordered and hydrophilic (Figure 5E-G,
section 2.3), suggesting that the enhanced aggregation observed in this long-lived
strain is not the result of an intrinsic pathological process accompanying proteostasis
decline. Instead, it could be the result of an extrinsic mechanism triggered by the
organism to remove soluble, toxic oligomeric species by assembling them into larger
insoluble deposits, in order to restore protein homeostasis.
Combining the experimental information of the protein aggregate abundances
with the in silico physico-chemical properties predictions thus represented a key
step in understanding the molecular bases of proteostasis disruption and its restoring.
Furthermore, it provided the first pieces of evidence, in a living organism, of a protec-
tive proteome-wide aggregate response activated upon ageing to restore functional
protein balance.
Chapter 3
Life Over the Solubility Edge
in ageing C. elegans
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3.1 Introduction
Almost a decade ago, Tartaglia and co-workers proposed the existence of a strong
anticorrelation between the aggregation rates, which were measures in vitro of the
limited group of proteins available in the literature at the time, and the corresponding
human mRNA expression levels measured in vivo [130]. This anticorrelation was
explained as a net result of two opposing effects on the primary sequence of a
protein. On one side, the effect of random mutations, which tend to increase the
aggregation propensity of the protein; and on the other side the effect of evolution,
which push to keep the protein soluble at the concentration required in the cell for
their biological roles [231–235]. Hence, proteins would have co-evolved with their
cellular environment to be sufficiently soluble at the levels at which they need to
be expressed in the cell for optimal functioning, therefore not much affected by the
cellular macromolecular crowding [236], but with almost no margin of safety to
respond to genetic or environmental factors that either decrease their solubility or
increase their cellular concentration [130]. This co-evolution involves the presence
of a complex network of cellular machineries, the protein homeostasis network,
responsible for maintaining proteome functional balance against aberrant folding and
aggregation, processes that can generate toxic species in the cell [72, 74, 77, 237].
As organisms grow old, however, the protein homeostasis network becomes impaired
and widespread aggregation occurs [90, 94, 95, 238]. Protein aggregation in turns
further disrupt protein homeostasis [68], forming a vicious circle of degeneration
[65, 67, 72, 74, 77, 82]. As already seen in Chapter 1, age is considered to be the
greatest risk factor for a variety of neurocognitive disorders, which represent the most
debilitating, expensive, and common medical conditions in recent times [24, 34] and
whose nearly universal hallmark is the formation of protein aggregates [61–63].
The concept by which proteins are expressed close to their solubility limits has
been referred to as the "life on the edge hypothesis" [130]. Suggested on the basis
of the limited experimental data available at the time, whether this concept could
have general validity for proteins in the cell remains an open question, which could
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help rationalize a number of observations on protein aggregation in ageing and
neurodegenerative diseases.
Using mass spectrometry data [90], here we provide the first proteome-wide
evidence for the life on the edge hypothesis in the nematode C. elegans, and we
show that proteins in the adult worm are actually living just over the edge of their
solubility. To determine to what extent proteins cross the solubility limit, we classify
three measured physical quantities related with protein levels, namely abundance,
aggregation and supersaturation, and we link them to the life on the edge hypothesis.
The observation that proteins are found in the adult nematode just over the solubility
limit prompts the question of how this limit is crossed upon ageing and if it is a
general threshold over which any protein would aggregate. To tackle these questions,
we show that with age there is a proliferation in the aggregate levels, which is not due
to an increase in the overall protein content in the worm, suggesting that the critical
concentration is a threshold that is protein-specific and that aggregation upon age
may be due to a decrease in the solubility rather than an increase in the expression
levels. By looking at the different contributions that supersaturation, abundance and
aggregation give to this age-dependent proliferation in aggregate levels, we suggest
that supersaturation plays a key role, specifically for the most abundant proteins, in
the process of healthy ageing, as the largest contribution to the total aggregate mass
is provided by the most abundant proteins. Further studies will be needed to establish
how these principles can be extended from healthy ageing to neurodegenerative
disorders, and from worms to humans.
3.2 Results
3.2.1 Life on and over the solubility edge in adult C. elegans
In order to test whether the life on the edge hypothesis holds true at a proteomic
level in an eukaryotic organism, we took advantage of recent in vivo proteome-wide
mass spectrometry data acquired in wild-type strain nematodes C. elegans focusing
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on one set up experiment in which total, soluble (supernatant) and insoluble (pellet)
protein abundances were measured in the adult worm [90]. By looking at the proteins
detected in at least two out of three replicas, we found that in the adult wild-type
worm (day 12 of adulthood from L4 stage), about 75% of the proteins detected are
found in the pellet fraction (Figure 3.1A, 2792 proteins). This observation implies
that nearly three quarters of all proteins detected is expressed at least at the critical
concentration. Of these proteins, we evaluated and normalised the total, supernatant
and pellet abundance in terms of mass spectrometry absolute LFQ values (see section
3.4.1). Defining the solubility as the supernatant abundance in the presence of a
pellet fraction, we observe that in adult worms nearly all proteins are lying on, or in
fact just above, the edge of their solubility (Figure 3.1B).
The findings that we have reported here, therefore, suggest that these data repre-
sent experimental evidence for the life on the edge hypothesis in an eukaryotic model
organism and indicate that widespread aggregation occurs, although the amounts of
aggregates are small in comparison to the total abundance. Such finding is also in
agreement with the trend previously observed for the E. coli proteome in a cell-free
reconstituted system [239].
3.2.2 Life over the solubility edge: the relationship between
aggregation, supersaturation and abundance of proteins
Since nearly all detected proteins in the adult worm are expressed on and just above
their solubility limits (Figure 3.1) widespread aggregation occurs, thus compromising
protein homeostasis. We next asked how can we measure, from the data, the extent
and the way in which a protein is exceeding the solubility limit. To tackle this
question, we define three main ways in which the landscape over the solubility
edge, represented by the Pellet-Soluble abundance plane (Figure 3.2) can be spanned
and analysed in terms of risk to the cellular protein homeostasis. Each way is
characterised by the evaluation of a physical quantity whose value increases in a
different direction with respect to the solubility limit.
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Fig. 3.1
Validation of the Life on the Edge hypothesis in adult worms
(A) Pie chart showing the percentage and number of aggregating (red filling) and
non-aggregating proteins detected in aged (day 12) wild-type worms. (B) Scatterplot
of protein total abundance (T ) plotted against soluble abundance (S) in log10 scale
for each protein quantified (see section 3.4.1). The colour code is matching the pie
chart choice. The unity line, corresponding to the solubility limit for all proteins
detected with an aggregated fraction (red points), is shown in black. For the proteins
that do not form insoluble deposits (grey points), we do not have an estimate of the
solubility limit, but only a lower bound for it (i.e. the total abundance).
The first quantity is supersaturation (σ), which is defined as the ratio between
the total abundance (T ) of a protein and its critical concentration C∗, which can be
approximated as the supernatant abundance (S) in the presence of a non-negligible
pellet fraction (P):
σ =
T
C∗ =
T
S
|P̸=0 (3.1)
With such a definition, supersaturation represents an experimental index of
aggregation propensity for a protein. The more the protein is supersaturated, the
more it is prone to aggregate.
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The second quantity is the protein aggregate load, defined as the pellet abundance
P (see section 3.4.1) and satisfying
P = T −S (3.2)
This variable gives information on the total mass of the aggregates of a given
protein. The third observable is the total protein abundance in presence of a detectable
aggregate load, (T |P ̸=0), which is a quantity proportional to the cellular protein
expression.
We evaluated supersaturation σ , aggregate abundance P and total abundance
T for all the 1828 proteins (see section 3.4.1) reported in the life on the edge plot
(Figure 3.1B, red points). These values refer to the proteome situation in the adult
day-12 nematode.
Since each quantity is maximised in a different direction with respect to the
solubility edge, different regions can be identified in the life over the solubility edge
landscape where proteins populate high values of supersaturation, aggregate or total
abundance. In order to show these regions and their overlaps, we highlighted the
20% most saturated, 20% most aggregated and 20% most abundant proteins (365
proteins in each set) with different colours in Figure 3.2 and used a subtractive
colour mixing model for their overlap, reporting a Venn diagram with the number of
proteins present in each intersection. Supersaturation, aggregation and abundance
have blue, yellow and red as base colours respectively.
We identified six different classes from the overlaps of the most supersaturated,
aggregated and abundant groups. We found that 290 proteins are only most super-
saturated (blue points in Figure 3.2), 34 proteins are only most aggregated (yellow
points in Figure 3.2) and 81 proteins are only most abundant (red points in Figure
3.2). Most abundant and most aggregated but not highly supersaturated proteins are
represented in orange in Figure 3.2 (256 entries), while 47 proteins appears to be
most supersaturated and most aggregated but not highly abundant (green points in
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Fig. 3.2
Visualisation of the most supersaturated, aggregated and abundant proteins
in the life over the edge solubility landscape
Scatterplot of pellet abundance (P) versus soluble abundance (S) in log10 scale (see
section 3.4.1) showing in colours the three classes of top 20% most supersaturated,
most abundant and most aggregated proteins and their intersections. Each class
contains 365 proteins. Number of proteins in each subgroup and relative colour code
are reported in the Venn diagram. Abundance data refer to day 12 wild-type worms.
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Figure 3.2). The black points in Figure 3.2, corresponding to 28 proteins, belong
to the region in which all the quantities have maximal values. Of the 1828 proteins
shown in the scatterplot of Figure 3.2, 1092 do not belong to any of the three sets,
and are shown in grey.
The overlaps between the most abundant, supersaturated and aggregated sets
provide information about the relationship between our physical quantities. While
there is a high overlap between the most aggregated and the most abundant proteins,
the most supersaturated set does not share a high number of proteins. Since super-
saturation represent an index of the aggregation propensity, we suggest that a vast
majority of the high abundant proteins have evolved to be less aggregation prone,
which is in agreement to what we predicted with our sequence-based algorithm
[90]. This trend is in agreement with previous findings that report an evolutionary
conserved trend of aggregation-prone proteins to be low abundant and subject to
decrease synthesis and high turnover [240]. However, the degree by which they are
more soluble is not high enough to avoid them from aggregating more than the low
abundant proteins.
On the other hand, the black proteins of Figure 3.2 (28 points) are highly abundant
and highly aggregation prone, therefore they also end up aggregating the most. Such
proteins, thus, represent a metastable subproteome in which the evolutionary pressure
might not be applied in the adult worm.
3.2.3 Aggregate proliferation in ageing C. elegans
Having established that proteins can cross over the solubility edge in terms of
supersaturation, abundance or aggregation, we now wish to probe if the critical
concentration is a property that is protein dependent, or if there is an overall critical
concentration over which all proteins aggregate. To address this question, we
used SILAC and absolute LFQ measurements of mass spectrometry total and pellet
protein abundance data upon ageing [90] to evaluate both the total and insoluble mass
variation of the proteome in the ageing C. elegans (Figure 3.3). Proteins predicted to
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be extracellular (see section 3.4.2) were excluded from the calculations, since being
functional in the extracellular space should have induced less evolutionary pressure
on them to evolve to higher solubilities relative to the intracellular proteins.
Fig. 3.3
Evolution of total and pellet amounts in ageing worms
Bar charts of the variations in intracellular proteome amounts upon ageing in
wild-type worms. The sum of the contributions of intracellular proteins relative
abundances are estimated at various time points with respect to day 1 of adulthood
(see section 3.4.2). (A) Total load variation upon ageing; 3078 proteins were
detected and quantified in the total fraction, for all the time points shown. (B)
Aggregate load variation upon ageing; 965 proteins were detected and quantified in
the insoluble fraction at all time points measured. (C) Correspondent total load
variation upon ageing calculated only for the subset of proteins having a detected
pellet fraction (965 proteins). Errors were calculated with a bootstrap method.
Eppendorf pictures are shown for each bar charts for better visualisation of the
quantity used for the analysis: Eppendorf in (A) and (C) imply the use of protein
total abundance measurements, while the Eppendorf in (B) indicates the use of
protein pellet fraction measurements. Bar charts are coloured according to the
proteins involved in the calculation: black for the 3078 proteins, and red for the 965
proteins.
We estimated the total amount of intracellular protein material (see section 3.4.2)
from the set of proteins detected in the total fraction at all time points (3078 proteins)
(Figure 3.3A). We do not observe any significant change in the overall intracellular
proteome amount upon ageing, even if about a third of proteins are found to change
in abundance of at least 2-fold upon age [90]. Using the data of insoluble abundances,
taking all proteins detected to form pellet in day 01 to day 17, we evaluated with
the same procedure the whole intracellular aggregate amount with respect to day
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01. Interestingly, we observe a sharp aggregate amount proliferation from day 12 of
adulthood (Figure 3.3B), which is not reflected by an increase in the total amount of
protein (Figure 3.3A). Also, this aggregate proliferation is not due to an increase in
the total amount of proteins having a detected insoluble amount either, namely the
supersaturated total amount. In fact, evaluating the total amount relative to day 01
for the 965 proteins forming aggregates throughout the days, we do not observe any
change upon ageing (Figure 3.3C).
We have shown that the worm undergoes a reshaping of its proteome composition
upon ageing without altering the total protein amount available in the cell. Even if
the reshaping of the proteome does not involve a change in the total protein amount,
it causes an overall change in the cellular environment that results into a boost
of the total aggregate fraction. We estimated that between day 6 and day 12 the
total aggregate load obtained by the contribution of each one of the 965 proteins
detected with insoluble fraction is almost doubled (Figure 3.3B). Taken together, our
results suggest that the mechanism by which proteins are further pushed far from
the solubility edge with ageing is not due to an overall increase in their abundance
content, but by some other mechanism, which reduces their solubility, which could
be the disruption of a protein control machinery. Also, since the aggregates are
increasing regardless of the total amount, this represents evidence that the critical
concentration is not a general threshold that proteins might overcome, but it is a
principle that is protein dependent, confirming the concept of the life on the edge.
3.2.4 Age-dependent aggregate proliferation in terms of
supersaturation, aggregation and abundance
Having established that there is a proliferation of the insoluble protein amount
starting from day 12 of adulthood, we now wish to probe which proteins and physical
parameters are responsible for such behaviour. To this extent, we estimated the
total (Figure 3.4A) and average (Figure 3.4B) contribution to the aggregate amount
relative to day 01 considering all the six subsets of proteins we defined in Figure
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3.2 from the overlaps of the 20% most supersaturated, abundant and aggregated
proteins at day 12. A Venn diagram showing the screened mapping of the most
supersaturated, abundant and aggregated proteins using the time-course insoluble
fraction data of Figure 3.2, where intracellular proteins have been removed, is shown
in Figure 3.4A. The total contribution to the aggregate amount relative to day 01
(Figure 3.4A, scatter plot) for each of the six resulting subsets was obtained by
summing up the values calculated for the Pellet amount of Figure 3.3B only from
the group of proteins belonging to the subset, whose number is indicated in the Venn
diagram. The average contribution to the aggregate amount relative to day 01 (Figure
3.4B), was obtained from the total contribution of Figure 3.4A by normalising to the
protein number in each subset.
Notably, proteins that are most supersaturated, abundant and aggregated on
average contribute the most to the aggregate proliferation we detect in the old worm
(black triangles, Figure 3.4B). Such proteins though are very few in numbers, hence
they do not contribute much to the overall total aggregate amount (black triangles,
Figure 3.4A). On the other hand, most abundant and most aggregated proteins
(orange triangles in Figure 3.4), contribute the most the total aggregate amount and
quite significantly to the average aggregate amount, despite their high number (182
proteins). Most interestingly, supersaturated proteins (blue squares, green circles,
and black triangles in Figure 3.4) are not contributing to the aggregate proliferation
unless they are abundant. Hence, taken together, our results indicate that upon
ageing, supersaturation does not seem to play a role in the disruption of the solubility
threshold. Since the present work is focused on the process of healthy ageing of the
nematode, we do not exclude that supersaturation may play a key role in case or
neurodegeneration [76, 131].
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Fig. 3.4
Contribution of supersaturation, aggregation and abundance to aggregate
amounts in ageing worms
Scatterplots of the contribution of the proteins belonging to the most supersaturated,
aggregated and abundant proteins and corresponding overlaps to the variations in
intracellular aggregate amounts upon ageing in wild-type worms of Figure 3.3B.
Dashed lines are shown between points only as a guide to the eye. (A) Total pellet
amount relative to day 01 of adulthood measured at different time points evaluated
for the subset of intracellular proteins belonging to the classes of top 20% most
supersaturated, most aggregated and most abundant and their intersections of Figure
3.2. Total contribution to the aggregate load for each subgroup is shown in a
different colour and marker. Number of proteins in each subgroup and relative
colour code are reported in the Venn diagram. (B) Average contribution, per protein,
of to the aggregate load variation relative to day 01 for each class shown in (A).
Errors were calculated with the bootstrap method used for Figure 3.3 (see section
3.4.2).
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3.2.5 Functional protein classes responsible for the age-dependent
aggregate increase
Finally, we identified the proteins most responsible for the increase in the aggregate
levels upon ageing of Figure 3.3, and report the list in Table 3.1. These 32 proteins
are the proteins that have the highest weight in the calculation of the change of
aggregate amount relative to day 01, and which can account for the fold change in
the aggregate levels. We found three major functional classes are associated with
these proteins: molecular chaperones (small heat-shock proteins sip-1 and hsp-25
and heat shock proteins hsp-90 and hsp-70), RNA-binding and translation (ribosomal
components and elongation factors); and structural activity (intermediate filaments,
actin, tubulin).
Small heat shock proteins have been previously detected to co-aggregate and
drive aggregation of proteins [241–245], in accordance with the hypothesis that in
vivo aggregation may have a cytoprotective function by sequestering potentially
toxic protein species [90, 245–247].
Ribosomal proteins and proteins related to translation functions have been previ-
ously observed to be significantly enriched in aggregate inclusions of older nema-
todes compared to younger nematodes [95], with implications on the lifespan of the
organism. Proteins belonging to this functional class, also, have been predicted to
be at the highest risk for oxidative destabilization, a suggested dominant source of
protein stability and solubility loss upon ageing [248].
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Table 3.1
List of proteins contributing the most to the aggregate proliferation
Protein ID, protein name, corresponding gene name and the protein family
according to the Uniprot database [211] are shown for the 32 proteins found most
responsible for the aggregate proliferation.
Protein ID Protein names Gene names Protein families
Q20363 Stress-induced protein 1 sip-1 F43D9.4 Small heat shock protein
(HSP20)
P53013 Elongation factor 1-alpha
(EF-1-alpha)
eft-3 F31E3.5;
eft-4 R03G5.1
TRAFAC class translation
factor GTPase
superfamily, Classic
translation factor GTPase,
EF-Tu/EF-1A subfamily
Q19286 Intermediate filament
protein ifb-2 (Cel IF B2)
(Intermediate filament
protein B2) (IF-B2)
ifb-2 F10C1.7 Intermediate filament
Q18688 Heat shock protein 90
(Abnormal dauer
formation protein 21)
daf-21 C47E8.5 Heat shock protein 90
Q19289 Intermediate filament
protein ifb-1 (Cel IF B1)
(Intermediate filament
protein B1) (IF-B1)
ifb-1 F10C1.2 Intermediate filament
Q45EJ8 Lin-5 (Five) Interacting
protein
lfi-1 CELE_ZC8.4
ZC8.4
Q21067 Intermediate filament
protein ifc-2 (Cel IF C2)
(Intermediate filament
protein C2) (IF-C2)
ifc-2 M6.1 Intermediate filament
P29691 Elongation factor 2 (EF-2) eef-2 F25H5.4 TRAFAC class translation
factor GTPase
superfamily, Classic
translation factor GTPase,
EF-G/EF-2 subfamily
Q9TY23 Prion-like-(Q/N-rich)-
domain-bearing
protein
pqn-22 C46G7.4
CELE_C46G7.4
O02056 60S ribosomal protein L4 rpl-4 B0041.4 Ribosomal protein L4P
Q5H9M9 Heat Shock Protein hsp-25 C09B8.6
CELE_C09B8.6
Small heat shock protein
(HSP20)
P27604 Adenosylhomocysteinase
(AdoHcyase) (EC 3.3.1.1)
(Protein dumpy-14) (S-
adenosyl-L-homocysteine
hydrolase)
ahcy-1 ahh dpy-14
K02F2.2
Adenosylhomocysteinase
Continued on Next Page. . .
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Protein ID Protein names Gene names Protein families
P09446 Heat shock 70 kDa
protein A
hsp-1 hsp70a
F26D10.3
Heat shock protein 70
O45815 ACTin act-5
CELE_T25C8.2
T25C8.2
Actin
Q9XW17 Cytokinesis, Apoptosis,
RNA-associated
car-1
CELE_Y18D10A.17
Y18D10A.17
Q93572 60S acidic ribosomal
protein P0
rpa-0 F25H2.10 Ribosomal protein L10P
Q20206 Ribosomal Protein, Small
subunit
rps-11
CELE_F40F11.1
F40F11.1
Ribosomal protein S17P
Q27389 60S ribosomal protein
L13a
rpl-16 M01F1.2 Ribosomal protein L13P
P04255 Histone H2B 1 his-11 ZK131.5;
his-15 ZK131.9;
his-29 F35H10.11;
his-34 F17E9.9;
his-44 F08G2.1
Histone H2B
G5EFP2 Uncharacterized protein CELE_ZK1321.4
ZK1321.4
P90900 Intermediate filament
protein ifa-4 (Cel IF A4)
(Intermediate filament
protein A4) (IF-A4)
ifa-4 K05B2.3 Intermediate filament
O17921 TuBulin, Beta tbb-1
CELE_K01G5.7
K01G5.7
Tubulin
Q9BKU5 Uncharacterized protein CELE_Y37E3.8
Y37E3.8
Ribosomal protein L15P
P10984 Actin-2 act-2 T04C12.5 Actin
Q93573
Translationally-controlled
tumor protein homolog
tct-1 F25H2.11 TCTP
Q27535 Probable arginine kinase
ZC434.8 (AK) (EC
2.7.3.3)
ZC434.8 ATP:guanido
phosphotransferase
B3WFT8 Uncharacterized protein C14F11.4
CELE_C14F11.4
P49405 60S ribosomal protein L5 rpl-5 F54C9.5 Ribosomal protein L18P
O17687 NASP (Human Nuclear
Autoantigenic Sperm
Protein) homolog
nasp-2 C50B6.2
CELE_C50B6.2
Continued on Next Page. . .
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Protein ID Protein names Gene names Protein families
P91917 Obg-like ATPase 1 ola-1 tag-210
W08E3.3
TRAFAC class
OBG-HflX-like GTPase
superfamily, OBG
GTPase, YchF/OLA1
subfamily
P54412 Probable elongation factor
1-gamma (EF-1-gamma)
(eEF-1B gamma)
eef-1G F17C11.9
Q20751 Eukaryotic translation
initiation factor 5A-2
(eIF-5A-2) (Initiation
factor five protein 2)
iff-2 F54C9.1 EIF-5A
Notably, the protein contributing the most to the aggregate proliferation is sip-
1, a small heat shock protein that becomes active under acidic conditions and is
essential for nematode development and reproduction [249]. Interestingly, RNA
binding proteins and cytoskeletal proteins have been identified as more specific
and prominent substrates of sip-1 with respect to other molecular chaperones [249].
Cytoskeletal proteins, indeed, have also been suggested to be specific substrates of
the Hsp20 molecular chaperone family [250].
3.3 Conclusions
We find first evidence of the general validity of the life on the edge hypothesis in the
adult wild-type nematode C. elegans, and show that supersaturated abundant and
aggregated proteins escape the evolutionary pressure. Also, we found that the way
proteins exceed the solubility edge reflects a sudden proliferation in the aggregate
levels which is independent of the intracellular total content, and which is not due to
supersaturation. Proteins most responsible for such an increase can be mapped into
three main functional classes, which have been previously associated with the protein
homeostasis machinery: structural proteins, proteins involved in translation, and
heat shock and small heat shock proteins. The findings that we have reported here,
therefore, suggest that critical concentration is a principle that is protein-specific
and not a general threshold which proteins might overcome to aggregate, and that
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the way proteins cross the edge is not by an increase in their overall expression
levels, but by decreasing their solubility due to some other cellular factors, such as
disruptions in the protein control machinery.
3.4 Materials and Methods
3.4.1 Calculations of total, soluble and pellet abundances in the
adult nematode
Data of protein abundances (absolute LFQ values) from proteomic-wide mass spec-
trometry measurements of WT strain nematode C. elegans were obtained from Table
S1F of Ref. [90]. The data contained up to three replicas of supernatant, pellet and
total fraction measurements per protein taken at day 12 of the nematode life with
respect to the exit of the L4 larval stage. For each type of measurement (either total,
supernatant or pellet) only proteins found in at least two replicas were considered in
the calculations, and average and standard error were evaluated.
To be consistent with the definition of protein solubility considered as the maxi-
mum soluble fraction in present of a non-negligible amount of pellet, we defined the
total (T), soluble (S) and pellet (P) abundance as follows
T =
2tav + sav + pav
3
(3.3)
S =
2sav + tav− pav
3
(3.4)
P =
2pav + tav− sav
3
(3.5)
where tav, sav, pav are the total average, supernatant average and pellet average
of the mass spectrometry LFQ values respectively. Proteins resulting with negative S
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and P values were excluded in the calculation. With this normalisation, no preference
is given to any specific quantity detected by mass spectrometry, and the Eq. 3.6
T = S+P (3.6)
holds true. Errors on T , S and P were obtained using the law of error propagation
of the independent variables tav, sav and pav. Only proteins satisfying the condition
of having a resulting percentage error not over 20% in all quantities were retained in
the analysis. This resulted in 1828 proteins, whose total abundance (T ) and soluble
abundance (S) are reported in log10 scale in Figure 3.1B with red filling markers.
Pellet abundance (P) and soluble abundance (S) of these 1828 proteins are plotted
in log10 scale in Figure 3.2. Also, we evaluated T and S for protein not having a
detectable pellet fraction, i.e. having pav = 0. Using the same percent error threshold
(⩽ 20%) for the sake of signal reproducibility, we show the 674 proteins not having
aggregates in Figure 3.1B (grey points).
3.4.2 Calculation of total and aggregate load variation
upon ageing
Data of protein absolute and relative abundances (absolute LFQ values and SILAC
values) for total and aggregate protein measurements in wild-type strain worms at
day 1, 6, 12 and 17 of adulthood were retrieved from Tables S1B,E of Ref. [90].
Amounts relative to day 1 of adulthood reported in Figure 3.3 for total (panel A),
total having pellet (panel B) and pellet (panel C) were calculated with the same
procedure, described as follows.
Only proteins detected and quantified in all the days and for both SILAC and
LFQ datasets were considered in the calculations. This resulted into 3694 proteins
with total measurements, of which 1083 also reporting pellet measurements. This
common ensemble was then filtered to remove proteins known, or predicted, to be
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extracellular. We relied on both the UniProt classification of extracellular proteins
(Subcellular location entry) [251], the outcome of the Signal P predictor of signal
peptides [252] and the WoLF PSORT [253] predictor of subcellular locations for the
removal of all possible extracellular proteins.
The remaining intracellular ensemble consisted in 3078 proteins with detected
total abundance at all time points (used for Figure 3.3A) and a subset of 965 having
also a detected pellet fraction (used for Figure 3.3B,C). For each protein, two
quantities were estimated: the abundance weight W of the protein pn to the whole
ensemble at a given time point di, defined as the ratio of the absolute LFQ value of
the protein and the sum of all the proteins absolute LFQs at the given di day
W (pn)|di =
LFQ(pn)|di
∑Nn=1 LFQ(pn)|di
(3.7)
where N is the number of proteins in the ensemble; and the abundance change
of the protein ∆A(pn)|d jdi between this given time point and any other time point
measured (d j). For calculation of ∆A(pn)|d jdi , we relied on the SILAC labelled data
∆A(pn)|d jdi =
SILAC(pn)|d j
SILAC(pn)|di
(3.8)
Protein loads change ∆L between time point d j, and time point di, are obtained
by summing the contribution from each protein of the weighted abundance increase
obtained by combining W (pn)|di and ∆A(pn)|
d j
di
∆L|d jdi =
N
∑
n=1
W (pn)|di ·∆A(pn)|
d j
di
(3.9)
To obtain loads variation relative to day 1 of adulthood without imposing a
preferential bias on the absolute LFQ data measured at day 1, load variations relative
to any day detected were normalised to the correspondent value for day 1 and
subsequently averaged
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Load change|d jd01 =
4
∑
n=1
∆L|d jdi
∆L|d01di
4
(3.10)
Using Eq. 3.10 total abundance load change upon age with respect to day 1 was
calculated for the detected intracellular proteome (3078 proteins) and is reported in
Figure 3.3A. Total amounts in presence of pellet and pellet amounts changes were
also calculated from the subset of 965 proteins, and are reported in Figure 3.3B,C.
Errors on each time point reported in Figure 3.3 were obtained using a bootstrap
method on the weighted abundance change ensemble.
Chapter 4
The interactome of misfolded protein
oligomers
76 The interactome of misfolded protein oligomers
4.1 Introduction
Misfolded oligomers formed at the early stage of the aggregation process are thought
to play a central role in the onset and progression of neurodegenerative diseases, as
they have been found to be the most toxic aggregated species to the cell [62, 98, 115,
146–151] (see Chapter 1, section 1.2.5). It is still unclear how these oligomers cause
the cell damage and their contribution to neurodegeneration. Experiments, aimed at
revealing the molecular mechanism of toxicity of the oligomers, have shown that:
• these aggregates can interact with and disrupt membranes [149, 150, 254–257];
• they are able to recruit and affect the functionality of proteins [82, 258];
• they can form pores on the cell membrane causing an uncontrolled exchange of
compounds between the intracellular and extracellular space [257, 259–262].
The mechanism of toxicity that involves the interaction with the lipid membrane
has been observed for oligomers formed with the HypF-N protein [150]. Even if this
protein is not associated with any disease, it can form amyloid-like aggregates which
have been shown to mimic the synaptotoxicity of Aβ aggregates in Alzheimer’s
disease [152]. HypF-N oligomers, when placed outside cells, are found to interact
with the lipid membrane [149, 150]. The cell viability is measured by quantifying
the damage upon disruption of the membrane, that leads to a calcium intake and
ultimately to apoptosis [149, 150]. Upon given conditions two types of HypF-N
oligomers can be formed, which are stable and have been well characterised in
structure. These two types of oligomers (type A and type B, see Figure 4.1) are
structurally different and result into a very different biological activity in terms of in-
teraction with the lipid membrane. Oligomers that expose to the surface hydrophobic
and structurally disorganised patches are able to penetrate the membrane, and cause
an influx of calcium ions that can lead to apoptosis, while oligomers characterised by
buried and structured hydrophobic regions cannot readily permeate the membrane
and remain attached to the outer surface [150].
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Fig. 4.1
Schematic representation of the two structurally different HypF-N oligomer
types
The known mechanism of toxicity is mediated by the interaction with the lipid
membrane cellular component. Type A oligomers, which show structurally
disorganised and solvent-exposed hydrophobic regions are able to penetrate the
membrane, while type B oligomers, which are more structured and have
hydrophobic patches buried in the core, cannot.
Adapted from [150].
While the interaction of extracellular oligomers with the membrane of cells has
been studied quite extensively, little is known about what happens when oligomers are
formed intracellularly, like the case of α-synuclein and tau, or when they penetrate
into the cells. Also, a recent study reported the existence of oligomeric species that
induce membrane leakage, but are not cytotoxic, showing hence the absence of one-
to-one relationship between the induction of cellular toxicity and the disruption of
membranes [263]. Given more than half of the cell dry mass is constituted by proteins
[167], characterising the interaction of the oligomers with the proteome cellular
component could provide a framework for discovering an alternative mechanism of
toxicity which could be relevant in the neurodegeneration process. The aim of this
work was therefore to identify protein binders of oligomers, by taking advantage of
the two structurally different type A and type B HypF-N oligomers. To address this
study, we used MS-based proteomics and bioinformatic analyses to characterise the
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interactome of misfolded oligomers (Figure 4.2), i.e. the pool of proteins that can
bind the oligomers.
Fig. 4.2
MS-based proteomic schematic workflow
Cultured murine microglia cells were lysed to extract the proteome which was then
subject to the presence of either type of oligomers. Proteins that bound to the
oligomers in the pulldown assay were then analysed by Liquid Chromatography
Tandem-mass Spectrometry (LC-MS/MS). Four biological replicas were performed
for each type of oligomer interactome. Resulting MS raw data were processed with
the MaxQuant software for quantitative proteomics, for identification and
quantification of the proteins in the samples. Processed data were subject to data
analysis and complemented with bioniformatics functional annotation analysis.
The two interactomes of type A and type B oligomers were obtained by using
quantitative proteomics. We find that the structural difference of the two oligomers
leads to a great difference in the degree of binding to proteins. The oligomers
with a small number of hydrophobic-exposed patches, type B, bind proteins much
more strongly than type A. The number of proteins that are pulled down with the
oligomers accounts for more than 2000 entries. Interestingly, the two pools of pro-
teins are basically the same, meaning that the structural difference of the oligomers
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is not responsible for binding specificity. Among the proteins found to interact with
the oligomers, we detect a significantly high enrichment in mitochondrial proteins,
molecular chaperones, ribosomal components and RNA binding proteins. Interest-
ingly, some of the proteins falling in these categories have previously been reported
to co-aggregate and be enriched in aggregate inclusions during ageing [95, 241–245].
4.2 Results
4.2.1 Reproducibility of MS data
To study the ability of type A and type B oligomers to interact with the protein
component of the cell, we extracted proteins from N13 murine culture cells and
we incubated them in vitro in the absence or in the presence of type A and type
B oligomers. After the incubation each sample was centrifuged to pull down the
oligomers and the resulting pellet fraction were subjected to MS-based proteomics
(see Materials and Methods, section 4.4). In order to ensure statistical significance of
the results, four biological replicas were performed. The resulting MS raw data from
all the replicas in the two conditions were processed with the MaxQuant software
(see Materials and Methods, section 4.4.2) and subsequent protein identities and
abundance data (iBAQ values in log10 scale, see Material and Methods section 4.4.2)
were retrieved.
To verify the consistency of the interactomes and the biological variability,
we report in Figure 4.3 the matrix of 6 correlation plots obtained comparing the
iBAQ intensities (in log10) of the 4 biological replicas per oligomer type (Figure
4.3A for type A oligomers and Figure 4.3B for type B oligomers respectively).
In each scatterplot of two compared replicas, green points represent abundance
data of proteins detected in both replicas, while red points at the corner of the plot
indicate abundances of proteins that have been detected only in one of the two
replicas considered. We observe very high correlations between the replicas for
both conditions, with Pearson’s coefficient of correlation ranging between 0.73 and
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(A) (B)
Fig. 4.3
Reproducibility of the MS data of the biological replicas
The matrix of 6 correlation plots between the iBAQ intensities of the 4 biological
replicas, for both oligomers types is shown. For each scatterplot (bottom left triangle
of the matrix) green points represent proteins that have been detected in both
replicas, while red points at the corners of the plot represent proteins that have been
detected only in one of the two considered replicas, and hence possessing only one
abundance value. Abundances values are iBAQ intensities in log10 units.
In the upper right triangle of the matrix, Pearson correlation coefficients of the
corresponding transposed scatterplots are shown, with colour code (from red to blue)
following the indicated values of correlation coefficient.
Along the diagonal, histogram of the log10 iBAQ abundances distribution of each
replicas are shown in grey with a gaussian fit line in black. Number of proteins
detected in the replica (N) are indicated in the top left corner of each distribution
plot. (A) Correlation matrix for the 4 biological replicas of the proteins interacting
with type A oligomers. (B) Correlation matrix for the 4 biological replicas of the
proteins interacting with type B oligomers.
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0.82 for the proteins found interacting in the sample with type A oligomers (Figure
4.3A), and ranging between 0.76 and 0.85 for the proteins pulled down with type B
oligomers (Figure 4.3B).
The results show that measurements of the abundances of the protein pulled
down with the oligomers are very reproducible and slightly more consistent against
B oligomers, mainly due to the presence of a stronger MS signal given by the higher
abundances of proteins detected after the incubation with with type B oligomers
(discussed in section 4.2.2). Also, more proteins have been detected in each replica
to bind type B oligomers than type A, as we can see from the number of proteins
shown in the distribution histogram of abundances of the correlation plots: 1957
to 2675 proteins detected with type A, (Figure 4.3A) and 2472 to 2787 proteins
detected with type B (Figure 4.3B).
4.2.2 The structural difference of the oligomers modulates the
binding strength to proteins
To get insights into the ability of the two different oligomers to bind proteins,
intensity-based absolute quantification (iBAQ) values of protein abundances (see
Materials and Methods, section 4.4.2) of type A and type B binders were compared
using MaxQuant. The iBAQ value is proportional to the amount of the protein in the
sample. This amount is the result of the contribution of two independent quantities:
the physiological abundance of the protein in the lysate, and the binding affinity of
the protein to the oligomer. Therefore, the iBAQ value can be considered a function
of the physiological abundance and the binding affinity to the oligomer.
In each biological replica, the physiological abundance of the protein in the lysate
is approximately conserved between the two different oligomeric samples, since the
oligomers were incubated with the same batch of extracted proteins. Hence, in a
given biological replica the comparison, for any protein binder, of the iBAQ values
of type B oligomers versus type A oligomers represent the difference in binding that
the oligomers exert on that protein.
82 The interactome of misfolded protein oligomers
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Fig. 4.4
Difference in binding power of type A and type B oligomers
(A) Scatterplot matrix of the replica-specific pairwise comparison of log10 iBAQ
values of proteins bound to B oligomers versus those bound to A oligomers. Black
points in each scatterplot represents proteins quantified in the biological replica both
in the sample of A interactors and in that of B interactors. Red points represent
proteins that have been detected only in one condition (either B bound or A bound)
in that specific replica. The presence of the greatest fractions of proteins above the
bisector line in all 4 replicas shows that B oligomers have much higher capacity in
binding proteins than do have A oligomers. (B) Volcano plot showing the average of
the ratios of B binders versus A binders taken per biological replica, in log2, and
their significance (see Material and Methods, section 4.4.2 for evaluation). The 2651
points are the number of proteins detected at least twice in the corresponding sample
of A binders and B binders.
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Figure 4.4A show the scatterplot matrix of the iBAQ values (in log10) of B
binders versus those of A binders per biological replica. Each black point represent
a protein quantified by MaxQuant to be in the sample of both oligomers (after the
incubation), in that biological replica. Red points are abundances detected only
for one condition, either binding to A oligomers (horizontal points) or binding B
oligomers (vertical points) again in that replica. Since nearly all points lie over
the bisector line (black line in each plot) in all replicas, type B oligomers bind all
proteins much more strongly that do type A oligomers. Therefore, the structural
difference of the two oligomers induces a different degree of binding to the proteome
cellular component.
This difference in binding affinity becomes even more clear in the volcano plot
shown in Figure 4.4B. Each black point in the plot is a protein which has been
detected to bind both B oligomers and A oligomers in at least two corresponding
biological replicas. On the x axis, the averaged ratio in log2 of the intensities from
iBAQ values of B binders over A binders is shown, and its corresponding significance
is plotted on the y axis (see section 4.4.2 for evaluation). Positive values on the x
axis indicate proteins able to bind more to B oligomers than A oligomers, while
negative values implies that these proteins bind stronger A oligomers. The clear cut
asymmetry of the plot towards positive values means that the cellular component
represented by proteins have much stronger affinity to bind B oligomers, which
have more structured and buried hydrophobic patches. Hence, structurally different
oligomers can lead to a different biological activity in terms of the interaction with
the proteome cellular component and the structural differences in the oligomers can
be responsible of the binding affinity to proteins.
4.2.3 The two types of oligomers interact with similar pools of
proteins
To shed light on the proteins contained in the interactomes of each oligomer, we
combined the results of all biological replicas per condition by estimating the median
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abundance fraction that each binder protein contributes to with respect to all the
binders found in the sample (see Materials and Methods, section 4.4.2). The median
abundance fraction represents a measure of the abundance weight that each protein
has with respect to the total mass of proteins that have been found to bind the
concentration of oligomers.
We define as shared binders between the two types of oligomers proteins detected
in at least three biological replicas in both conditions. Complementarily, we define
as specific binders proteins that have been detected at least thrice in one condition,
but have never been detected in the other.
We found that 2280 proteins are common binders of the two types of oligomers
(blue points, Figure 4.5), while only 18 protein are found only in one conditions (17
bound to type B oligomers and 1 bound to type A oligomers, red points in Figure
4.5). 17 of these 18 proteins, however, have been detected in the lowest range of
abundance values ( log10 percentages in abundances « -2 ), hence we cannot exclude
the possibility that the signal in the other condition was present but:
1. resulted lower than the detection threshold of the mass spectrometer
2. was discarded due to the partial stochasticity of the peptides quantification in
the MS process, in which only the top 20 peptides that are eluting in a given
time frame are kept for MS/MS analysis (see Materials and Methods, section
4.4.1)
Therefore, the abundance percentage of these 17 specific binders is statistically
not high enough for them to be considered exclusive binders of the given oligomer
type.
Only one protein that binds only to type B oligomers is found in the upper
range of the abundance fraction, more than one standard deviation above the average
logged-abundance of the ensemble of B binders, and can be considered a specific
binder. This protein, SET, which accounts for 0.066% of the total abundance of
proteins in the sample (see Figure 4.5, highest red point in the vertical stack), is a
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Fig. 4.5
Oligomers bind the same pool of microglia proteins
Scatterplot of the median percentage in abundance of proteins binding type B
oligomers versus protein binding type A oligomers (in log10). Blue points in the
plot represent proteins detected binding both oligomers in at least three replicas out
of four. Red points at the corners are proteins that have been detected at least three
times bound to one oligomer type and never detected to bind to the other oligomer
type. Errors are median absolute deviations (see Materials and Methods, section
4.4.2 for calculations). Abundance percentage data span about 6 orders of
magnitude and are highly correlated in the two conditions (binding to A oligomers
and to B oligomers). The Pearson’s correlation coefficient for the shared binders of
the two types of oligomers in indicated on the upper left of the scatterplot.
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multitasking protein which has been reported to be involved in transcription, histone
chaperoning, nucleosome assembly and apoptosis [211, 264].
Given that more than 99% of the proteins detected are binding both the two
types of oligomers types and that the signal of specific interactors is not statistically
significant, we can conclude that despite their different binding strength, the two
structurally different oligomers bind the same pool of proteins, therefore defining a
single interactome. The number of interactors from this in vitro experiment is more
than 2200 and spans about six orders of magnitude in the ensemble of abundance
fractions, ranging from ∼ 10−5% up to ∼ 2.7% abundance weight in the oligomer
samples (0.44 in log10 scale, Figure 4.5).
Also, Figure 4.5 shows that the relative abundances of binders are conserved in
the two conditions, since the correlation between the abundance percentages in the
two conditions is about 0.897. Such strong correlation implies that, regardless of the
overall intensity of binding, proteins bind the two structurally different oligomers in
the same proportions. The different relative abundance among the proteins in the
sample is therefore independent of the structure of the oligomer. The type of oligomer
influences the total amount of protein that bind the oligomer, but not the relative
abundances within the oligomers interactome neither the specificity of the proteins.
In terms of relative abundances, we can conclude that the two oligomers bind similar
proteins in similar proportions and hence result into a similar interactome.
In the next sections, we characterise the biological features of the constituents
of the interactome. We used relative abundance data from the sample of type B
oligomers as reference for the interactome as they are more accurate (see correlations
in Figure 4.3 and section 4.2.1), but the results of the biological features (e.g.
biological processes, pathways and functions enriched) are to be considered general
for the two types of oligomers (see Material and Methods, section 4.4.3).
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4.2.4 The biological constituents of the misfolded oligomers
interactome
Next we characterised the interactome of the misfolded oligomers, by calculating the
enrichment of protein groups belonging to specific biological categories with respect
to the reference mouse proteome (23619 proteins) used in the processing of MS data
(see Materials and Methods, section 4.4.3). Annotation terms in protein families,
KEGG pathways and GO categories that resulted significantly enriched are plotted
in Figure 4.6. We find that RNA binding proteins (pink coloured bars in Figure 4.6)
appear in many annotation terms and are the most overrepresented in the oligomers
interactome. In this class, the strongest signal comes from ribosomal components
or translation-related proteins, which have in most annotations a relative maximum
enrichment (RME, see Materials and Methods, section 4.4.3) higher than 0.6, an
enrichment ratio (ER) bigger than 4 and corrected p-values smaller than 10−4. Class
I and II aminoacyl-tRNA synthetase, splicing factor SR and the spliceosome terms
are also greatly enriched in this class.
Proteins belonging to the protein homeostasis network (orange coloured bars
in Figure 4.6) are also at the top of the significantly highly enriched terms. In
terms of protein families, we find all components of the peptidase T1A family and
nearly all of the peptidase T1B (RME=0.82, p<10−4), together with the 14-3-3, the
TCP-1 chaperonin and the Hsp 70 family (RME of 0.86, 0.73 and 0.44 respectively,
with p-values p<10−3, p<10−4 and p<0.01). In terms of KEGG pathways, the
strongest signal comes from the proteasome and protein export pathways, both
highly significant.
Another group of enriched annotation categories that are among the most over-
represented in the interactome is constituted by mitochondrial proteins and protein
involved with energy metabolism (green bars in Figure 4.6). Indeed, the mitochon-
drion is the cellular component that is mostly enriched after the ribosome, with an
enrichment ratio of 3 and a pvalue p<10−4. The citrate cycle, fatty acid metabolism
and oxidative phosphorylation are the most relevant pathways overrepresented for
88 The interactome of misfolded protein oligomers
Fig. 4.6
Functional enrichment of the proteins in the oligomers interactome
Enrichment of protein families, KEGG pathways and GO categories of proteins in
the oligomers interactome. The interacting proteins were grouped and categorised
according to their functional annotations, see section 4.4.3. Highly significant
(p<0.01) overrepresented annotation terms are bar-plotted according to their
enrichment ratio (ER). Values of relative maximum enrichment (RME) (see
Materials and Methods, section 4.4.3) are shown inside the bars. Stars next to the
bars indicate the significance of the enrichment, calculated with the Fisher exact test
and corrected with the Benjamin- with the following scheme: **=p<0.01,
***=p<10−3, ****=p<10−4.
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this class in the interactome. Also, all the members of the Acyl-CoA dehydrogenase
family have been detected to bind the oligomers, hence having an ER>0.75 and a
RME of 1 (with p<10−4).
Notably, among the KEGG pathways enriched in the interactome, we find the oc-
currence with high significance of Parkinson’s, Alzheimer’s and Huntington diseases,
the most important neurodegenerative disorders (yellow bars in Figure 4.6).
4.2.5 Mitochondrial and ribosomal proteins are the preferential
binders of misfolded oligomers
Figure 4.6 and Figure Figure 4.5 show which are the main biological components of
the oligomers interactome and what are the different abundance fractions within the
single binders respectively.
In order to understand if the difference in abundance between two given binders
is due to a different binding affinity or just to a difference in their natural abundance
in the cell, we compared the abundances of the binders in the interactome with
their natural abundances in microglia obtained using proteome-wide MS abundance
data of mouse microglia cells recently published by Sharma and co-workers [207].
Proteins IDs of the interactome sets were mapped and matched to the available
set of data of the proteome of microglia cells. iBAQ values in log10 scale (to
ensure a normal distribution) from both sets were zscored, resulting into abundances
distributions shifted to have mean value centered in 0 and standard deviation equal
to 1. With this transformation, the distributions of protein abundances in the two sets
were directly comparable. Figure 4.7 shows the result of this comparison. We do not
observe a correlation between the two abundances, which suggests that misfolded
oligomers have some preferential binders, to which they interact with more affinity.
Also, protein cellular levels are not sufficient to reproduce the different abundance of
the protein binders in the interactome sample.
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Fig. 4.7
Difference of natural abundance of proteins in microglia is not sufficient to
explain the abundance percentages in the interactome
Scatterplot of zscored iBAQ abundances of B binders versus proteins in microglia
taken from [207]. Errors are obtained from MAD (median absolute deviation) with
normalisation for the zscore transformation.
Hence, we asked if there are any biological categories that can significantly
differentiate the degree of binding of their components to the oligomers with respect
to their natural abundance. Using the mathematical method of 2D functional anno-
tation enrichment developed by Cox and Mann [169] (see Materials and Methods,
section 4.2.5), we were able to quantitatively identify which biological properties
are differentially expressed in the oligomers sample with respect to the microglia
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proteome sample. We tested the 2D enrichment to all functional annotation terms
of protein families (1553 entries), KEGG pathways (287 entries), GO biological
processes (5192 entries), GO cellular components (950) and GO molecular functions
(1809 entries) that were present in the interactome. To calculate the enrichment
score in each sample, we used the rankings of abundances of the proteins in the
interactome set, and the corresponding ranking of abundances in the microglia set.
Only terms that resulted significant (p<0.05 after multiple hypothesis correction with
the BH method) from the MANOVA test on the paired 2D enrichment scores were
kept. This resulted into 6 protein families, 32 KEGG pathways and 78 GO categories,
of which: 16 GO biological processes (GOBP), 39 GO cellular components (GOCC)
and 23 GO molecular functions (GOMF), (see legend of Figure 4.8, containing the
list of significant terms found for each group).
These annotation terms represents pathways, processes, families, functions or
components whose constituents are systematically more abundant or less abundant
with respect to all the other proteins, in either the interactome sample or the microglia
sample. In particular, we wanted to characterise which functional terms, if any,
define sets of proteins that can be considered the most vulnerable species in the cell
for the interaction with misfolded oligomers. Vulnerability could come from two
behaviours:
• from group of proteins that are not particularly abundant, but have specific char-
acteristic which make them have the strongest affinity to bind the oligomers,
and hence would be preferentially chosen as interactors
• from group of proteins which are abundant, so even if their binding affinity is
not as high, they would have many more chances to bind the oligomers
Hence, we are interested in characterising which functional terms include pro-
teins that are highly binding the oligomers and low abundant in the microglia (second
quadrant in Figure 4.8) as these proteins group would have potentially the strongest
affinity to bind the oligomers, and which functional terms define sets whose compo-
nents are highly binding the oligomers but are also naturally very abundant in cells
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Fig. 4.8
Misfolded oligomers preferentially bind mitochondrial and ribosomal proteins
2D functional annotation enrichment from abundance rankings of the proteins in the
oligomers interactome (B binders) with respect to cellular occurrences in microglia.
Terms of protein families (FAMILIES, circles with black borders), KEGG pathways
(KEGG, squares with yellow borders) and GO categories (triangles) are present. GO
biological processes (GOBP) are triangles with red borders, GO cellular components
(GOCC) are inverted triangles with green borders, while GO molecular functions
(GOMF) are sideways triangles with blue borders. Only significant terms in the
enrichment are reported in the plot (p-value<0.05, obtained with MANOVA and
only relevant regions are highlighted, see section 4.2.5 for explanation). Legend of
the annotation terms is found in the next page, with bold labels corresponding to
terms found in the relevant regions. Filling colours of relevant terms are matched
with the classification of Figure 4.6.
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(values over the bisector in the first quadrant of Figure 4.8). Annotation terms in
the area of the second quadrant and upper triangle of the first quadrant in Figure 4.8
define ensemble of proteins that are most vulnerable to the oligomers. We found
that overall, RNA-binding proteins (especially involved in translation), protein of the
mitochondrion or involved in energy metabolism, proteins associated with neurode-
generative pathways and one family of proteins belonging to the protein homeostasis
category are the only categories most vulnerable to the oligomers, compared to all
the categories found overrepresented in the sample (Figure 4.6).
In particular, we find that mitochondrial proteins, in particular mitochondrial
ribosomal components (numbers 42, 58, 79 and 90 in Figure 4.8) and the respiratory
complex I (numbers 75 and 106 in Figure 4.8, 30 protein components) are preferential
binders of oligomers, since they are highly abundant in our sample but highly
depleted in the microglia one. Indeed, not only we found so many significant
annotation terms for mitochondrion in the 2D enrichment, but nearly all these terms
are found in the second quadrant, so they are consistently over-abundant in the
oligomers with respect to their cellular abundance. One protein family is also found
in this area of the 2D enrichment plot, with a low, negative enrichment score in
microglia but a positive enrichment in the oligomers sample, which makes it another
strong affinity potential binder: it is the short chain dehydrogenases/reductases (SDR)
family, also involved in energy metabolism (number 1 in the second quadrant of
Figure 4.8), a family of enzymes [265–267] of which we found 24 proteins members
in the oligomers interactome. Notably, we do not find any term belonging to this class
in the opposite region, i.e. where proteins are abundant in the cell but do not bind
strongly to the oligomers (4th quadrant). In this region we find mainly annotation
terms related to proteins involved in the structure of the cell, e.g. leukocyte cell-cell
adhesion, actin filaments binding, stress fiber and the DOCK family (number 38,
105, 54 and 3 respectively, see Figure 4.8).
Beside the mitochondrion (number 61 in Figure 4.8), another cellular component
found depleted in the microglia but upregulated in the oligomers is the membrane:
integral components of membrane (number 91), mitochondrial membrane proteins
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(number 85 and 86) and proteins of the ER membrane (number 76) are all the
remaining annotation terms of the second quadrant.
The only two mitochondrial terms not found in the second quadrant are the
KEGG oxidative phosphorylation pathway and the proton-transporting ATP synthase
complex (number 12 and 57 respectively in the first quadrant of Figure 4.8), which are
extremely overexpressed in the oligomers sample and with medium-high abundance
values in microglia respectively. In this region, where only the oligomers binders
are highly enriched (see Material and Methods, section 4.2.5) we find 6 of the 7
KEGG pathways (squares in Figure 4.8) that resulted as vulnerable to the oligomers,
one of which is the oxidative phosphorylation pathway. Interestingly, four of these
pathways are disease-related pathways (yellow squares in the figure), three of which
are neurodegenerative: Parkinson’s, Alzheimer’s and Huntington, number 36, 13
and 15 respectively. The remaining disease pathway is the non-alcoholic fatty liver
disease (NAFLD) (number 29 in the figure), which is also connected with oxidative
phosphorylation. Also, we find another of the three protein families vulnerable to
the oligomers: the Rab family of small GTPases (number 5, light blue circle in the
figure).
The last protein family found to be highly enriched in the oligomers is also
extremely abundant in the microglia: it is the TCP-1 chaperonin family (8 members
found in the sample out of the 8 present in mouse, number 2 in Figure 4.8), involved
in the folding and chaperoning of some cytosolic proteins such as actin and tubulin
[268–270]. Together with ribosomal components or protein involved with translation
(RNA binding proteins, pink filled terms in the first quadrant of Figure 4.8, numbers
43, 68, 94, 8, 45, 87, 89 and 82) and the citrate cycle (TCA, energy metabolism,
number 52 and 37 in Figure 4.8) these classes represent the strongest binders to the
oligomers, probably mostly due to their high cellular abundance.
Notably, ribosomal components and RNA-binding proteins, while being known
to be impaired in Huntington’s pathogenesis and other neurodegenerative pathologies
[271–273], have also been recently reported to interact with oligomers of Huntingtin
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[258]. Our finding from the HypF-N systems hence suggest the presence of a general
predisposition of these kind of proteins to bind oligomeric species, and potentially im-
ply another general mechanism of toxicity induced by misfolded oligomers. This is
also the case of molecular chaperones, which have been both detected to co-aggregate
with aggregated species in vivo [90] and to modulate the process of protein aggre-
gation itself [87, 274–280]. Most interestingly, we find evidence of high binding
affinity with mitochondrial proteins, from the ribosomal components to the respi-
ratory complex I in the oxidative phosphorylation pathway. Even if mitochondrial
impairment and dysfunction has been associated with neurodegeneration, especially
in terms of oxidative stress [281–288], the potential interaction of mitochondrial
proteins with oligomers was previously unknown. The possible binding to these
varied key cellular classes suggest the idea of a multi-hit model of neurodegeneration,
in which toxicity might be the result of the gain of function of these vulnerable, key
proteins from the direct interaction with the oligomers, or might arise from the loss
of function of these protein homeostasis/energy related components upon interaction
with the oligomeric species. In both scenarios, this aberrant interaction with multiple
protein components could lead to a direct impairment of the protein homeostasis
machinery, and a subsequent homeostasis collapse.
4.3 Conclusions
In this chapter, we have characterised the interaction of two structurally different
soluble oligomeric species with the protein component of the cell. We have found
that the two types of oligomers bind a common pool of proteins, while their structural
difference only result into a different binding power to the protein molecules. Type
B oligomers, with their hydrophobic patches buried and structured in the assembly,
bind much stronger proteins than do type A oligomers, which have the hydrophobic
patches unstructured and exposed to the solvent.
More than 2000 proteins are pulled down with the oligomers, defining the shared
oligomers interactome. Only one protein resulted as a specific binder to type B
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oligomers, while no proteins resulted specific to type A. Of all the biological cat-
egories found among the set of oligomers interactors, the most outnumbered ones
belong to the classes of RNA-binding and ribosomal proteins, mitochondrial proteins
and proteins involved in the energy metabolism or disease pathways, lipid-binding
and DNA binding proteins and protein homeostasis components. However, in terms
of a quantitative preferential binding and vulnerability of proteins to oligomers, by
comparing the natural abundances of proteins in microglia with the abundances of
proteins in the oligomers sample, we have found that among the proteins found to
interact with the oligomers, we detect a significantly high enrichment and affinity to
mitochondrial proteins, ribosomal/RNA-binding components, the TCP-1 chaperonin
family and proteins involved in neurodegenerative pathways. The potential aberrant
interaction of these key proteins with the oligomers suggest a general mechanism
of toxicity induced by the interaction of misfolded oligomers with these protein
components of the cell. This mechanism could hold true for the ribosomal compo-
nents, since interaction with other oligomeric species with ribosomal components
has been reported previously this year and impairment of ribosomal biogenesis had
been previously associated with neurodegeneration. We do not have evidence yet
for a toxicity induced by interaction with mitochondrial proteins, but many studies
highlight mitochondrial dysfunction during neurodegeneration.
Taken together, this work provide powerful insights into the relationship between
proteins and misfolded oligomers. Also, the information contained in the interac-
tome could represent a valuable reference tool for other kind of studies focused
on the interplay between oligomeric species and specific pathways of biological
components.
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4.4 Materials and Methods
4.4.1 Sample preparation and MS run
The sample preparation involves the steps of the processing of the biological sample
until the proteins that bound the oligomers are loaded into the gel, and was carried
out by Dr. Benedetta Mannini in the Vendruscolo group. Steps of the process are
briefly described in the subsections below.
Preparation of HypF-N oligomers
Protein expression and purification were carried out as described previously [150].
The content of endotoxins in HypF-N protein solution samples was determined by
toxin sensor Limulus Amebocyte Lysate (LAL) assay kit (Genscript, Piscataway, NJ,
USA) and resulted to be ∼ 0.02EU/ml. Oligomeric aggregates of HypF-N were
prepared by incubating the protein for 4 h at 25 °C and at a concentration of 48µM
in two different experimental conditions:
1. 50mM acetate buffer, 12% (v/v) TFE, 2mM DTT, pH 5.5 (condition A)
2. 20mM TFA, 330mM NaCl, pH 1.7 (condition B)
The oligomers were centrifuged at 16100g for 10 min and resuspended in buffer.
Cell cultures
Murine N13 microglia cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) F12 supplemented with 10% fetal bovine serum (FBS), 1.0% non-essential
amino acids, glutamine and antibiotics. The cell culture was maintained in a 5.0%
CO2 humidified atmosphere at 37 °C and grown until 80% confluence for a maximum
of 20 passages.
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Pull down assay
Proteins from N13 cell cultures were extracted using the ProteoExtract Native
Membrane Protein Extraction Kit (Calbiochem, Darmstadt, Germany) according to
the manufacturer’s protocol. 10000000cell/ml of microglial cell lysate and 24µM
type A or type B oligomers were incubated in isolation or in combination in a final
volume of 400µL for 1 h at 37 °C under gentle shaking and then centrifuged at
16100g for 10 min. Aliquots of the pellet fractions were subjected to SDS-PAGE
using 4-12% Bis-Tris polyacrylamide gels.
MS experiment
The MS experiments were carried out at the Cambridge Centre for Proteomics, which
provided us the final mass spectrometry raw files. 1D gel bands were excised and
transferred into a 96-well PCR plate. The gel bands were cut into 1mm2 pieces (10
fractions), destained, reduced (DTT) and alkylated (iodoacetamide) and subjected to
enzymatic digestion with trypsin overnight at 37 °C. After digestion, the supernatant
was pipetted into a sample vial and loaded onto an autosampler for automated
LC-MS/MS analysis.
All LC-MS/MS experiments were performed using a nanoAcquity UPLC (Waters
Corp., Milford, MA) system and an LTQ Orbitrap Velos hybrid ion trap mass spec-
trometer (Thermo Scientific, Waltham, MA). Separation of peptides was performed
by reverse-phase chromatography using a Waters reverse-phase nano column (BEH
C18, 75µm i.d. x 250mm, 1.7 µm particle size) at flow rate of 300nL/min. Peptides
were initially loaded onto a pre-column (Waters UPLC Trap Symmetry C18, 180µm
i.d x 20mm, 5 µm particle size) from the nanoAcquity sample manager with 0.1%
formic acid for 3 minutes at a flow rate of 5µL/min. After this period, the column
valve was switched to allow the elution of peptides from the pre-column onto the
analytical column. Solvent A was water + 0.1% formic acid and solvent B was
acetonitrile + 0.1% formic acid. The linear gradient employed was 3-30% B in 40
minutes (the total run time, including wash/equilibration steps was 60 minutes). The
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LC eluant was sprayed into the mass spectrometer by means of a nanospray ion
source.
All m/z values of eluting ions were measured in the Orbitrap Velos mass analyzer,
set at a resolution of 30000 and scanned from m/z 380-1500. Data dependent scans
(Top 20) were employed to automatically isolate and generate fragment ions by
collision-induced dissociation (NCE:30%) in the linear ion trap, resulting in the
generation of MS/MS spectra. Ions with charge states of 2+ and above were selected
for fragmentation.
4.4.2 MS data processing and analysis
MaxQuant processing
Mass spectrometry raw files were processed with the MaxQuant software [205]
(version 1.5.3.17). As a protein reference sequence database, we used the swissprot
mouse reference proteome (only reviewed entries) obtained on 09 June 2015 from the
Uniprot database [211, 251, 212]. Peak lists search were performed automatically
with the Andromeda search engine [204] within the MaxQuant environment, which
uses a reversed-decoy version of the specified FASTA database to adjust the false
discovery rates (FDR) of peptides and proteins. Peptides and proteins false discovery
rates (FDR) were kept at default values of 0.01.
The iBAQ quantification was switched on to allow quantification of protein
abundances with the iBAQ (intensity-based absolute quantification) method [203].
Only "unique" peptides were used for the quantification, i.e. every peptide detected
was used only in one protein group for quantification. This ensures, to a good approx-
imation, independence of the resulting protein abundances, while the independence
assumption would not hold if we used non-unique peptides present in several protein
groups.
The 10 fractions in each of the 4 biological replicas in each condition (i.e. in the
sample with type B or type A oligomers) were processed altogether in the MaxQuant
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environment. The feature "Match between runs" was set to True in order to maximise
the chances of identification of peptides in case of a low signal, which is the case for
the proteins treated with type A oligomers.
The iBAQ method for measuring protein abundance
We define as protein abundance in the oligomers sample of a given biological
replica the iBAQ value calculated by MaxQuant for the protein. In the iBAQ
quantification, the abundance signal of a given protein is the sum of all the intensities
of its detected peptides, divided by the number of theoretically expected peptides
for the protein. This normalisation is required for fixing the dependency of the
resulting intensity of the protein signal towards its size, as bigger proteins will result
in higher abundances. The number of theoretically expected peptides is automatically
calculated by MaxQuant with an in silico digestion of the protein with the protease
used in the experiment.
Proteins in the cell span a wide range of abundances, from few copies to millions
copies per cell. This wide distribution of abundances seems to follow a power law,
and it is maintained with the intensity-based iBAQ quantification. Hence, when
dealing with absolute iBAQ abundances or variables derived from iBAQ values and
representing abundances of proteins (abundance percentage, see next section), given
the log-normality of the distribution, we apply the logarithmic scale to the data
(usually log10) for a better visualisation of the scatterplots (see Figure 4.3, Figure
4.4A and Figure 4.5).
Evaluation of binding differences
The volcano plot in panel B of Figure 4.4B shows she difference in binding that
the two types of oligomers exert on proteins (x axis) and its corresponding p-value,
calculated with a dependent t-test. The difference in binding, per protein, was
calculated as follows. iBAQ abundances were obtained from four biological replicas
in the two conditions (binding to type B and type A oligomers). In a given biological
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replica, the same batch of proteins from the microglia cells were subjected to interact
with type B (condition B) or type A (condition A) oligomers. Hence, we calculated,
per biological replica, the pairwise ratio rki of the iBAQ abundances in condition B
(iBAQB) over condition A (iBAQA) for the replica k of the protein i
rki =
iBAQB|ki
iBAQA|ki
(4.1)
which give us the binding difference between B and A in a specific biological
replica for a given protein. To obtain the difference in binding strength that the two
types of oligomers exert on a given protein (B/A)|i, we subsequently averaged the
ratios rki over the replicas. When dealing with proteomic data, mean values and stan-
dard deviations to represent average behaviours of quantities are not recommended,
since they are very sensitive to outliers. Hence, to average the ratios we used the
median value of the rki and considered as its error the median absolute deviation
(MAD), two measures that are more robust to outliers. Finally, we computed the
log2 on the (B/A)|i to show in Figure 4.4B the fold difference in binding between
type B and type A oligomers F(B/A)|i. The median fold binding difference that
oligomers B have with respect to oligomers A, for a given protein i, is therefore:
F(B/A)|i = log2
(
mediank
[
iBAQB|ki
iBAQA|ki
])
(4.2)
where positive values indicates a protein is binding type B oligomers stronger
than type A, while negative values indicate the opposite behaviour.
Evaluation of percentages in abundance
From the distribution of protein abundances (iBAQ values) of the oligomers binders,
we can estimate the average abundance fraction that each protein contributes to with
respect to all the others. We define as binders only proteins detected in at least three
replicas. For each oligomeric condition (A or B) we calculated, per biological replica
k, the percentage of abundance (%A and %B) of a protein i with respect to the sample:
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%A|ki =
iBAQA|ki
∑
NkA
j=1 iBAQA|kj
·100 (4.3)
%B|ki =
iBAQB|ki
∑
NkB
j=1 iBAQB|kj
·100 (4.4)
where NkA and N
k
B are the number of proteins in the k biological replica in the
sample A and B respectively. The average abundance percentage is then obtained,
for each protein i, by taking the median of the %|ki over the 4 k biological replicas.
The error on each abundance percentage is the median absolute deviation (MAD). In
a log10 scale, the resulting abundance percentages distributions for all the proteins
in the two conditions show a gaussian behaviour. The comparison of the average
abundance percentages in the two conditions is reported in the scatterplot of Figure
4.5.
4.4.3 Functional annotation enrichment analysis
To complement the MS analysis with relevant biological insights, we used five
functional annotation classes :
• Protein families, from the Uniprot database [211, 289, 251]
• KEGG pathways, from the Kyoto Encyclopedia of Gene and Genomes [290–
292]
• and the Gene Ontology (GO) annotation [293–295], subdivided into:
– Biological processes
– Cellular components
– Molecular functions
These functional classes contain lists of protein families, pathways, biological
processes etc. which are referred to as "annotation terms" and can contain from one
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single protein (very specific term, e.g. "mnmg family" protein family, which has a
single protein in mouse) to thousands of proteins (very broad term, e.g. "cytoplasm"
cellular component, which nearly reaches 6000 protein).
The most common procedure for enrichment analysis of functional annotations
from -omics type of data consist in the calculation of the enrichment ratio (ER) of
a given annotation term with its significance [296–299]. The ER is based only on
the number of proteins found in the sample belonging to the annotation term, with
respect to the number of proteins belonging to the term present in a wider reference
ensemble and the relative sizes of the sample and the reference ensemble. In a
specific example where the annotation term chosen is the GO cellular component
"ribosome", the enrichment ratio will tell how much over-numbered ribosomal
components are among the proteins in the interactome (compared to the number of
all ribosomal proteins in the proteome of a mouse), and what is the probability to
obtain such a number of ribosomal components in the sample by chance.
Calculation of the ER with its significance is a valuable approach for under-
standing how many and who are the biological constituents of the interactome of
oligomers, but it does not provide information on the different contributions that
the different terms give when it comes to binding to the oligomers. To this regard,
a recent method has been suggested (1D and 2D annotation enrichment, [169]), to
evaluate statistical enrichment not only in terms of number of components found
for a given annotation term in the sample, but in terms of the values found for the
components of the annotation term in the sample. While this method was developed
to compare transcriptomics with proteomics data, we extended its formalism to
our comparison of protein abundances bound to the oligomers with physiological
abundances of proteins in microglia.
The abundance-specific enrichment score with its statistics is described in the sub-
section "2D enrichment analysis for the preferential binders of oligomers". The next
section, "Enrichment ratios for the biological constituents of the interactome", de-
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scribes the usual procedure for calculating number-specific enrichment ratios. These
analyses were implemented and performed in the python language environment.
Both enrichment calculations of protein binders to the oligomers are reported
from the type B oligomers sample. Indeed, we have already shown that we can
address the binding of proteins to the two oligomeric types as a single interactome
since there is no significant difference in the proteins enriched selectively in the two
oligomers. Also, the functional terms significantly overrepresented in the ensemble
of proteins detected in at least three replicas for both oligomers types are highly
conserved and do not increase if we use as as reference set for the interactome of
oligomers the ensemble of proteins that bind at least 3 times type B oligomers binders.
Therefore, since abundance data are required for 2D enrichment calculations, for
the sake of consistency we consider proteins detected in at least 3 experiments in
the type B oligomers sample to be representative of the oligomers interactome in all
enrichment calculations (both for enrichment ratio and for 2D enrichment, described
below).
Enrichment ratios for the biological constituents of the interactome
The enrichment ratio (ER) measures the overrepresentation of a specific annotation
term in the sample under study, compared to a reference population. Our proteome
of reference, which we used in the input of MaxQuant as a reference database of
protein sequences (see Materials and Methods, section 4.4.2), is the swissprot mouse
proteome, containing 23619 entries.
For every protein entry (protein ID), both in the interactome sample (protein
binders to type B oligomers in at least 3 replicas) and in the reference proteome, we
retrieved all the annotation terms containing the protein, for all five annotation classes.
The Uniprot search database [251, 289, 300] was used to obtain the annotation terms
associated to each protein (whether existent) for both the protein family class and
the GO categories. The Bioservices python package [301] was implemented in the
analysis to match a protein ID with all its KEGG pathways.
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For the interactome sample, this resulted in 1553 protein families, 287 KEGG
pathways and 8125 GO terms, of which: 5192 biological processes (GOBP), 1809
molecular functions (GOMF) and 950 cellular components (GOCC), which were all
tested for enrichment.
Next, since we are interested in highlighting in Figure 4.6 the main ontology
content enriched in our interactome, we mapped the 8125 GO terms to their corre-
sponding SLIM GO terms [302]. SLIM go terms offer a high-level view on the three
gene ontologies (GOBP, GOMF and GOCC) by collecting the most important terms
for a proteome without going to the details of the specific fine grained terms. Using
the Bioservices python package [301], the GO terms of the reference proteome were
mapped to 136 SLIM GO categories, of which 67 SLIM GO biological processes,
40 SLIM GO molecular functions and 29 SLIM GO cellular components.
For of all the annotation terms of the 1553 protein families, 287 KEGG path-
ways and 136 SLIM GO categories, we calculated the enrichment ratio (ER), the
relative maximum enrichment (RME) and the significance with a fisher exact test
with adjusted p-values from the Benjamini-Hochberg (BH) correction for multiple
hypothesis testing [303]. For a given annotation term t, the ER is calculated as
the number of observed components #obs(t)|sample, with respect to the number of
expected components #pred(t)|sample, namely:
ER(t) =
#obs(t)|sample
#pred(t)|sample =
#obs(t)|sample
#obs(t)|re f
tot|re f · tot|sample
=
f (t) in sample
f (t) in re f
(4.5)
where f (t) is the frequency of the annotation term, #obs(t)|re f is the number of
components of t in the reference, and tot|sample and tot|re f are the sample size and
reference size respectively.
Given the finite sizes of the sample ensemble and the reference ensemble for a
specific annotation term, the ER is bound to have a maximum value. Hence, it can
be very informative to evaluate the relative maximum enrichment (RME), which we
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define as the ratio between the calculated ER and the maximum ER (ERmax) that
could be obtained for the specific annotation term. The RME is a quantity in the
[0,1] range, where 0 indicates no enrichment, and 1 indicates that the annotation
term has reached its maximum value possible in the sample.
The maximum enrichment ERmax can differ among annotation terms depending
on one condition. If the size of the annotation term t in the reference, i.e. #obs(t)|re f ,
is bigger than the sample size tot|sample, then the maximum number of components
that can be observed for t in the sample are equal to the sample size tot|sample, and
ERmax(t):
i f tot|sample < #obs(t)|re f :
ERmax(t) =
1
#obs(t)|re f
tot|re f
=
tot|re f
#obs(t)|re f
(4.6)
depends only on the ratio of the reference size and the size of the annotation term
t. The relative maximum enrichment then becomes:
RME(t) =
ER(t)
ERmax(t)
=
#obs(t)|sample
#obs(t)|re f
tot|re f · tot|sample
· #obs(t)|re f
tot|re f =
#obs(t)|sample
tot|sample (4.7)
which is simply the frequency f (t) of the annotation term in the sample.
On the contrary, if the size of the annotation term in the reference is smaller than
the sample size, then ERmax(t) becomes independent of the number of components
in the reference:
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i f tot|sample ≥ #obs(t)|re f :
ERmax(t) =
#obs(t)|re f
tot|sample
#obs(t)|re f
tot|re f
=
tot|re f
tot|sample
(4.8)
and remains the simple ratio of the dimension of the two ensembles (the reference
and the sample). The relative maximum enrichment in this case becomes the fraction
of the components of t in the sample:
RME(t) =
ER(t)
ERmax(t)
=
#obs(t)|sample
#obs(t)|re f
tot|re f · tot|sample
· tot|sample
tot|re f =
#obs(t)|sample
#obs(t)|re f (4.9)
Figure 4.6 reports a barchart of the ERs of the annotation terms that resulted
very significant (p<0.01) in the protein families, KEGG pathways and SLIM GO
terms. Near the edge inside each bar, the RME is shown for each term, and the
significance of the ER is indicated with the star notation (**=p<0.01, ***=p<10−3,
****=p<10−4 ).
2D enrichment analysis for the preferential binders of oligomers
The 2D annotation statistics procedure [169] was adapted to our study and im-
plemented within a python script in the analysis workflow. The 2D annotation
enrichment method formulated in [169] is a statistical method that wish to test from
two paired distribution whether a subset of entries exhibits a deviated behaviour
in at least one of the two distribution. It is a 2-dimensional generalisation applied
to the joint distribution of two numerical quantities of the 1D enrichment statistics
method, which tests for every subset of a population (in our case an annotation term)
whether the corresponding numerical values (in our case protein abundances) tend to
be systematically smaller or larger than the global distribution of the population (i.e.
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the abundance distribution of all the protein abundances in the sample) (see Figure
4.9A). In this work, protein abundances in microglia and in the interactome were
the two numerical quantities for the joint distribution. In particular, we refer to the
median percentage in abundances described in section 4.4.2 and section 4.2.5 for
both the protein binders sample (type B, at least 3 replicas) and the microglia sample
from [207] (mapped to the oligomers, at least 3 replicas), which are plotted after
zscore normalisation in Figure 4.7).
The 2D annotation enrichment p-value [169] is defined as the result on the
multivariate analysis of variance (MANOVA, e.g. [304]) of the ranked multivariate
abundance data, where the data are replaced by ranks in each dimension separately,
from 1 to N where the value 1 is given the least abundant protein, and N to the most
abundant protein being N the number of proteins in the sample. Another assumption
of the formalism, beside the requirement of the ranking transformation for the 2D
generalisation non-parametric two-sample test [305], is independence of the values
in the distribution [169]. Since both our MS data and the microglia MS data from
[207] use unique peptides for protein quantification during the MS processing (see
section 4.4.2), the assumption is fulfilled and the method can be applied.
In this work, the 2D annotation enrichment p-value on the ranked abundances
of microglia and oligomers binders for a give annotation term t represents the
probability for t to be globally over-abundant or depleted in either the microglia
sample or the oligomers sample (see Figure 4.9B). While it is also possible to only
look for enrichment in large values (one-sided test), we chose to perform a two-sided
test and test significance also for deviation to lower abundances since we are also
interested in proteins that bind preferentially to the oligomers despite being naturally
low abundant.
Since we are now interested in determining the preferential binders of oligomeric
species, we considered the full GO categories in the calculations, which comprises
broad and fine-grained ontologies. We tested the 1553 protein families, 287 KEGG
pathways, 5192 biological processes (GOBP), 1809 molecular functions (GOMF)
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(A)
(B)
Fig. 4.9
Scheme of the 2D annotation abundance enrichment analysis
(A) Example scheme of the position-based enriched score which is calculated for
each abundance data distribution in the 2D enrichment plot. The enrichment score
ranges from -1 to +1 and is calculated for a given annotation term. A value near -1
indicates that the components of the annotation term (green distribution) under study
have abundance values that are systematically lower than the remaining values of the
distribution. A value close to +1 indicate that the annotation term consists of entries
whose abundances are systematically larger than the remaining distribution, while a
value of 0 indicates that the term is not distributed differently than the rest of the
data. (B) Scheme of the relevant regions of 2D enrichment in our study. The
enrichment score for abundance in oligomers binders is plotted against the
corresponding enrichment score of abundance in microglia. The empty region near
the origin, represented by a void circle, is the result of the cut-off imposed by the
significance. The remaining part of the plane rectangle can be subdivided into 8
areas corresponding to correlating, non-correlating and anti-correlating regions, of
which we highlighted the 5 most relevant for the purpose of this study. These
regions are highlighted to display the general possible behaviour of annotation
terms, so shapes and limits should not be taken literally but only as a reference.
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and 950 cellular components (GOCC) of the interactome sample. Resulting p-
values for the MANOVA of the 2D enrichments were adjusted using the Benjamini-
Hochberg method [303] for multiple hypothesis testing in each functional class
separately.
Fo annotation terms that result as significantly deviating the abundance oligomers
and microglia level joint distribution, we evaluated a position-enrichment score
s which quantifies the abundance deviation in both distributions. Per abundance
distribution (either microglia or oligomers), s calculates how much a given annotation
term t is ranked higher (or lower) as as group, compared to the ranking of all proteins,
hence quantifying the systematical over-abundance or depletion of its components
(see Figure 4.9A). It is defined as:
s =
2(Rt −Rc)
n
(4.10)
where Rt is the average abundance ranking of the proteins belonging to the anno-
tation term t, Rc is the average ranking of the remaining proteins of the distribution,
i.e. the complementary ensemble, and n is the sample size. With such a definition, s
ranges from -1, in case of terms present at systematically lower abundances, to +1,
for terms made of components with the highest abundances in the sample.
Combining the position-enrichment scores of the microglia distribution and the
oligomers distribution, we obtain for each annotation term a number pair (sx,sy),
which is the coordinate-wise difference of average abundance ranks in the single
distributions. sx quantifies the enrichment in abundance of the microglia, while sy
is the enrichment in abundance for the oligomers. The resulting 2D enrichments
s = (sx,sy) are confined to the square −1≤ sx ≤ 1 and −1≤ sy ≤ 1, where the point
(sx,sy) = (0,0) corresponds to annotation terms that are not distributed differently
from the global distribution of value pairs. Figure 4.9B shows a scheme of the 2D
enrichment oligomers/microglia plan with the different regions relevant for our study
highlighted in violet, orange and blue. The violet region represents annotation terms
that identify sets of proteins that are highly binding the oligomers but also naturally
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highly abundant in microglia. The orange areas correspond to terms that are only
at the top or at the bottom of the abundance distribution in either one of the two
variables. In particular, we are interested in the regions where either proteins are
quite strongly binding the oligomers, so they have average values for binding despite
being very rare in microglia (left orange circle), or proteins that are just top binders
of the oligomers without them being particularly abundant in microglia (top orange
circle). Last, the blue regions represent annotation terms showing anti-correlating
behaviour: either proteins with the highest affinity to bind the oligomers while
being present in low copies naturally, so that the are found extremely enriched in
the oligomers sample nonetheless (second quadrant), or proteins that despite being
extremely abundant, are not affine to the oligomers and hence are depleted in the
interactome (fourth quadrant).
Figure 4.8 in section 4.2.5 shows the results positional enrichment scores of
protein abundances in the oligomers sample with respect to protein abundances in
microglia, for all the annotation terms that resulted significant.
Chapter 5
Conclusions and Perspectives
In this dissertation I presented a quantitative and high-throughput approach of MS-
based proteomics complemented with bioinformatic computational methods. Quanti-
tative proteomics is emerging as a very powerful tool for the direct description at the
molecular level of complex biological systems, as it allows en masse information on
proteins, which perform most of the functions in the cell. The computational methods
I used, implemented and contributed to the development of, enable the prediction of
the physico-chemical properties of proteins from the knowledge of their amino acid
sequences, and characterise the collective proteins behaviour in terms of biological
properties like cellular pathways and molecular functions. Combining MS-based
experimental data with these biophysical analyses is a strategy that can be used to
tackle many biological questions. In this work, I applied this strategy for the study of
protein homeostasis and protein aggregation, two major related key concepts in the
studying of ageing and neurodegenerative disorders. In order to provide insights into
the molecular basis of ageing and neurodegeneration, we rely on the choice of key
model systems. The first system is the nematode C. elegans, a model organism for
ageing research. In chapter 2 and 3 we analysed MS data from nematode C. elegans
to quantify proteome changes upon ageing and characterise them in terms of physico-
chemical principles. We found that ageing in C. elegans results in a significant
proteome remodelling implicating protein stoichiometry imbalances and widespread
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aggregation, which is differently modulated in long-lived and short-lived strains.
Although most abundant proteins are less aggregation prone, they contribute the
most to the aggregate load, as we found that nearly all the proteins in the adult worm
are expressed just above their solubility limits. Despite the wide protein remodelling,
we found that the total intracellular protein amount remains constant upon ageing.
Nonetheless, aggregate levels are nearly dubbing in the same time interval, suggest-
ing that aggregation in the adult nematode is not caused by an increase in abundance,
but is a result of a protein-dependent decrease in solubility due to extrinsic factors
like disruption of the protein homeostasis network and unbalance in stoichiometries.
Also, widespread aggregation occurs in both long-lived and short-lived strains, but
proteins in the bigger insoluble deposits of the long-lived strain are more charged,
hydrophilic and less aggregation prone than those found in the smaller insoluble
deposits of the short-lived strain, suggesting the presence of an extrinsic regulatory
mechanism that enhances the aggregation process into forming insoluble inclusion
to potentially sequester cytotoxic oligomeric and prefibrillar species. The hypothesis
that misfolded oligomers formed at the early stage of the aggregation process may
play a key role in the cytotoxicity of neurodegeneration prompted the second part
of this work. We performed MS based proteomics to characterise the interaction
of proteins with misfolded oligomers. In particular, our model system were two
stabilised and well-characterised, structurally different types of oligomers (HypF-N
type A and type B). We took advantage of their structural difference to investigate
the different biological response upon interaction with proteins. We found that this
structural difference modulates the strength of the binding with proteins, but not
the specificity. Hence, our model oligomers bind the same pools of proteins, with
preferential binding towards mitochondrial and ribosomal proteins, and molecular
chaperones.
I believe that the study of the interactome I performed for HypF-N oligomers can
bring many advantages. First, it represents a useful collection of information which
could be used as a starting point for investigating specific processes mediated by the
interaction of oligomers. On this note in particular, it is in my interest to investigate
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in the future the interaction of oligomers with mitochondria. To this regard, I am
interested in understanding whether the interaction of oligomers with mitochondrial
proteins, especially ribosomal components and proteins of the respiratory complex I,
can occur in vivo and if it can induce cytotoxicity. Also, in order to understand if
interaction with proteins intracellularly can be a general mechanism of toxicity for
misfolded oligomers, I have planned to study, in collaboration with Dr. Benedetta
Mannini, the interactome of other misfolded oligomeric species. Specifically, I am
interested in testing the stable oligomers of the proteins mostly involved in neurode-
generation: α-synclein, A-β40 and A-β42 oligomers. I believe that characterising
these interactomes will also help us gaining molecular insights into the similarities
and differences of neurodegenerative disorders and dementia, and hopefully pointing
to a targetable pathway for disease intervention. Lastly, I would like to address
not only the interactions these oligomers have with proteins, but also the different
response the organism would give to the presence of different misfolded oligomers.
To tackle this question, I would like to investigate in collaboration with Michele Perni
and Dr. Benedetta Mannini, again with MS based proteomics complemented with our
computational methods, the proteome changes in C. elegans with time upon exposure
to the different oligomers, especially in term of the protein homeostasis network.
Also, it would be interesting to check if widespread aggregation can be induced
in worms by the presence of the oligomers, and which are the physico-chemical
features of the induced aggregates.
From the point of view of the development of computational methods, I would
like to develop a method that would take into consideration the uncertainties in
the MS data for the functional enrichment analyses, as I believe it could be very
important in reducing the presence of potential false positives arising from noisy data.
Furthermore, I would like to upgrade the CamSol intrinsic method in order to be able
to account for structural correction in the sequence-based aggregation propensity
calculations. Such an upgrade would allow the possibility of estimating, indeed,
not only the aggregation propensity from the unfolded state, as CamSol intrinsic is
giving at the moment, but also the aggregation propensity from the folded state.
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In conclusion, I anticipate that proteome-level studies of the type that I have
described in this thesis will become increasingly capable of revealing the network
of interactions that maintain the proteome in its functional state, and the specific
processes that become impaired in ageing and in misfolding diseases. This endeavour
will keep me, as well as many other researchers, occupied for several years to come!
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